Studie über das leukämogene Potential der Hoxb4-DeltaProlin Mutante in einem murinen Knochenmarkstransplantationsmodell und den Effekt der Hemmung von Histondeacetylasen in vitro und in vivo by Cusan, Monica
  
Aus der Medizinischen Klinik und Poliklinik III  
 
Klinikum Großhadern / Ludwig-Maximilians-Universität München 
 
Vorstand: Prof. Dr. med. Wolfgang Hiddemann 
 
 
 
 
 
Studie über das leukämogene Potential der Hoxb4-ΔProlin 
Mutante in einem murinen Knochenmarkstransplantationsmodell 
und den Effekt der Hemmung von Histondeacetylasen in vitro 
und in vivo 
 
 
 
Dissertation  
zum Erwerb des Doktorgrades der Medizin  
an der Medizinischen Fakultät der  
Ludwig-Maximilians-Universität in München 
 
 
vorgelegt von  
 
Monica Cusan 
 
 
aus  
 
Portogruaro, Italien 
 
Jahr 
 
2012 
 
 Mit Genehmigung der Medizinischen Fakultät 
der Universität München 
 
 
 
 
 
 
 
 
 
 
Berichterstatter:    Prof. Dr. med. Christian Buske  
 
 
Mitberichterstatter:   Priv. Doz. Dr. Irmela Jeremias  
     Priv. Doz. Dr. Michael Albert 
     Prof. Dr. Christian P. Sommerhoff 
     Prof. Dr. Stefan Endres 
 
  
 
 
Dekan:   Prof. Dr. med. Dr. h.c. M. Reiser, FACR, FRCR 
 
 
Tag der mündlichen Prüfung: 04.10.2012 
 
 
 
 
 
 From the Department of Medicine III 
 
University Hospital Großhadern, Ludwig-Maximilians-University 
Munich 
 
Director: Prof. Dr. med. Wolfgang Hiddemann 
 
 
 
 
 
Investigation of the leukemogenic potential of the Hoxb4-
ΔProline mutant in a murine bone marrow transplantation model 
and the effect of the histonedeacetylase inhibition in vitro and in 
vivo 
 
 
 
Thesis Submitted for a Doctoral Degree in Human Medicine 
at the Faculty of Medicine, 
Ludwig-Maximilians-University in Munich 
 
 
submitted by 
 
Monica Cusan 
 
 
from 
 
Portogruaro, Italy 
 
 
Year 
 
2012 
 With permission from the Faculty of Medicine 
University of Munich 
 
 
 
 
 
 
 
 
 
 
Supervisor/Examiner:   Prof. Dr. med. Christian Buske  
 
 
Co-Examiner:    Priv. Doz. Dr. Irmela Jeremias  
     Priv. Doz. Dr. Michael Albert 
     Prof. Dr. Christian P. Sommerhoff 
     Prof. Dr. Stefan Endres 
     
 
 
 
Dean:    Prof. Dr. med. Dr. hc. M. Reiser, FACR, FRCR 
 
 
Date of Oral Exam: 04.10.2012 
 
 
 
 
 
   Index 
 
1. Introduction........................................................................................................................................ 1 
1.1. Hematopoiesis .............................................................................................................................. 1 
1.1.1 The hematopoiesis ................................................................................................................. 1 
1.1.2.The hematopoietic hierarchy .................................................................................................. 2 
1.1.3. Stem cells and hematopoietic stem cells ............................................................................. .3 
1.2. Leukemia ...................................................................................................................................... 7 
1.2.1 Acute leukemia ....................................................................................................................... 7 
1.2.2 Leukemic stem cells ............................................................................................................. 10 
1.2.3 Molecular pathways leading to leukemia ............................................................................. 11 
1.2.4 Chromosomal translocations in AML.................................................................................... 14 
1.3. The homeobox genes................................................................................................................. 15 
1.3.1 The homeobox genes in hematopoiesis and leukemogenesis ............................................ 15 
1.3.2 Cofactors of the HOX genes ................................................................................................ 20 
1.3.3 Hoxb4 ................................................................................................................................... 22 
    1.3.3.1 Hoxb4 in the hematopoiesis .......................................................................................... 25 
    1.3.3.2 Hoxb4 as amplification tool of HSCs............................................................................. 26 
    1.3.3.3 The proline-rich domain................................................................................................. 28 
    1.3.3.4 The downstream targets of Hoxb4 ................................................................................ 30 
1.4. Epigenetic changes in cancer..................................................................................................... 31 
1.4.1 Histone deacetylases (HDACs)............................................................................................ 32 
1.4.2 Histone deacetylases inhibitors (HDACi) ............................................................................. 34 
1.5. The murine bone marrow transplantation model of leukemia .................................................... 35 
1.6. Aim of the study .......................................................................................................................... 36 
2. Materials ........................................................................................................................................... 39 
2.1. Mice and related reagents and equipment ................................................................................. 39 
2.2. Mammalian cell lines and prokaryotic cells ................................................................................ 39 
2.3. Oligonucleotides ......................................................................................................................... 40 
2.4. Plasmids, genes and proteins .................................................................................................... 41 
2.5. Antibodies ................................................................................................................................... 42 
2.6. Reagents, media and apparatus ................................................................................................ 43 
2.6.1 Molecular biology.................................................................................................................. 43 
2.6.2 Cell and tissue culture .......................................................................................................... 45 
2.6.3 Miscellaneous....................................................................................................................... 47 
2.6.4 Software ............................................................................................................................... 48 
3. Methods............................................................................................................................................ 49 
3.1. Mice maintenance....................................................................................................................... 49 
3.2. Cloning of constructs .................................................................................................................. 49 
3.3. Mutagenesis of Hoxb4 constructs .............................................................................................. 49 
3.4. Transient transfection of packaging cell lines for VCM production ............................................ 50 
3.5. Preparation of high titer stable virus-producing cell lines ........................................................... 50 
3.6. Titration of the retroviral conditioned medium (VCM)................................................................. 51 
3.7. Culture conditions of cell lines and murine bone marrow cells................................................... 51 
   Index 
 
3.8. Retroviral transduction of primary bone marrow cells.................................................................51 
3.9. Bone marrow transplantation and assessment of mice .............................................................53 
3.10. FACS analysis of murine primary cells ....................................................................................54 
3.11. In vitro and ex vivo functional assays of murine BM cells: proliferation and CFC assay .........55 
3.12. Cytospin preparation and Wright-Giemsa staining ..................................................................55 
3.13. Histological and immunohistochemical analysis ......................................................................55 
3.14. Delta-colony forming unit-spleen (∆CFU-S) assay ..................................................................56 
3.15. Quantification of competitive repopulating units (CRU-assay) ................................................56 
3.16. Total RNA / genomic DNA isolation and cDNA preparation  ...................................................57 
3.17. Southern blot .............................................................................................................................57 
3.18. Integration analysis: bubble LM-PCR ......................................................................................58 
3.19. Western blot .............................................................................................................................58 
3.20. Immunoprecipitation..................................................................................................................60 
3.21. Polymerase chain reactions .....................................................................................................61 
3.22. Immunostaining and confocal laser microscopy scanning fluorescence microscopy...............61 
3.23. Statistical analysis.....................................................................................................................62 
4. Results ..............................................................................................................................................63 
4.1. Cloning and expression of Hoxb4 constructs..............................................................................63 
4.2. Titration of the viral conditioned medium ....................................................................................65 
4.3. Transduction of primary bone marrow cells ................................................................................65 
4.4. In vitro assays .............................................................................................................................66 
4.4.1 Effect of Hoxb4 and its mutants on liquid expansion of BM progenitor cells........................66 
4.4.2 Immunophenotype of in vitro expanded BM progenitor cells................................................68 
4.4.3 Morphology of in vitro expanded BM progenitor cells...........................................................76 
4.4.4 Colony forming cells (CFC)-assay in vitro ............................................................................77 
4.4.5 Intracellular localization.........................................................................................................79 
4.5. In vivo assays..............................................................................................................................80 
4.5.1 ∆Colony forming unit in the spleen (∆CFU-S) assay............................................................80 
4.5.2 Hoxb4 BM transplantation experiments in mouse model .....................................................83 
   4.5.2.1 Peripheral blood (PB) analysis at 4th week after transplantation ....................................83 
   4.5.2.2 The long term engraftment: analysis of chimerism in PB ...............................................83 
   4.5.2.3 The long term engraftment: analysis of differentiation profile in PB ...............................84 
   4.5.2.4 Overexpression of Hoxb4-∆Pro is associated with acute leukemia in transplanted      
mice................................................................................................................................................84 
   4.5.2.5 Clinical features of the Hoxb4-∆Pro associated leukemia..............................................90 
   4.5.2.6 Colony forming cell assay (CFC) ex vivo......................................................................103 
   4.5.2.7 Retroviral integration analysis.......................................................................................108 
   4.5.2.8 Effect of the proline-rich region deletion on the CRU frequency (CRU assay).............110 
5. Discussion ......................................................................................................................................115 
6. Summary.........................................................................................................................................121 
7. Zusammenfassung ........................................................................................................................123 
8. References......................................................................................................................................125 
   Index 
 
9. Acknowledgments......................................................................................................................... 135 
10. Selected publications.................................................................................................................. 136 
Chapter 1 – Introduction 
Introduction 
1.1 Hematopoiesis 
1.1.1 The hematopoiesis  
The term hematopoiesis indicates the controlled production of the blood cells. 
The blood cells, leukocytes, erythrocytes and platelets, are continuously 
produced and released from the bone marrow on a daily base to replace altered 
cells and to enrich the pool of necessary cells in response to increased demand, 
like in case of injury, bleeding or disease. The control of the blood cells 
production undergoes homeostatic mechanisms, which are modifying their 
turnover and re-establishing the steady state after the stress situation is resolved. 
The first site of primitive hematopoiesis is the yolk sac in the first few weeks of 
gestation. In this first time of blood cell production putative hemangioblasts, which 
correspond to the common mesodermal precursors of endothelial and 
hematopoietic lineages, give rise to a temporary embryonic hematopoietic 
system. During the gestational development these precursors are believed to 
migrate to the fetal liver, and from this to the spleen and bone marrow (Weissman 
2000, Morrison 1995a). This migration is due to molecular changes as well as to 
modifications of cell surface adhesion molecules (Hirsch 1996). From 6 weeks 
until 6-7 months of fetal life liver and spleen are the major hematopoietic organs, 
which continue to produce blood cells until about 2 weeks after birth. The bone 
marrow becomes the major hematopoietic organ from 6 to 7 months of fetal life. 
The adult multilineage blood system is maintained by pluripotent hematopoietic 
stem cells (HSC), which have the capacity to self-renew, to differentiate 
hierarchically giving rise to all the different mature progeny cells of the blood, and 
can long-term repopulate myeloablated recipients. By performing in vitro 
clonogenic and in vivo transplantation assays at least five classes of partially 
independent hematopoietic cells in the murine embryo/fetus have been defined: 
the primitive present in the yolk sac, the pro-definitive (myeloid progenitors), the 
meso-definitive (lymphoid-myeloid progenitors), the meta-definitive (neonatal 
repopulating HSCs and CFU-S) (these tree classes located in the para-aortic 
splanchnopleura), and adult-definitive (adult definitive repopulating HSCs), which 
appear in the aorta-gonad mesonephros (AGM) region, in the liver, thymus, 
spleen and bone marrow (Dzierzak 2003, Dzierzak 2008).    
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Based on many reports the human embryonic development seems to significantly 
parallel the mouse development (Fig 1.1.1). Adult HSCs can divide 
asymmetrically into one daughter HSC and a committed progenitor, and the fate 
determination depends on a number of essential hematopoietic transcription 
factors. For example, PU.1 drives the cell into myeloid lineage, while GATA-1 
induces erythropoietic and megakaryocytic differentiation. Moreover, the lineage 
differentiation can also be influenced by several exogenous factors, like the 
growth factors IL-3, SCF, IL-6 and G-CSF.  
 
Fig 1.1.1. Development of the hematopoietic system (Bonnet 2003). 
 
1.1.2 The hematopoietic hierarchy 
The cells of mature hematopoietic progeny derive from a limited number of 
committed hematopoietic progenitors, which arise from even more rare 
hematopoietic stem cells (HSCs) (Weissman 2000). The self-renewing HSCs are 
termed long-term repopulating HSCs (LT-HCSs) for their ability to confer long-
term engraftment on lethally irradiated recipients, and they generate the short-
term repopulating HSCs (ST-HSCs) with limited self-renewal and increased 
proliferation capacity. ST-HSCs subsequently give rise to multipotent progenitors 
(MPPs) that generate committed progenitors of different lineages: the common 
myeloid progenitor (CMP) for the myeloid-erythroid lineage, and the common 
lymphoid progenitor (CLP) for the lymphoid lineage. The CMP in turn gives rise to 
the granulocyte-macrophage progenitors (GMPs) and the megakaryocyte-
erythrocyte progenitors (MEPs) that are restricted to churning out mature 
granulocytes, macrophages or mast cells and megakaryocytes or erythrocytes, 
respectively. The CLPs generate all mature lymphoid cell types including B and T 
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lineage cells, dendritic and NK cells. Dendritic cells can be generated from both 
CLPs as well as CMPs. Thus the hematopoietic hierarchy is composed of the 
stem cells, the committed progenitors and their progeny, the mature blood cells of 
all lineages. The first level where we can observe a profound homeostatic control 
of the high turnover rate of the hematopoietic system is within the HSCs 
compartment. Moreover, a significant homeostatic control is also necessary at 
the level of more committed multipotent, oligopotent, and lineage-restricted 
progenitor cells, if one considers the even larger proliferative and developmental 
capacity of these progenitors (Bryder 2006) (Fig. 1.1.2). 
 
Fig. 1.1.2. A representative scheme of the hematopoietic developmental hierarchy. The cell 
surface markers of many of these cells types are known for the murine and human system. 
However, many markers have been described only for few mouse strains, while the absolute 
lineage potential and developmental relationship of some of the subsets indicated have not been 
yet completely characterized. The differentiation of HSCs into multipotent, oligopotent, and 
lineage-specific progenitors is generally associated with increased proliferative index, although 
this characteristic is not absolute and has not been resolved for all stages of development. The 
side population activity represents the capacity of efflux dyes, and it is restricted to HSCs and 
their immediate downstream multipotent progenitors. Of note is that the different multipotent 
progenitor subsets in human system have not been functionally resolved to a significant degree 
like for the murine hematopoiesis (Bryder 2006). 
 
1.1.3 Stem cells and hematopoietic stem cells 
Stem cells can be classified into two main categories, embryonic and adult stem 
cells. Stem cells are clonogenic cells capable of both self-renewal and 
multilineage differentiation. Some adult tissues like blood, skin, gut etc. need a 
constant turnover of cells for tissue renewal. Tissue stem cells, which are adult 
stem cells, respond to this need as they consist of multipotent progenitors. After 
3 
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the observation that cellular recovery can be achieved following lethal irradiation 
by transplanting bone marrow, it was defined that the ability of such transplants to 
reconstitute hematopoiesis can be attribute to a few extremely rare stem cells 
found predominantly in the bone marrow but capable of mobilization into 
peripheral tissues via the blood vascular system. Since then, HSCs have been 
the best characterized stem cells at the phenotypic and functional level, and the 
hematopoietic system has been the proving ground for most of the experimental 
procedures and conceptual paradigms for the stem cells biology in general. 
HSCs and indeed most stem cells can be defined by certain unique properties, 
sometimes referred as “stemness”, the most prominent of which are self-renewal, 
multipotency, and quiescence. During their lifespan, humans produce 
approximately 1016 blood cells of different types. The hallmark properties of the 
HSCs were defined in 1963 by Till and McCulloch. In a mouse model they have 
identified a population of clonogenic BM cells able to generate myeloid-erythroid 
colonies in the spleen of lethally irradiated hosts. These clonogenic cells in some 
cases gave rise to cells that also could be transferred to secondary hosts and 
there reconstitute all blood lineages (Till & McCulloch 1961; Siminovich 1963). 
With the development of clonal assays for all major hematopoietic cell lineages, 
cell sorted-based separation of monoclonal antibody- or dye-stained BM subsets 
led to the isolation of candidate stem cell populations (Osawa 1996). In vivo 
limiting dilution analysis of these cells allowed the characterization of at least 2 
classes of multipotent cells, long-term (LT-HSC) and short-term repopulating 
hematopoietic stem cells (ST-HSC), the last ones able to self-renew for a definite 
interval (≈8 weeks in mice) (Passagué 2003, Morrison 1995). Stem cells have the 
ability to self-renew, and are able to persist in recipients for long period of time 
after transplantation, continuously replenishing the blood with mature 
differentiated cells or remaining quiescent. The competitive repopulating units 
(CRUs) represent a functionally defined class of very primitive HSCs with the 
potential of long-term reconstitution of all hematopoietic lineages in recipient 
animals. The CRU-assay allows not only the quantification of these primitive 
HSCs, but also allows establishing a competitive pressure on the HSCs 
originating from the compromised irradiated host, from the transduced HSCs and 
the cotransplanted competitor HSCs (Szilvassy 1990, Miller 1997).  
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Self-renewal. Self-renewal is the property of a stem cell to generate progeny with 
exact stem cell properties of the parental cell. A stem cell can divide 
symmetrically to give rise to two daughter stem cells, each possessing stem cells 
properties, or alternatively, asymmetrically, wherein one daughter cell is a stem 
cell and the other is a rapidly cycling downstream progenitor with a reduced 
capacity of self-renewal (Warner 2004). The downstream progenitor of an HSC 
displays a partially increased proliferation capability and it leads to clonal 
expansion and production of numerous committed progenitors and more 
differentiated hematopoietic cells. The short-term repopulating stem cell gives 
rise to the non-self-renewing oligolineage progenitors which in turn give rise to 
progeny that are more restricted in their differentiation potential, and finally to 
functionally mature cells. In a steady state bone marrow HSCs divide rarely but 
mostly asymmetrically to retain their original pool numbers as well as to produce 
the entire complement of cells necessary for normal hematopoiesis, which is the 
result of a sophisticated equilibrium between self-renewal and differentiation. The 
mechanisms regulating the fate decision are poorly understood. However, many 
gene families have been associated to this process, like the Hox genes family 
(Antonchuk 2001, Buske 2002), the Wnt family (Reya 2003), and the Polycomb 
group (Lessard 2003). Other factors have been reported to play a role in the 
maintenance of quiescence as well as in the activation of HSCs, like Notch 
(Karanu 2000) and Hedgehog (Bhardwaj 2001), in particular in relation to the 
function of the stem cell niche in the bones.  
Multipotency. The adult stem cells are multipotent, i.e. are able to give rise to all 
the cells of a given tissue, while the embryonic stem cells are able to give rise to 
all the cells of every tissue of an organism, which is called totipotency. The HSCs 
are multipotent cells capable to long-term repopulate both the lymphoid and 
myeloid hematopoietic compartments via differentiation into committed 
progenitors, which can proliferate extensively but have increasingly limited 
differentiation potential (Orlic 1994). In leukemias the HSCs undergo a loss of 
multipotency in form of block of differentiation and/or dysregulation of certain 
lineage specific transcription factors. 
Plasticity and heterogeneity. In the recent years many efforts have been done 
in order to investigate the possibility that adult mammalian stem cells may 
differentiate across tissue lineage borders, which could represent an 
5 
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extraordinary tool to establish new therapeutic issues as tissue regeneration. The 
first studies using BM cells or HSCs to regenerate other tissues have been 
controversial (Goodell 2003, Raff 2003). The more promising results were 
obtained in an effort to define the capacity of enriched BM populations to restore 
myocardial function in infarct models (Orlic 2001). In a number of reports BM 
cells have been described to repopulate renal, neuronal, cardiac and liver tissues 
in response to certain injuries, but the significance of these results still remains to 
be clarified. Interestingly, some authors have suggested that tissue-committed 
stem cells (TCSCs), which express mRNA/protein for different markers, could be 
normally present in the adult BM compartment (Kucia 2005).  
An opposite concept that has been developed is the heterogeneity of HSCs. 
Although a relatively simple surface phenotype may be ascribed to HSCs (for 
example, Thy1.1+Lin-Sca+ckit+) (Morrison 1994) and is of enormous value in their 
prospective enrichment, it is also evident that even highly purified HSC 
populations are heterogeneous, either with respect to other surface markers or 
functions (Weissman 2000b, Morrison 1995b). Whereas a model invoking stem 
cell heterogeneity may account for the majority of recent findings, reprogramming 
of HSCs, albeit at a low rate, may best explain the contribution of purified HSCs 
to liver, as shown by the experiments of Lagasse et al (Lagasse 2000), where 
purified HSCs seemed to differentiate into hepatocytes in vivo (Orkin 2002). 
Quiescence. Quiescence or the relatively slow cycling of HSCs, in contrast to the 
rapidly proliferation of the downstream progenitors, is necessary to protect the 
stem cell compartment from toxic and oxidative stress and to prevent 
consumption of the regenerative cell pool, an occurrence known as stem cell 
exhaustion (Cheng 2000). Bonnet et al have calculated the frequency of HSCs to 
be 1 in 10,000 to 100,000 cells in peripheral blood. The HSCs occupy in relatively 
larger number well defined “stem cell niches” in adult BM where they are normally 
in an inactive state (Bonnet 2002). It was demonstrated by 5-bromo-2´-deoxy-
uridine (BrdU) incorporation studies (for the measurement of cell proliferation) in 
mice, that approximately 75% of long-term repopulating HSCs were in the G0 
phase/quiescence at any given time in steady state BM (Cheshier 1999). LT-
HSCs divide very rarely and give rise to the more proliferative ST-HSCs which in 
turn give origin to the non-self-renewing lineage committed progenitors. HSCs 
can however proliferate rapidly symmetrically in response to myelosuppressive 
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chemotherapy or irradiation prior BM transplantation to give rise to committed 
progenitors as well as copies of more HSCs, which then return to the quiescent 
state (Dixon 1981). The control of the quiescent state is especially crucial in 
conditions of stress, such as myelotoxic injury, to prevent hematopoietic death. 
There is little information about the molecular events that promote this process, 
though the BM microenvironment or the “stem cell niche” is believed to play an 
important role generating signals that regulate the self-renewal and the 
differentiation of normal stem cells (Lemischka 1997).  
 
1.2 Leukemia 
1.2.1 Acute leukemia 
The leukemias are a group of diseases in which the common manifestation is a 
malignant, unregulated proliferation of cells originating from the bone marrow. 
Leukemia may involve any of the blood-forming cells or their precursors and may 
be found throughout the body, including brain, liver, spleen, and lymph nodes. 
Although each type of leukemia progresses differently, the unregulated 
proliferating cells (1) usually displace normal BM cells, (2) can interfere with 
normal marrow function, (3) may colonize other organs, and (4) eventually lead to 
death if not treated. Based on the progress, leukemias are distinguished into 
chronic (first described in 1845 by Bennet and Virchow, Bennet 1845, Virchow 
1846) and acute leukemias, which were described 25 years later when patients 
with “white blood” were observed to die rapidly after a short debilitating illness 
(Friedrich 1857, Ebstein 1889). Acute and chronic leukemias can be 
distinguished based on their presenting signs and symptoms, and the cell type 
involved. Acute leukemias are characterized by rapid onset of clinical signs (e.g., 
infection, haemorrhage, and pallor) and symptoms (e.g., fatigue, weakness, bone 
and joint pain), by the detection of normocytic anemia, neutropenia and/or 
thrombocytopenia, and death occurs within months if treatment is not initiated. In 
1976 the FAB (French-American-British) classification of leukemias was 
introduced, which was based on the number of blasts (immature cells of myeloid 
or lymphoid origin) of at least 30% of all nucleated bone marrow cells, and on the 
morphology of these cells. The proposed World Health Organization classification 
has modified the percentage of blasts to 20% in either peripheral blood or bone 
marrow (Brunning 1999). The diagnosis of acute myeloid leukemia can be based 
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also on the presence of less than 20% of blasts in the bone marrow, if typical 
chromosomal aberrations are detected. Overall, peripheral blood white cell 
counts can be increased, decreased, or within reference range, although they are 
typically increased. The use of light microscopy is the initial step in the diagnosis 
of acute leukemias, which are classified cytomorphologically into acute myeloid 
(AML) and acute lymphoblastic leukemia (ALL) on the basis of the blasts’ 
morphologic similarity to myeloblasts or lymphoblasts. For example, Auer rods 
(spindle-shaped pink-red inclusions composed of azurophilic granule derivatives) 
may be seen in the cytoplasm of any subtype of human AML. The old FAB 
classification system used a combination of Romanowsky-based stains and 
cytochemical reactions, including staining for myeloperoxidase, chloracetate 
esterase, non-specific esterase, and stains with Sudan black B, periodic acid 
Shiff and TdT. In 2008 the World Health Organization has published the 4th 
revision of the classification of tumors of hematopoietic and lymphoid tissues 
(Figure 1.2.1). The guidelines presented there include the analysis of PB and BM 
specimens, the assessment of blasts and blast lineage by morphological, 
immunophenotypical and cytochemical analyses, as well as the evaluation of 
genetic features, like the karyotype (for the detection of chromosomal 
alterations), and point mutations (like NPM1, CEBPA, FLT3, and RUNX1), which 
have been demonstrated to be significantly associated with different prognosis. 
Chromosomal alterations have been seen consistently in leukemic cells. Using 
standardized banding high-resolution techniques, almost all leukemic cells will 
present a clonal cytogenetic abnormality of one type or another. These 
abnormalities can be of number (ploidy) or of structure (translocations, deletions, 
and rearrangements). The follow up of these molecular markers in patients 
showing morphological remission enable to detect groups of patient at high risk of 
relapse. The persistence of these markers is defined as minimal residual disease 
(MRD). 
Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasm associated with 
eosinophilia and abnormalities of PDGFRA, PDGFRB, 
or FGFR1 
• Chronic myelogenous leukemia, BCR-ABL1 positive     
• Polycythemia vera                                             
• Essential thrombocythemia                                
• Chronic eosinophilic leukemia, n.o.s.   
• Chronic neutrophilic leukemia 
• Primary myelofibrosis 
• Mastocytosis 
• Myeloproliferative neoplasm, unclassifiable 
• Myeloid and lymphoid neoplasms associated with 
PDGFRA rearrangement 
• Myeloid neoplasms associated with PDGFRB 
rearrangement  
• Myeloid and lymphoid neoplasms associated with FGFR1 
abnormalities  
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) Myelodysplastic syndromes (MDS) 
8 
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• Chronic myelocytic leukemia 
• Atypical chronic myeloid leukemia, BCR-ABL1 negative 
• Juvenile myelomonocytic leukemia 
• Myelodysplastic/myeloproliferative neoplasms, unclassifiable 
Provisional entity: refractory anemia with ringsideroblasts and 
thrombocytosis 
• Refractory cytopenia with unilineage dysplasia 
- Refractory anemia 
- Refractory neutropenia 
- Refractory thrombocytopenia 
• Refractory anemia with ring sideroblasts 
• Refractory cytopenia with multilineage dysplasia 
• Refractory anemia with excess blasts 
• Myelodysplastic syndrome with isolated del(5q) 
• Myelodysplastic syndrome, unclassifiable 
• Childhood myelodysplastic syndrome 
Provisional entity: refractory cytopenia of childhood 
Acute myeloid leukemia and related neoplasms Acute leukemia of ambiguous lineage 
• Acute undifferentiated leukemia 
• Mixed phenotype acute leukemia with t(9;22)(q34;q11.2);   
BCR-ABL1 
• Mixed phenotype acute leukemia with t(v;11q23); MLL 
rearranged 
• Mixed phenotype acute leukemia, B-myeloid, n.o.s. 
• Mixed phenotype acute leukemia, T-myeloid, n.o.s. 
Provisional entity: natural killer (NK) cell lymphoblastic 
leukemia/lymphoma 
 
Precursors lymphoid neoplasms 
• Acute myeloid leukemia with recurrent genetic abnormalities 
- AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
- AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); 
CBFB-MYH11 
- APL with  t(15;17)(q22;q12); PML-RARA 
- AML with t(9;11)(p22;q23); MLLT3-MLL 
- AML with t(6;9)(p23;q24); DEK-NUP214 
- AML with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-
EVI1 
- AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-
MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
• Acute myeloid leukemia with myelodysplasia-related changes 
• Therapy-related myeloid neoplasms 
• Acute myeloid leukemia, n.o.s. 
- AML with minimal differentiation 
- AML without maturation 
- AML with maturation 
- Acute myelomonocytic leukemia 
- Acute monoblastic/monocytic leukemia 
- Acute erythroid leukemia 
                 Pure erythroid leukemia 
                 Erythroleukemia, erythroid/myeloid 
- Acute megakaryoblastic leukemia 
- Acute basophilic leukemia 
- Acute panmyelosis with myelofibrosis 
• Myeloid sarcoma 
• Myeloid proliferations related to Down syndrome 
- Transient abnormal myelopoiesis 
- Myeloid leukemia associated with Down syndrome 
• Blastic plasmacytoid dendritic cell neoplasm 
 
B lymphoblastic leukemia/lymphoma 
 
• B lymphoblastic leukemia/lymphoma, n.o.s. 
• B lymphoblastic leukemia/lymphoma with recurrent 
genetic abnormalities 
- B lymphoblastic leukemia/lymphoma with t(9;22) 
(q32;q11.2); BCR-ABL1 
- B lymphoblastic leukemia/lymphoma with t(v;11q23); 
MLL rearranged 
- B lymphoblastic leukemia/lymphoma with t(12;21) 
(p13;q22); TEL-AML1 (ETV6-RUNX1) 
- B lymphoblastic leukemia/lymphoma with 
hyperdiploidy 
- B lymphoblastic leukemia/lymphoma with 
hypodiploidy 
- B lymphoblastic leukemia/lymphoma with 
t(5;14)(q31;q32); IL3-IGH 
- B lymphoblastic leukemia/lymphoma with 
t(1;19)(q23;p13.3); TCF3-PBX1 
 
T lymphoblastic leukemia/lymphoma 
Mature B-cell neoplasms Mature T-cell and NK-cell neoplasms 
• T-cell prolymphocytic leukemia 
• T-cell large granular lymphocytic leukemia 
• Chronic lymphoproliferative disorder of Nk-cells 
• Aggressive NK-cell leukemia 
• Systemic EBV positive T-cell lymphoproliferative disease 
of childhood 
• Hydroa vacciniforme-like lymphoma 
• Adult T-cell leukemia/lymphoma 
• Extranodal NK/T-cell lymphoma, nasal type 
• Enteropathy-associated T-cell lymphoma 
• Hepatosplenic T-cell lymphoma 
• Subcutaneous panniculitis-likeT-cell lymphoma 
• Mycosis fungoides 
• Sézary syndrome 
 
 
Primary cutaneous T-cell disorders 
• Primary cutaneous CD30 positive T-cell 
lymphoproliferative dosirders 
- Lymphomatoid papulomatosis 
- Primary cutaneous anaplastic large cell lymphoma 
• Primary cutaneous gamma-delta T-cell lymphoma 
• Primary cutaneous CD8 positve aggressive 
epidermotropic cytotoxic T-cell lymphoma 
• Primary cutaneous CD4 positive small/medium T-cell 
lymphoma 
• Chronic lymphocytic leuekemia/small lymphocytic lymphoma 
• B-cell prolymphocytic leukemia 
• Splenic B-cell marginal zone lymphoma 
• Hairy cell leukemia 
- Splenic B-cell lymphoma/leukemia, unclassifiable 
- Splenic diffuse red pulp small B-cell lymphoma 
- Hairy cell leukemia variant 
• Lymphoplasmacytic lymphoma 
- Waldenström macroglobulinemia 
• Heavy chain diseases 
- Alpha heavy chain disease 
- Gamma heavy chain disease 
- Mu heavy chain disease 
• Plasma cell lymphoma 
• Solitary plasmocytoma of bone 
• Extraosseous plasmocytoma 
• Extranodal marginal zone lymphoma of mucosa-associated 
lymphoid tissue (MALT lymphoma) 
• Nodal marginal zone lymphoma 
• Paedriatic nodal marginal zone lymphoma 
• Follicular lymphoma 
• Paedriatic follicular lymphoma 
• Primary cutaneous follicle centre lymphoma 
• Mantle cell lymphoma 
• Diffuse large cell lymphoma (DLBCL), n.o.s. 
- T-cell/hystiocyte rich large B-cell lymphoma 
- Primary DLBCL of the CNS 
- Primary cutaneous DLBCL, leg-type 
- EBV positive DLBCL of the elderly 
Peripheral T-cell lymphoma, n.o.s. 
Angioimmunoblastic T-cell lymphoma 
Anaplastic large cell lymphoma, ALK positive 
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Anaplastic large cell lymphoma, ALK negative 
Hodgkin lymphoma 
• Nodular lymphocyte predominant Hodgkin lymphoma 
• classical Hodgkin lymphoma  
- Nodular sclerosis classical Hodgkin lymphoma 
- Mixed cellularity classical Hodgkin lymphoma 
- Lymphocyte-depleted classical Hodgkin lymphoma 
Histiocytic and dendritic cell neoplasms 
• DLBCL associated with chronic inflammation 
• Lymphomatoid granulomatosis 
• Primary mediastinal (thymic) large B-cell lymphoma 
• Intravascular large B-cell lymphoma 
• ALK positive large B-cell lymphoma 
• Plasmablastic lymphoma 
• Large B-cell lymphoma arising in HHV8-associated multicentric 
Castleman disease 
• Primary effusion lymphoma 
• Burkitt lymphoma 
• B-cell lymphoma, unclassifiable, with features intermediate 
between DLBCL and Burkitt lymphoma 
• B-cell lymphoma, unclassifiable, with features intermediate 
between DLBCL and classical Hodgkin lymphoma 
 
Post-transplantation lymphoproliferative disorders (PTLD) 
• Early lesions 
- Plasmacytic hyperplasia 
- Infectious mononucleosis-like PTLD 
• Polymorphic PTLD 
• Monomorphic PTLD (B- and T/NK-cell types) 
• Classical Hodgkin lymphoma type PTLD 
• Histiocytic sarcoma 
• Langerhnas cell histiocytosis 
• Langerhans cell sarcoma 
• Interdigitating dendritic cell sarcoma 
• Follicular dendritic cell sarcoma 
• Fibroblastic reticular cell tumor 
• Indeterminate dendritic cell tumor 
• Disseminated juvenile xanthogranuloma 
Fig 1.2.1. WHO classification of hematopoietic and lymphoid neoplasms (Vardiman 2009, 
Vardiman 2010). n.o.s.: not otherwise specified. 
 
1.2.2 Leukemic stem cells 
The cells within a certain cancer are heterogeneous and a growing amount of 
evidences suggest that cancers originate from a rare population of cancer stem 
cells (CSCs) with unlimited proliferation potential, which induce the generation 
and growth of a tumor (Bonnet 1997, Reya 2001). This can explain the treatment 
failure of therapies currently in use, which are cytotoxic to the tumor bulk, but are 
not able to exhaust the cancer stem cells. The blood-related cancer leukemias 
were the first diseases for which human cancer stem cells, or leukemic stem cells 
(LSCs), were isolated through the ground breaking work of Bonnet and Dick 
(Bonnet 1997, Dick 2003). Most of the therapies currently used for acute 
leukemias have been designed to target the high proliferating malignant blasts. 
However, one hallmark of the human LSCs studied so far is the quiescence, 
which is protecting them from the toxicity of the common chemotherapeutic 
agents (Holyoake 1999). Nowadays, the characterization of the LSCs is based on 
the immunophenotype analysis together with functional assays in vivo like the 
xenotransplantation of primary human AML cells in immunodeficient NOD-SCID 
mice. It has been shown that the LSCs reside in the CD34+CD38- or 
CD34+/CD38+ subpopulation, which match with the phenotype of the normal 
HSCs, but the LSCs differentially express also other markers, like CD123/IL3-Rα 
or CD33 (Jordan 2000, Taussig 2005). This allowed the design of a promising 
therapeutic approach with the administration of an IL3/diphteria toxin fusion 
protein to transplanted animals (Feuring-Buske 2002). This treatment schedule 
10 
Chapter 1 – Introduction 
has been used for a phase I clinical study for patients with chemo-refractory AML. 
Another intriguing aspect of the LSCs is that they can arise from both self-
renewing HSC and non-self-renewing progenitor populations which are supposed 
to re-aquire HSCs specific features (Goardon 2011). This could allow the 
development of more effective drugs targeting e.g. common leukemogenic self-
renewal pathways displayed by all the different LSCs, which could be used in 
combination with conventional therapies (e.g. imatinib, chemotherapy) (Passegué 
2005). 
 
1.2.3. Molecular pathways leading to leukemia 
The carcinogenesis is a multistep process where the cancer cell acquires 
increasing numbers of somatic mutations leading to disruption of determinant 
biological pathways. In details, the cancer cells can gain and lose important 
functions: initially a clonal event causes increased proliferation, while further 
mutations drive to block of differentiation, leading to malignant transformation. 
This is characterized by self-sufficiency in growth signals, resistance to 
antigrowth and apoptotic signals, capacity to change the microenvironment and 
to induce angiogenesis and metastasis (Hanahan 2000). The genetic alterations 
lead in most of the cases to the activation of an oncogene and to the inactivation 
of a tumor suppressor gene. In general many genetic alterations and leukemic-
associated fusion genes are perturbing the normal hematopoietic differentiation 
programs, but in most of the cases further cooperative mutations are necessary 
to allow a full malignant transformation, as supported by murine transplantation 
models (Kelly and Gilliland 2002). Additional supports to this hypothesis are 
coming from the observations that there are inherited gene mutations 
predisposing to the development of leukemia and that in many sporadic AMLs 
more than one mutation can be detected. A significant group of genes that are 
altered in the leukemogenesis are the proto-oncogenes as shown in the Fig. 
1.2.3a (Domen 2000, Fröhling 2005). In detail, the genetic mutations observed in 
acute leukemia can be classified in three groups: (1) activating mutations of 
genes in the tyrosine kinase-RAS/BRAF or -FLT3 receptor signal transduction 
pathway (Ozeki 2004), leading to increased cell proliferation and/or survival of 
leukemic progenitor cells (class I mutations, e.g. BCR-ABL, TEL-PDGFRB and 
other translocations); (2) inactivating mutations of genes encoding hematopoietic 
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transcription factors, resulting in disturbed cell differentiation (class II mutations, 
e.g. RUNX1-ETO, RUNX1-EVI1, TEL-RUNX1, CBFB-SMMHC, RUNX1 point 
mutation, PML-RARA) (Speck 2002); and (3) inactivating mutations of the tumor 
suppressor gene p53. 
 
Fig 1.2.3a. Deregulated pathways leading to leukemia (Passegué 2003). 
 
Additionally in the AML with normal karyotype other mutations have been 
identified in the last few years, which have been shown to correlate differentially 
with the prognosis, and are therefore often included in the panel of the routine 
investigations in order to help in taking adequate therapeutic decisions. These 
mutations include partial tandem duplications (PTD) of the MLL gene, internal 
tandem duplications (ITD) or tyrosine kinase domain (TKD) mutations of the FLT3 
gene, and mutations in the NMP1 (Nucleophosmin1), CEBPA, NRAS and WT1 
genes (Fig 1.2.3b). At present many efforts are done in developing molecular 
therapies which are targeting these aberrantly mutated factors.  
Gene Biological/clinical features Frequency 
NPM1 Protein with pleiotropic functions; associated with 
FLT3-ITD/TKD mutations 
25-35% of AML;  
45-62% of CN-AML 
FLT3 
     - ITD 
     - TKD 
Class III receptor tyrosine kinase 
In frame mutation 
Point mutation 
 
28-34% of CN-AML 
11-14% of CN-AML 
CEBPA Transcription factor mediating lineage specification 
and differentiation into mature neutrophils 
Predominantly in CN-AML 
MLL PTD; rationale for use of DNA 
methyltransferase/histone deacetylase inhibitors 
5-11% of CN-AML 
RAS No prognostic significance 9% of CN-AML 
WT1 Wilms tumor gene 10% of CN-AML 
Fig 1.2.3b. Gene mutations predominantly occurring in cytogenetically normal AML. CN: 
cytogenetically normal (American Society of Hematology, 2007). 
 
A number of experiments have shown that the prevention of cell death is one of 
the crucial events in myeloid leukemogenesis and may even be the first step that 
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defines a platform for additional mutations (Delia 1992). Mutations leading to the 
overexpression of the anti-apoptotic proteins like Bcl-2 have been shown to be 
involved in malignant transformation in follicular lymphoma, lymphoid leukemia as 
well as in myeloid cells. Many groups are focusing on the research on gain-of-
function mutations that promote constitutive self-renewal, such as stabilization of 
β-catenin. Stabilized β-catenin has been shown to promote the self-renewal of 
stem cells and other types of progenitor cells (Reya 2001), and activation of β-
catenin and deregulation of Wnt signalling pathway is a common phenomenon in 
cancer (Polakis 2000). Additionally, other factors playing a role in the epigenetic 
regulation of the DNA have been identified to be relevant in the leukemogenesis. 
The TET1 protein has been described to catalyse the conversion of cytosine-5 
methylation (5mC) to 5hmC, which seems to affect the methylation pattern of 
DNA. TET1 has been described to be fused to MLL in the t(10;11)(q22;q23), 
leading to a dysregulated expression of tumor suppressors and oncogenes 
(Lorsbach 2003). Moreover, TET2 has been reported to be mutated in 12.1% of 
primary (Abdel-Wahab 2009) and in 34.2% of secondary myeloid malignancies 
(Delhommeau 2009). 
A further classification of AMLs is based on their onset. We can distinguish 
primary AMLs, which appear to arise de novo, and the secondary AMLs, which 
can develop from myelodysplasia and other hematological diseases, such as 
myeloproliferative diseases (s-AML) or follow previous treatment with highly 
mutagenic cytostatic drugs or after irradiation for various types of primary tumors 
(therapy related, t-AML). Secondary AMLs are more often observed in elderly 
patients and are associated with a worse prognosis. The myelodysplastic 
syndromes (MDSs) are very heterogeneous hematopoietic disorders 
characterized by increasing deficiency of normal bone marrow function, 
pancytopenias, and tendency to progress to AML. Clonal cytogenetic 
abnormalities can be identified in approximately 50% of MDS. Also the MDSs can 
occur de novo or as therapy-related. The majority of patients with MDS and AML 
diagnosed at major centres are de novo diseases (80-90%), whereas the 
therapy-related MDS/AMLs are less frequent (10-20%). The International 
Prognostic Score System (IPSS) helps to identify MDS patients with higher risk of 
progression to AML or with bad prognosis, and it is based on the percentage of 
blasts in the bone marrow, on the grade of cytopenias, and on BM cytogenetic 
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analysis. The genetic alterations in the de novo and the therapy-related cases are 
often the same in MDS and in AML, although they occur with different 
frequencies.  
 
1.2.4. Chromosomal translocations in AML 
Chromosomal aberrations are a common finding in many cancers and their 
occurrence correlates with the biology and the progression of the tumor. In the 
solid cancers the diagnosis is made relatively late in their development, and it is 
supposed that several chromosomal rearrangements can accumulate after an 
initial genetic event. In the leukemia the presence of clonal chromosomal 
aberrations represents at the moment the strongest prognostic factor for 
prediction of response to therapy and survival, and the cytogenetic analysis of 
AML samples allows the classification of three risk groups: favourable, 
intermediate, or adverse. In 80% of AML cases at least one chromosomal 
rearrangement has been reported (Pandolfi 2001) and over 100 chromosomal 
translocations have been cloned (Gilliland 2002). Leukemia-associated fusion 
proteins generally function as aberrantly activated signalling factors or 
transcriptional regulators that directly perturb the proliferation and differentiation 
program of hematopoietic cells, as it has been shown from a variety of 
experimental models. One of the components of each fusion protein is often a 
transcription factor (AML1, CBFβ, or RARα) whereas the fusion partner has 
normally a different function, like the control of cell survival and apoptosis as well 
as structural function in the nucleus like PML. Interestingly, in many AMLs the 
type of fusion protein often defines the specific stage of maturation arrest in the 
differentiation cascade (Tenen 2003), and they seems to act through common 
mechanisms, like the recruitment of aberrant corepressor complexes, alteration 
of chromatin remodelling, and disruption of specific intracellular compartments 
(Alcalay 2001). It has been demonstrated that the chimeric fusion protein or the 
activation of a certain proto-oncogene by a single translocation event can be 
responsible alone for the transformation (Rabbitts 1991, Rabbitts 1994). The 
cloning of chimeric genes and the assessment of their oncogenic potential using 
e.g. mouse bone marrow transplantation models is one of the useful tools to 
identify new proto-oncogenes and one of the first steps that can be taken to 
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understand the mechanisms of leukemic transformation. The most common 
chromosomal abnormalities are reported in Table 1.2.4. 
Rearrangement Frequency Prognosis 
AML1-ETO t(8;21)(q22;q22) 5-12% Favourable 
Inv(16)(p13q22) or t(16;16)(p13;q22) (CBFβ-MYH11) 10-12% Favourable 
PML-RARα t(15;17)(q22;q12) and variants 5-8% Favourable 
Involving MLL 11q23 5-6% Intermediate 
Others, e.g. del(5q), -5, del(7q), -7  5-6% Unfavourable 
Complex karyotype (≥ 3 abnormalities)  Unfavourable 
Table 1.2.4. Common chromosomal abnormalities found in AML. AML1 encodes Core-Binding 
Factor α (CBPα); ETO is Eight-Twenty-One gene; CBFβ: Core-Binding Factor β; MYH11 encodes 
smooth Muscle mYosin Heavy chain; PML: ProMyelocytic Leukemia gene; RARα: Retinoic Acid 
Receptor α; APL: acute promyelocytic leukemia; MLL: Mixed Lineage Leukemia gene. 
 
1.3 The homeobox genes  
1.3.1. The homeobox genes in hematopoiesis and leukemogenesis 
Homeobox genes encode nuclear transcription factors, which regulate the 
morphogenesis and cellular differentiation during the embryonic development of 
several animals. In mammals, Hox genes are mainly grouped in the primordial 
Hox cluster and in the ParaHox cluster, which are supposed to derive from the 
duplication of a putative ProtoHox cluster of four genes early in evolution (Fig 
1.3.1a, Garcia-Fernandez 2005a and 2005b). Moreover, the homeobox genes of 
vertebrates can be classified in two subgroups: the clustered Hox genes, which 
are linked on a chromosome, and the non-clustered, or divergent, homeobox 
genes. The highly conserved homeobox sequence motif (homeobox means 
binding to the DNA), which encodes the homeodomain, a 60 amino-acid helix-
turn-helix DNA-binding domain, is the common element defining these two broad 
classes of genes. Based on this homology, different Hox genes have been shown 
to recognize similar regulatory sequences in vitro, although the specific sequence 
they recognize, the affinity of DNA binding, and the transactivating potential 
depend on the co-factors that are recruited, like Pbx and Meis/Prep. The 
aminoacidic substitution at position 211 (N→A) has been shown to abolish alone 
the DNA binding (Beslu 2004). The clustered homeobox genes (class I 
homeobox genes) are evolutionary highly conserved, and their organization in 
clusters mirrors the temporal and spatial expression during the development of 
body structures along the anterior-posterior body axis (Krumlauf 1994). In 
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mammals, this class of genes comprehends 39 hox genes organized into four 
genomic clusters (A-D) located on four different chromosomes (HOXA on 7p15, 
HOXB on 17q21, HOXC on 12q13, HOXD on 2q31). Additionally 13 paralogous 
groups have been identified, which include several Hox genes that belong to 
different clusters but have similar homeobox sequence (Fig 1.3.1b).  
 
Fig 1.3.1a. Genesis and evolution of Hox and Parahox clusters. It has been postulated that an 
ancestral ProtoHox-like gene underwent a series of cis-duplications giving rise to an ancestral 
Hox-like cluster that consisted of the ProtoHox cluster linked to the ancestor of even-skipped 
homeotic gene (Evx) and mesenchyme homeobox (Meox). Segmental tandem duplications 
generated a set of primordial ParaHox, Meox, Hox and Evx genes, which was subsequently 
separated into two clusters at the level of the posterior ParaHox gene caudal-type homeobox 
(Cdx) and the Meox gene (red arrow). Subsequent cis-duplications, expansions and genome 
duplications led to the current mammalian full set of extended Hox and ParaHox genes, 
consisting of four clusters of each cluster type (A-D). A further gene cluster, EHGbox (not shown), 
has been identified, consisting of gastrulation brain homeobox (Gbx), motor neuron restricted 
(Mnx) and engrailed (En). This cluster derives through a cis-duplication of a founder gene that 
was probably linked to the ProtoHox gene. Colour codes for the four paralogous groups are: 
Anterior, purple; Group 3, yellow; Central, green; Posterior, red. Gsh, genomic screened 
homeobox; Xlox, Xenopus laevis homeobox 8 (Garcia-Fernàndez 2005b).  
 
Hox genes exhibit a high degree of homology to the clustered homeotic genes 
(HOM-C) of the fruit fly Drosophila melanogaster, which are located in two gene 
clusters, the Antennapedia (Ant-C) and bithorax complexes (BX-C). The study of 
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these genes has been initially useful to understand the function of the 
mammalian hox genes. Non-clustered or non-Hox homeobox genes (class II 
homeobox genes) are more divergent and numerous (approximately 160 in the 
humans) (Tupler 2001), and are dispersed throughout the genome. Gene 
expression analyses of both mouse and human BM samples revealed that the 
majority of Hox genes of the A, B, and C clusters are expressed in lineage- and 
stage-specific combinations in HSCs and, for the most part, are preferentially 
expressed in HSC-enriched subpopulations and in immature progenitor 
compartments and downregulated during differentiation and maturation 
(Sauvageau 1994, Pineault 2002). Nowadays, the expression of homeobox 
genes has been characterized for normal tissues, for cancer cells as well as for 
other diseases, like metabolic disorders. In the normal development the 
homeobox genes are controlling proliferation and differentiation, which are major 
clues in the cancer development. In fact it is known since many years that 
homeobox genes play an important role in the oncogenesis, and in particular they 
can be disregulated in AML by several mechanisms, like chromosomal 
translocations.  
For example, in the t(7;11) and t(2;11) the HOXA9 and HOXD13 are 
dysregulated through fusion with the gene encoding the nucleoporin 98 kDa 
(NUP98) nuclear protein (Nakamura 1996, Raza-Egilmez 1998, Kroon 2001, 
Pineault 2004). The overexpression of HOXA9 alone has been reported to 
strongly correlate as single gene with the poor prognosis in a set of 6817 AMLs 
(Golub 1999). Another well characterized example is represented by the 
chromosomal aberrations involving the MLL gene (11q23), that leads to the 
overexpression of the hox genes HOXA6, HOXA7, HOXA9, and the Hox cofactor 
myeloid ecotropic viral integration site 1 (MEIS1) (Schoch 2003). This expression 
pattern is common in many AML patient samples (Lawrence 1999; Kawagoe 
1999, Yeoh 2002). The MLL (mixed lineage leukemia) gene is the human 
homolog of the Drosophila Thritorax gene and is the archetypal member of the 
Trithorax group of genes that encode chromatin modifiers that are required for 
the proper maintenance of hox genes expression during development. 
Rearrangements involving MLL gene, generated as a consequence of 
chromosomal translocations fusing N-terminal sequence of MLL to 1 of over 40 
functionally diverse groups of C-terminal fusion partners, constitute 5% of all AML 
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cases and 22% of those with acute lymphoblastic leukemia (De Braekeleer 
2005). Interestingly, also in a number of AML cases, bearing rarer translocations, 
like t(8;16)(p11;p13) where the MYST3-CREBBP fusion gene is expressed, the 
hoxgenes HOXA9, HOXB9, HOXA10, and MEIS1 are also overexpressed. 
Interestingly, the upregulation of other genes like HOXC4 has been reported in 
the NB4 PML-RARα-positive cell line following all-trans retinoic acid–induced 
(ATRA-induced) differentiation, as well as in BM from acute PML patients during 
ATRA treatment (Kim 2005). The dysregulated HOX expression has been 
confirmed to be a signature of AML, as well as in lymphoid leukemias where MLL 
expression is disregulated (Imamura 2002).  
Considering their transcriptional specificity, hox genes are able to function as 
both transcriptional repressors and activators. By performing in vitro co-
precipitation assays, Shen et al have shown that the CBP-p300 histone 
acetyltransferase (HAT) is binding to representative Hox proteins from each 
paralog groups (HOX4, 6, 7, 9, 10, 12, 13), but not to the non-Hox homeodomain 
cofactors Pbx and Meis. Moreover the Pbx-binding motif within the Hox proteins 
is not required for CBP binding (Shen 2001). The Hox-CBP interaction variably 
reduces the Hox-DNA binding: the higher paralogs tested (groups 9 through 11) 
seemed to show somewhat greater sensitivity to CBP-induced blocking of DNA 
binding than the lower paralog proteins from groups 1 to 8. This could be 
explained by the ability of the AbdB-like Hox proteins to directly bind to DNA 
without cofactors, while Hox proteins from 1 to 8 paralog groups can strongly 
interact with DNA only in the presence of other cofactors, like Pbx and/or PREP1. 
Moreover, Hox proteins are not acetylated by CBP, whereas they are reported to 
even inhibit CBP activity in vitro and in vivo (Shen 2001).  
In summary, the Hox proteins are essential for the embryonic development, play 
a key role in defining the cellular identity and regulate genes involved in the cell 
division, cell adhesion and migration, morphological differentiation and apoptosis 
(Ulijaszek 1998) (Fig 1.3.1c). The Hox genes expression is mostly regulated by 
the Polycomb group proteins (PcG), which were first identified in Drosophila and 
are highly evolutionary conserved. They are known to maintain specific 
repressive states of hox genes expression patterns within body segments 
development from flies to humans (Lewis 1978). The PcG proteins are 
components of multimeric transcriptional repressor complexes, which include 
18 
Chapter 1 – Introduction 
DNA-binding and chromatin remodelling factors, as well as noncoding small 
RNAs, and RNA interference machinery, and they are essential in maintaining 
cell fate, sustaining stem cells and lineage specification (Rajasekhar 2007). 
 
Fig 1.3.1b. Clustered hox genes organization. Each of the four cluster contains 8-11 genes, which 
are located on four different chromosomes (Chr.7, 17, 12, and 2, respectively). Identical clusters 
can be aligned into paralogous groups (identical colours) based on the sequence homology within 
their homeobox regions, and with the homeotic genes of the Drosophila HOM-C cluster. A box 
above a gene summarizes the important hematopoietic phenotypes exhibited upon engineered 
overexpression of that hox gene. Brackets under one or more genes, denote mouse knockout 
models where the role of the indicated gene(s) was assessed in hematopoiesis (Argiropoulos 
2007).  
 
 
19 
Chapter 1 – Introduction 
Fig 1.3.1c. Hox downstream targets include a significant number of factors involved in numerous 
cellular processes like organogenesis, cellular differentiation, cell adhesion and migration, cell 
cycle and apoptosis (Svingen 2006).  
 
Recently, Hox proteins have been reported to act as general downstream DNA-
binding proteins recruited by BMP/Smad pathway, which regulate a broad range 
of morphogenetic events during embryonic development, and their transcriptional 
activities are regulated by Smad proteins (Li 2006). Additional studies have 
revealed that Hox genes transcription is controlled by a modular system of 
enhancers located within a few kilobases up- or downstream of the gene. 
Generally, each enhancer can orchestrate tissue- and spatially-specific subsets 
of expression patterns and can often independently modulate other regulatory 
factors. Through accurate analysis of these regulatory regions other important 
regulators of Hox gene expression have been identified, like the retinoic acid and 
retinoid X receptors, the Cdx family proteins, Krox20, Kreisler, members of the 
AP-2 family of transcription factors, and Sox/Oct heterodimers. Intriguinly, Hox 
proteins themselves via interaction with the Pbx and Meis families of cofactors 
are capable to regulate the Hox genes expression themselves. Some of these 
factors are involved in the leukemogenesis. For example, the caudal-type 
homeobox transcription factor 2 (CDX2), which belongs to the ParaHox cluster, 
affects Hox gene expression during embryogenesis, is aberrantly overexpressed 
in 90% of patients with AML, whereas it is absent in normal hematopoietic 
progenitors (Scholl 2007), and its overexpression induces a transplantable AML 
in murine models (Rawat 2004). Taken together, these observations allow 
gaining additional alternative explanations for Hox-induced leukemogenesis and 
contribute to better understand the hierarchy of Hox genes regulation in AML 
(Rice 2007). 
 
1.3.2 Cofactors of the Hox genes 
The Hox genes have been reported to need the interaction with heterologous 
cofactors to display their functional specificity. The cofactor Pbx1 belongs to 
subclass of homeodomain proteins, named PBC family, where PBC indicates the 
conserved motif at the N-terminus of their homeodomain. This PBC subclass 
together with the MEIS family belongs to the TALE superclass of non-Hox 
homeodomain proteins, characterized by a Three-Amino-Acid-Loop Extension 
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within the homeodomain. Pbx1 and Meis1 were both found expressed in 
subpopulations of BM cells expressing Hox genes, but also had distinct gene-
specific differences in their expression pattern throughout hematopoiesis. The 
primary interaction between Pbx and Hox occurs between the three amino acids 
loop in the Pbx homedomain, and a tryptophan-containing hexapeptide motif 
(YPWM) N-terminal to the homeodomain in almost all Hox proteins, with the 
exception of the paralog groups 11-13 (Chang 1995, Chang 1996). In particular, 
Hox9 has been shown to directly interact with Pbx and Meis/Prep proteins 
separately, Hox13 only with Meis/Prep, and Hox10 with both Pbx and Prep. 
Moreover, the occurrence of functional trimeric interactions between Hox, Pbx 
and Meis proteins on native Hox enhancers have also been observed (Jacobs 
1999). These interactions seem to be Hox protein- and cellular context-
dependent in the regulation of hematopoietic cell behaviour. It has been 
suggested that the Hox genes acquire a more stringent DNA binding selectivity 
when they cooperatively bind to these cofactors (Mann 2000), but the in vivo 
effects of this binding are not yet completely understood. Depending on the 
target, Hox-Pbx complexes can act as transcriptional activators or as 
transcriptional repressors (Fig 1.3.2). Moreover, it has been suggested from 
several works that the transcriptional effect is not only determined by the 
presence or absence of cofactors, but also and especially by the recruitment of 
other factors into the complex depending on the cell signalling involved and/or on 
the extracellular signals (Saleh 2000).  
 
Fig. 1.3.2. A model for the function of Hox-Pbx complexes. The N-terminal activation and 
repression domains of Hox and Pbx proteins are believed to make intramolecular contact with 
their respective homeodomains. When Hox and Pbx or other cofactors of the Meis/Prep family 
interact on cooperative sites on DNA, their domains became exposed to the interaction with 
coactivators and corepressors such as CBP and HDAC1 and -3. In certain cellular conditions, the 
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net repressor function dominates. However, in response to enhanced PKA signalling or to 
treatment with the HDAC inhibitor TSA, net activation function could prevail (top). Other changes 
could affect this balance, like an increase in the amount of coactivator or an increase of affinity for 
the Hox N-terminus or for Pbx. However, other possible interactions cannot be excluded. The 
black vertical arrows indicate increases or decreases in HAT (e.g. CBP) or HDAC activity. AD, 
HOX activation domain; RD, PBX repression domain; black box, homeodomain; small white 
circle, HOX YPWM motif (Saleh 2000). 
 
In fact, the abolishment of Pbx-binding with a Hox protein does not only lead to 
the loss of Hox function, but can even antagonize the Hox downstream effects. 
Interestingly, the interaction with Pbx has been recently shown to reduce the 
Hoxb4-dependent self-renewal of hematopoietic stem cells (Beslu 2004). 
However, this effect was observed under overexpression of Hoxb4, which may 
not completely reflect in vivo functional roles of Hoxb4-Pbx interaction.  
 
1.3.3 Hoxb4  
Hoxb4 (initially called Hox-2.6) has been described for the first time in the mouse 
in 1988 as related to the Drosophila Deformed gene (Dfd), encoding a protein of 
250 amino acids. Interestingly, in several tissues the presence of different 
transcripts (at least 6 ranging from 2.4 to 10 kb), which are differentially detected 
with the time during embryonal and post-natal development, has been reported 
(Graham 1988). Nowadays, Hoxb4 is known to significantly increase self-renewal 
and proliferation of primitive murine and human hematopoietic progenitor cells in 
vitro and in vivo without perturbing the differentiation (Buske 2002). The Hoxb4 
gene is conserved in chimpanzee, dog, cow, mouse, rat, chicken, and zebrafish, 
and it is expressed in fetal and adult tissues. In situ hybridization analysis of 
mouse embryos showed that the Hoxb4 is expressed in tissues derived from the 
ectoderm: spinal cord, hindbrain, dorsal root ganglia, and the Xth cranial ganglia. 
In mesodermal derivatives, Hoxb4 is expressed in the kidney, the mesenchyme 
of stomach and lung, and the longitudinal muscle layer of the gut, whereas it is 
not detected in structures derived from embryonic endoderm (Graham 1988). At 
present, several screening methods have been employed to define consensus 
databases, which are based on all the reports where expression profiling results 
of known genes have been investigated. In the database of GeneSapiens 
(www.genesapiens.org) it is possible to obtain information about the 
transcriptome of human genes. In Fig. 1.3.3a and 1.3.3b the available data 
regarding the expression of Hoxb4 in normal tissues and in cancers are reported.  
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Brun et al have shown in Hoxb4-deficient mice that the lack of this gene leads to 
hypocellularity in hematopoietic organs (spleen and BM) and impaired 
proliferative capacity, demonstrating that it is not required for the generation of 
HSCs or the maintenance of normal hematopoiesis. In the murine model 
established from these authors the animals showed a reduction in red blood cell 
counts and in hemoglobin values, and a mild reduction in the numbers of 
primitive progenitors and stem cells in adult BM and fetal liver, whereas lineage 
distribution was normal. In these Hoxb4-deficient mice the primitive progenitors 
had normal cell cycle kinetics during endogenous hematopoiesis, whereas the 
proliferative capacity of BM Lin- Sca1+ c-kit+ stem and progenitor cells was 
reduced in vitro and in vivo after transplantation of BM and fetal liver derived 
stem cells.  
 
Fig. 1.3.3a. Expression of Hoxb4 in normal tissues. (www.genesapiens.org). 
 
Interestingly, in this mouse model the lack of Hoxb4 led to a change in the 
expression of several other Hox genes and of genes controlling the cells cycle 
regulation, as demonstrated by mRNA analysis from fetal liver (Brun 2004).  
Several others works have reported Hoxb4 overexpression in different types of 
cancer, like ovarian carcinoma (Hong 2010), cervical carcinoma (Lopez 2006), 
osteosarcoma, lung and breast carcinoma (Bodey 2000). However, the 
significance of these findings has still to be investigated. 
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Fig. 1.3.3b. Expression of Hoxb4 in cancers. (www.genesapiens.org). 
 
In the last decades many efforts have been focused to understand the regulation 
of Hoxb4 expression. The transcription factors NFY and YY1 have been reported 
to bind the promoter and two intron sequences of Hoxb4 regulating its expression 
during the embryonic development (Gilthorpe 2002). Additionally, the 
transcription factors USF-1, USF-2 and MITF have been shown to bind to the E-
box binding site within the Hoxb4 promoter. USF-1 and USF-2 induce Hoxb4 
expression in presence of signals to self-renew in stem cells downstream of 
activated MAPK pathway (Giannola 2000). Some promoter sequences seem to 
be determinant for the maintenance of the expression initiated by the intronic 
enhancer, whereas other sequences in the 3’ untranslated region (UTR) are 
responsible for the preservation of the specific and correct anterior boundary in 
the paraxial mesoderm throughout embryonic development. Other control 
mechanisms have been suggested to occur at transcriptional and post-
transcriptional levels. It has been shown that the 3’UTR is required to destabilize 
Hoxb4 transcripts, while the 5’UTR to stabilize them, although in different 
domains of the paraxial mesoderm (Brend 2003). Recently, the homeodomain 
transcription factor Prep1 has been shown to bind to the 3’UTR of the mRNA of 
Hoxb4 leading to the inhibition of its translation and the full length of the 3’UTR 
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has been shown to be necessary for this effect (Villaescusa 2009). Although the 
promoters and other controlling regions of the majority of Hox genes maybe 
contribute to the proper spatio-temporal regulation of these genes, their role in 
the development of cancer disease remain unknown. 
 
1.3.3.1 Hoxb4 in the hematopoiesis 
Several hox genes of the Hox A and B clusters, such as HOXB3 and HOXB4, are 
highly expressed in the most primitive hematopoietic cell types, like the CD34+ 
cells of the BM (Sauvageau 1994) (Fig. 1.3.3.1a). The engineered 
overexpression of Hoxb4 in hematopoietic progenitor cells induces a dramatic 
increase in the proliferation and self-renewal of HSCs without affecting the 
normal differentiation. Moreover, this gene is the only Hox gene, which is able to 
convert in vitro cultured progenitor cells from the early yolk sac and differentiating 
embryonic stem cells into HSCs capable to long-term engraft lethally irradiated 
primary and secondary recipient mice (Kyba 2002). In a recent report a Hoxb4-
YFP reporter mouse model has been used to investigate in detail its normal 
expression in the hematopoietic system, where it has been shown to be 
expressed in BM Lin-Sca1+c-kit+ cells, in AGM-derived CD45+CD144+ cells, in 
HSCs isolated from yolk sac and placenta, whereas its expression in the fetal 
liver HSCs was significantly lower than in the BM derived HSCs (Hills 2011). 
Despite these determinant reports on the Hoxb4 activity, the induced expansion 
of HSCs has not been yet completely clarified. 
In Fig. 1.3.3.1b the structures of the Hoxb4 gene (A) and Hoxb4 protein (B) are 
reported. 
 
CD34-CD34+/CD38low CD34+/
CD38m ed/high
HO XB4
HO XB3
HO XA10
Hem atopoietic Cell Num ber
 
 
 
 
 
Fig 1.3.3.1a. Expression of hox genes (HoxB3, B4 and A10) in human BM cells. Hox genes are 
expressed in early hematopoietic progenitor cells, and their expression decreases during the 
differentiation (Sauvageau 1994). 
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A) 
 
PBX-ID HD 
 
Fig. 1.3.3.1b. A) Structure of the Hoxb4 gene. B) Structure of Hoxb4 protein. PBX-ID: Pbx 
interaction domain; HD: homeodomain. 
 
In the protein sequence two known domains are present: the Pbx-interacting 
domain at position 142-147, and the homeodomain at position 163-218. As other 
Hox proteins, Hoxb4 dimerizes with the cofactor Pbx1. Mutational studies, where 
the Pbx-binding motif YPWM was mutated by the substitution W→G, have shown 
that the direct Hoxb4-Pbx interaction is not required for the HSC-expanding 
activity of Hoxb4, as mentioned above. Interestingly, the down-regulation of Pbx1 
through a vector encoding its antisense sequence led to a further increase of 
Hoxb4-mediated HSCs expansion. This suggests that these two genes might 
affect the hematopoietic cells behaviour by different mechanisms (Krosl 2003). 
The deletion of the homeodomain of Hoxb4 (substitution N→A) leads to the loss 
of its DNA-binding ability and thereby to the loss of its proliferation activity (Beslu 
2004). Between the amino acids 71 and 123 there is a proline rich region where 
no structural domains have been described so far. The function of this putative 
domain has been investigated in the present work.  
 
1.3.3.2 Hoxb4 as amplification tool of HSCs 
A number of Hox genes have been overexpressed using e.g. retroviral vectors in 
early murine as well as human hematopoietic progenitor cells, showing significant 
effects on the proliferation and differentiation programs. As unique Hox gene, 
Hoxb4 dramatically enhances the proliferation of primitive murine hematopoietic 
cells both in vivo and in vitro without perturbing their differentiation or the 
production of mature progeny (Thorsteinsdottir 1999, Kondo 2003). By retroviral 
transduction of primitive lineage-negative human cord blood cells, Hoxb4 has 
been shown to increase the number of secondary CFCs both in semisolid and 
142-147 118-123 163 218 
Proline-rich Region 
   71          88 
B) 
A)
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liquid suspension cultures, to amplify the number of cells with LTC-IC (long-term 
culture-initiating cells) activity, to promote the development of B cells in vivo, and 
to increase the number of cells able to repopulate NOD/SCID mice (Buske 2002). 
Moreover, the stable overexpression of Hoxb4 has been reported to considerably 
increase the hematopoietic development of human embryonic stem cells in vitro 
(Bowles 2006). Performing serial transplantations in mice Sauvageau et al have 
demonstrated that the Hoxb4-transduction of BM progenitor cells induces a 
50fold increase in the number of transplantable HSCs, compared to control cells 
(Sauvageau 1995). Additionally, when limiting dilution transplantation assays are 
performed, the long-term competitive repopulating units (CRUs) are amplified as 
well by Hoxb4 without leading to any impairment of homeostatic control of the 
HSCs population size or of the rate of production and maintenance of mature 
cells (Antonchuk 2001). All these observations have suggested that Hoxb4 could 
be used as tool to obtain a controlled amplification of genetically modified 
hematopoietic stem cells. However, the long term effect in the differentiation 
potential of this amplified HSCs need to be investigated, considering the 
impairment in lymphoid-myeloid differentiation observed when high-level ectopic 
Hoxb4 expression in human CB-CD34+ cells was induced (Schiedlmeier 2003). 
Since its identification, Hoxb4 has not been reported to display any involvement 
in hematologic malignancy, and its ectopic expression has been applied to 
amplify HSCs. However, in a recent report the retrovirus-mediated Hoxb4 
expression in hematopoietic repopulating cells led to monoclonal leukemia in 2 
out of 2 dogs and 1 out of 2 maquaques, approximately 2 years after 
transplantation (Zhang 2006, Zhang 2008). In these cases retroviral integration 
events were of clonal nature, affected the expression of oncogenes and were 
therefore suggested to be determinant for the leukemogenic process in 
collaboration with the ectopic overexpressed Hoxb4. This result confirms the risk 
of combining integrating vectors and proliferation-inducing genes for clinical 
application (Larochelle 2008). These considerations led to the development of a 
model for Hoxb4 protein delivery without genetic manipulation, ruling out the risk 
of retroviral integration-associated transformation. Since Hoxb4 protein can 
passively translocate through cell membrane, other researchers have cultured 
human LTC-ICs (long term culture-initiating cells) and NOD-SCID-repopulating 
cells (SRC) on stromal cells genetically modified to secrete Hoxb4, obtaining an 
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expansion of more than 20- and 2.5fold of these primitive HSCs over their input 
numbers, respectively (Amsellem 2003). In parallel to these investigations, the 
clinical established antiepileptic drug valproic acid (VPA) had been reported to 
enhance the potential of engraftment of human umbilical cord blood 
hematopoietic stem cells. Seet et al have shown that human VPA-treated 
CD45+CD34+ progenitor cells were able to reconstitute hematopoiesis in 
NOD/SCID mice with a six-fold higher efficiency than control cells. A probable 
explanation for this effect was the higher proportion of these cells residing in the 
S phase and the 2.5fold upregulation of Hoxb4 expression (Seet 2008). More 
recently, Tang et al have treated human BM cells from normal donors and from 
aplastic anemia/MDS patients with exogenous recombinant Hoxb4 protein, and 
reported a significant LTC-ICs expansion in vitro, therefore suggesting a 
promising therapeutic employment of human Hoxb4 in BM failure (Tang 2009). 
 
1.3.3.3 The proline-rich domain 
The N-terminal half of human Hoxb4 protein contains a proline rich region 
between aminoacids 71-123 (50% P). Among these residues there is a stretch of 
15 consecutive prolines, and a similar stretch occurs also in the Hoxb4 sequence 
from chimpanzee, cow, mouse and rat. The long proline stretch is not conserved 
in dog, chicken and zebrafish (Fig 1.3.3.3). Of note, the canine Hoxb4 protein is 
much longer than the human one (459 vs. 251 aa). In the panel below partial 
sequences of Hoxb4 proteins from different species are aligned. 
Homo sapiens    62  VQRYAACRDPGPPPPPPPPPPPPPPPGLSPRAPAPPPAG--ALLPEPGQR 109 
Pan troglodytes 62  VQRYAACRDPGPPPPPPPPPPPPPPPGLSPRAPAPPPAG--ALLPEPGQR  109 
Canis lupus      201  VQRYAACRDPGPPPPPSPH-------------PLCYTXG--ALLPEPGQR                  235 
Bos Taurus        62   VQRYAACRDPGPPPPQPPPPPPPPPPGLSPRAPAQPPSG--ALLPEPGQR109 
Mus musculus  62   VQRYAACRDPGPPPP-PPPPPPPPPPGLSPRAPVQPTAG--ALLPEPGQR  108 
Rattus norveg.  62   VQRYAACRDPGPPPP-PPPPPPPPPPGLSPRAPVQSTAG--ALLPEPGQR  108 
Gallus gallus     60   EQLYPSCQSSGHQAA-----------VLSPRGHVHPPAGLQSHLSEPNHP             98 
Danio rerio         60   DPPYSSCQGPGQPAA-----------VISPRGHVLPTTALSTPLPEPSHH               98 
Fig. 1.3.3.3. Comparison between proline regions of Hoxb4 of different species. 
 
Homology between human (h) and murine (m) protein sequence: 89% 
identity 
h- MAMSSFLINSNYVDPKFPPCEEYSQSDYLPSDHSPGYYAGGQRRESS FQPEAGFGRRAAC  
m-MAMSSFLINSNYVDPKFPPCEEYSQSDYLPSDHSPGYYAGGQRRESGFQPEAAFGRRAPC  
 
h- TVQRYAACRDPGPPPPPPPPPPPPPPPGLSPRAPA PPPAGALLPEPGQRCEAVSSSPPPP   
m-TVQRYAACRDPGPPPPPPPPPPPPPP- GLSPRAPVQPTAGALLPEPGQRSEAVSSSPPPP  
 
h- PCAQNPLHPSPSHSACKEPVVYPWMRKVHVSTVNPNYAGGEPKRSRTAYTRQQVLELEKE  
m-PCAQNPLHPSPSHSACKEPVVYPWMRKVHVSTVNPNYAGGEPKRSRTAYTRQQVLELEKE  
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h- FHYNRYLTRRRRVEIAHALCLSERQIKIWFQNRRMKWKKDHKLPNTKIRSGGAAGSAG 
m-FHYNRYLTRRRRVEIAHALCLSERQIKIWFQNRRMKWKKDHKLPNTKIRSGGTAGAAG 
 
h- GPPGRPNGGPRAL  
m-GPPGRPNGGPPAL  
 
Interestingly, through all these species Hoxb4 presents several WW(/SH3) 
domains, which have been described to be responsible for binding to specific 
protein interaction modules, like RPLPPLP in Src or PPPψPPPPψP in Abl 
proteins (Kay 2000), and the p300 binding consensus sequences PXXPXXP in 
Smad4, PXXP in p53, and PXPXP in EKLF (Dornan 2003). Of note, the proline 
repeat domain of p53 (PXXP/PXPXP, where X denotes any amino acid) has 
been suggested to bind directly to the transcriptional activator p300, and mediate 
the DNA-dependent acetylation of p53 (Dornan 2003). This domain seems to 
play a critical role in the transmission of anti-proliferative signals downstream of 
the p53 protein (Walker 1996), and it has been suggested to maintain the latent, 
low affinity DNA binding conformation of p53 (Müller-Tiemann 1998). The proline 
is a critical amino acid present in many ligands responsible for protein-protein 
interactions. Different proline-rich sequences that bind to specific protein 
interaction molecules have been described (Kay 2000) and transcriptional 
activation domains are often rich in Ser, Thr and Pro residues. A significant 
example is represented by the proline-rich N-terminal half of Hoxd4, which has 
been reported to exert a transcriptional activation function in a system where it 
was fused to the GAL DNA-binding domain (Rambaldi 1994). These observations 
were supported by other deletion analyses, where conserved regions flanking the 
homeodomain have been reported to be necessary for the Hoxd4-mediated 
activation. Interestingly, the transcription factor AP2 contains a proline-rich 
transcriptional activation domain, and has been shown to inhibit the activity of 
Hoxd4. AP2 and Hoxd4 contain functionally similar proline-rich transcriptional 
activation domains, and AP2 is expressed in a similar spatial and temporal 
pattern as many hox genes during the development. Based on these similarities, 
Hox proteins and AP2 have been proposed to collaborate during the embryonic 
development (Rambaldi 1994).  
In the protein databases a proline stretch similar to the one present in Hoxb4 can 
be found in few other unrelated proteins, like in the murine formin 1; in the 
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essential capsid protein Mv-ORF2 of MNPV baculovirus; in the MGC82812 
protein of X.laevis, in a putative protein of Monodelphis domestica; in a protein 
similar to JUN in Gallu gallus genome; in a putative membrane protein of 
Emiliana huxleyi virus 86; in an unnamed protein in Tetraodon nigroviridis. The 
role of the proline reiterations in all these proteins remains unknown, although for 
the formin-1 for example it has been reported to induce the production of many 
circular transcripts. 
Interestingly, in the USCS genome databases several human ESTs of Hoxb4 
have been reported: in the human adult and fetal lung tissue a sequence starting 
after the proline-rich region has been described by Bonaldo et al (Bonaldo 1996, 
BM972326, EST AW182319, www.ncbi.nlm.nih.gov/ncicgap.). The importance of 
this P stretch for the function of all these proteins remains unclear.  
 
1.3.3.4 The downstream targets of Hoxb4 
Many efforts have been done to understand the regulation and function of Hox 
genes, however their downstream targets remains often unknown. Several 
studies have reported a number of factors affected by Hoxb4 expression, which 
are involved in similar signalling pathways in differentiating ES cells and in adult 
HSCs. A recent work based on ChIP-chip analysis showed, that Hoxb4 binds to 
promoter regions of many genes involved in cell division, cell cycle, and 
chromosome organization and biogenesis, without direct binding to HSC 
regulatory genes. However, among these genes Myb, Erg, Gfi1b, Gata3, and 
Sox17 seem to be indirectly regulated by Hoxb4 (Oshima 2011). Other factors 
have been previously reported to be activated by Hoxb4, like Bambi, a 
pseudoreceptor that also inhibits the TGF-β and BMP signalling, and the TALE 
class homeodomain gene Irx5, which seems to direct repress the epidermal 
development factor BMP4 in Xenopus (Schiedlmeier 2007, Theokli 2003). 
Others, like the small GTPase Rap1 expressed early in the gastrulation, are 
negatively regulated by Hoxb4 (El-Kadi 2002). Another interesting finding about 
the Hoxb4 function in zebrafish suggested a correlation between the clustering of 
hox genes and post-transcriptional regulation of downstream genes. Woltering et 
al have shown that the microRNA-10, which is located closely to Hox-4 
paralogues, acts to repress Hoxb1a and Hoxb3a within the spinal cord, and that 
this repression works cooperatively with Hoxb4 (Woltering 2008).  
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Taken together, all these results suggest that Hoxb4 is involved in important 
endogenous cellular pathways modulating the cell cycle, differentiation, and 
apoptosis processes of progenitor cells, whereas it modulates the reaction of 
HSCs and EB cells to exogenous stimuli derived by the microenvironment (Fig 
1.3.3.4). In the present work we compared the in vitro and in vivo effect of the 
mutation of different domains of Hoxb4 in a murine BM transplantation model.  
 
Fig 1.3.3.4. Important regulatory pathways affected by Hoxb4 in adult hematopoietic stem and 
progenitor cells and EBs. (LSK: lineage-/Sca1+/ckit-; EB: embryoid bodies). These results are 
based on microarray expression profiling analyses using Affimetrix GeneChips Mouse Genome 
430 2.0. Affiliations of the genes with the indicated pathways are based on published reports in 
various mammalian systems. Arrows indicate up-/down-regulation of gene expression as a 
consequence of Hoxb4 induction (Schiedlmeier 2007). 
 
1.4 Epigenetic changes in cancer 
The cancer development is the result of a stepwise process characterized by the 
accumulation of heritable changes leading to growth advantage, and eventually 
to therapy resistance.  
The most relevant gene classes involved in this process are the tumor 
suppressor genes, which become inactivated and cannot inhibit survival and cell 
growth, and the oncogenes, which become activated and promote survival and 
proliferation. Often a combined alteration of one or more genes belonging to both 
classes leads to malignant transformation. These alterations include changes in 
the number of gene copies and in the protein sequence, or increased gene 
transcription. Another class of alterations includes covalent modifications of 
amino acids residues of histone proteins (e.g. acetylation), and methylation of 
cytosine residues within CpG dinucleotides (called “CpG-islands”) in the DNA 
(Fig. 1.4). These modifications are called epigenetic changes, they include 
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mitotically and meiotically heritable variations without alteration of the primary 
DNA sequence, and a growing body of evidence relates them closely to cancer. 
In particular, the methylation of clusters of CpGs in the promoter of genes has 
been associated with heritable gene silencing. However, the epigenetic 
alterations are reversible, whereas the genetic alterations are not. The 
mechanisms of gene silencing induction are not yet completely understood, but it 
is already known that a group of repressive proteins (the methyl-CpG-binding-
domain proteins, MBDs) binds to methylated cytosines, and this complex seems 
to involve histone deacetylases (HDACs). These enzymes remove acetyl groups 
from lysines of histones, conferring them a positive charge which enhances their 
affinity for negatively charged DNA. This leads to a dense packaging of the 
nucleosomes and therefore to a reduced transcription (“closed chromatin 
structure”).  
In opposite cellular contexts where the cytosines are not methylated, the histone 
acetyltransferases (HATs) transfer acetyl groups to histone proteins leading to 
activation of transcription of target genes in collaboration with transcription factors 
and other co-factors (Gronbaek 2007). CBP (CREB binding protein) and p300 
seem to mediate the transcription control exerted by Hox proteins leading to the 
expresson of target genes (“open chromatin structure”) (Ito 2000).  
 
Fig 1.4. Chromatin structure of active and inactive promoters of targeted genes (Gronbaek 2007). 
 
1.4.1. Histone deacetylases (HDACs) 
Histone deacetylases (HDACs) catalyze the deacetylation of lysine residues 
within DNA bound core histone proteins (Lopez 1993). These enzymes work in 
opposition to histone acetyltransferases (HATs), which catalyze lysine acetylation 
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(Kuo 1998). The HDACs can deacetylate several proteins in particular cellular 
contexts (Glozak 2005). In mammals 18 different HDACs have been identified, 
which are classified into four classes based upon their homology with an 
archetypal HDAC found in yeast, and have been reported to control different 
cellular processes (Fig. 1.4.1a). 
 
Fig. 1.4.1a . Classes of mammalian HDACs. Different classes can be inhibited by different HDAC 
inhibitors (Mariadason 2008).  
 
HDACs do not directly bind to DNA, whereas they are part of high molecular 
weight (1-2MDa) multimeric transcriptional co-repressor complexes that are 
recruited by sequence-specific transcription factors to promoter regions. Different 
co-repressor complexes recruit different HDACs. Functionally, two different 
mechanisms have been suggested to mediate the gene expression control by 
HDACs: the acetylation of histones and the acetylation of sequence-specific 
DNA-binding transcription factors (Fig 1.4.1b) (Gu 1997; Ammanamanchi 2003). 
Acetylation or de-acetylation of transcription factors can either increase or 
decrease their DNA binding activity, leading to enhanced or repressed 
transcription. The substrates of HDAC are proteins involved in gene expression, 
cell proliferation, differentiation and apoptosis, but they can also deacetylate a 
number of non-histone proteins, that are not involved in transcription processes, 
like signal transduction mediators, DNA repair enzymes, nuclear import 
regulators, chaperone proteins, structural proteins, inflammation mediators and 
viral proteins (Glozak 2005).  
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Fig. 1.4.1b. Non-histone substrates for class I and II HDACs (Mariadason 2008). 
 
 
1.4.2 Histone deacetylase inhibitors (HDACi)  
In the last decades, inhibition of HDACs has emerged as additional strategy to 
reverse aberrant epigenetic changes associated with cancer, and several classes 
of HDACi have been found to have potent and specific anticancer activities in 
preclinical studies. Since the 1990s the inhibition of HDACs has been shown to 
suppress tumor cell growth/survival, to induce growth arrest, differentiation and 
apoptosis of cancer cells ex vivo as well as in vivo in tumor-bearing animal 
models and are included in clinical trials as anti-tumor agents (Richon 1998, 
Insinga 2005, Kim 2004). Moreover, the HDACi have been shown to display anti-
angiogenetic, anti-invasive and immunomodulatory activities in vitro and in vivo. 
They have been also shown to induce teratogenesis, and this effect is also 
mediated by the inhibition of histone deacetylases (Eikel 2006) (Fig 1.4.2).  
 
Fig 1.4.2. Multiple HDAC inhibitors-activated antitumor pathways (Xu 2007).  
 
In the present work the HDAC-inhibitor valproic acid (VPA, 2-propylpentanoic 
acid), which is an established drug in the long-term therapy of epilepsy, has been 
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used to treat hematopoietic progenitor cells overexpressing Hoxb4 and its 
mutants. Göttlicher et al had already shown that at the therapeutically employed 
doses VPA inhibits co-repressor-associated HDACs and strongly induces the 
differentiation in several types of transformed cells (Göttlicher 2001, Kramer 
2003, Liu 2007, Münster 2007). The treatment thereby with VPA could unmask 
the key role of the HDAC-activity in the transformation process of cancer cells. 
 
1.5 The murine bone marrow transplantation model of leukemia 
At present a number of mouse models, like ubiquitous or conditional knock-ins 
and knock-outs, targeted and random in vivo gene perturbation, retrovirally 
transduced bone marrow transplantation of irradiated recipient mice and 
transgenic mouse models, have been reported to represent reliable and 
reproducible systems to investigate the pathogenesis of leukemia at molecular 
level. The murine bone marrow transplantation model used in the present work is 
based on ex vivo retroviral gene transfer of primary 5-flurouracil (5-FU)-enriched 
hematopoietic progenitor cells and on their subsequent transplantation into 
lethally irradiated syngenic mice. The treatment with 5-FU 4 days prior bone 
marrow collection from donor mice aims to reduce the pool of proliferating 
progenitor cells inducing the activation of more primitive HSCs to reconstitute it, 
and thereby making these HSCs more susceptible to the retroviral transduction.  
Several studies have demonstrated that ectopic overexpression of proto-
oncogenes (Rawat 2004) and of proto-oncogenes combinations (Kelly 2002a, 
Kelly 2002b) can induce acute leukemia in mice using this model, and most 
importantly, this disease maintain the characteristics of the corresponding human 
leukemias. Single genes which are known to be mutated in human leukemias can 
be singularly investigated for their leukemogenic potential, whereas it is possible 
at the same time to identify potential cofactors collaborating to the 
leukemogenesis, which have not been yet identified in the primary leukemic 
human samples.  
For example, the retrovirally induced overexpression of the fusion gene AML1-
ETO or of the mutant FLT3-ITD alone fails to induce leukemic transformation in 
vivo. However, in a mouse model where these two genes were coexpressed the 
complete leukemic transformation has been observed, in primary, secondary and 
tertiary murine recipients. This suggests that these two genes could collaborate 
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even in human leukemia development (Schessl 2005, Palmqvist 2006). With the 
murine transplantation models it is possible to investigate the subset of cells 
giving rise to the leukemic bulk, and thereby to identify single events responsible 
for the leukemic transformation and additional mutations necessary for the full 
leukemic transformation. One example is done by the leukemia model 
established in our laboratory, where the overexpression of the CALM/AF10 fusion 
gene led to a myeloid leukemia that was propagated by a lymphoid progenitor 
cell. In these experiments, the hierarchy within the leukemic stem cells have been 
described (Deshpande 2006).  
Moreover, these models are of use for the identification of key regulators of 
normal hematopoiesis, which are disrupted in the leukemias or other hematologic 
malignancies.  
The hematopathology subcommittee of the Mouse Models of Human Cancers 
Consortium has proposed a classification of nonlymphoid hematopoietic 
neoplasms in mice, in order to provide recommendations for classification of 
mouse diseases as models for the human hematopoietic neoplasms. In this 
proposal the murine non-lymphoid leukemias have been subclassified in myeloid 
(without maturation, with maturation, MPD-like, myelomonocytic, monocytic), 
erythroid, megakaryocytic, and biphenotypic leukemias (Kogan 2002). 
We used the retroviral mediated murine bone marrow transplantation model to 
investigate the leukemogenic potential of the hox gene HOXB4 and its mutants. 
Additionally, we investigated by mutagenesis the importance of its single domains 
in the normal function of this powerful stem cell specific gene.  
 
1.6 Aim of the study 
Hoxb4 has been described as one of the most important factors responsible for 
the proliferative potential and self-renewal of hematopoietic stem cells in vivo and 
in vitro models. Nowadays, the regulatory mechanisms and the downstream 
pathways controlled by Hoxb4 are not completely understood. In many reports 
Hoxb4 has been employed as exogenous protein or as engineered expressed 
gene to obtain an ideal amplification of stem cells ex vivo, in order to ensure a 
sufficient pool of transplantable HSCs in BM transplantations. Until now few 
reports have underlined this gene as a potential factor involved in the 
leukemogenic process, and these were almost based on integration events using 
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retroviral transduction systems. However, the contribution of Hoxb4 to the 
transformation in these cases was probably reduced to the increased proliferation 
of a subset of cells already mutated by a genomic mutation.  
In the present work we attempted to clarify the mechanism responsible of the 
benign phenotype observed in high proliferating hematopoietic progenitor cells 
where Hoxb4 is overexpressed and which domain of its structure might avoid the 
unregulated and aberrant proliferation of the HSCs. In particular we investigated 
the less known proline rich region at the N-terminal sequence of Hoxb4 and the 
leukemogenic effect of its deletion in a murine transplantation model. We 
hypothesized that, like already known for other proteins, the proline domain 
maybe displays transactivation activity which might mediate the downstream 
effects of Hoxb4. This work is giving more insights in the complicated machinery 
of the normal phenotype of the stem cells and contributes to understand the fine 
regulated biology of the BM progenitor cells, which if deregulated results in the 
leukemic development. Moreover, the employment of drugs inhibiting putative 
cofactors of Hoxb4 like the histone deacetylases could help to define new 
potential targets responsible for the malignant transformation in our model. 
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2. Materials 
2.1 Mice and related reagents and equipment  
Mice strains: strains used as bone marrow transplant donors/recipients were 
either C57Bl6/Ly-Pep3b (Pep3b) or the F1 hybrid of (C57BL/6Ly-Pep3b x C3HeJ) 
([PepC3]F1, Ly5.1/CD45.1 positive) or hybrid of (C57Bl/6J x C3H/Hej) ([B6C3]F1, 
Ly5.1/CD45.1 negative).  
Avertin solution: Stock solution was prepared by adding 15.5 ml ter-amyl 
alcohol to 25 grams Avertin (2-2-2 Tribromoethanol) (both Sigma-Aldrich®, St. 
Louis, MO) and dissolved overnight. For working solution, 0.5 ml of the stock 
solution was added to 39.5 ml of cell culture grade phosphate buffered saline 
(PBS) and dissolved with a magnetic stirrer.  
Erythrocytes lysis buffer: 0.8% NH4Cl with 0.1 mM EDTA (Stem Cell 
Technologies, Vancouver, Canada). 
Formalin: 10% solution of formaldehyde (Sigma-Aldrich®, St. Louis, MO) in 
water.  
5-Fluorouracil: 50 mg/ml stock solution (Medac, Hamburg, Germany). Working 
solution was 6 ml of the solution above mixed with 4 ml of phosphate buffered 
saline. 
Heparinized capillaries: plastic capillaries (Microvette CB 300) for collection of 
blood, 15 I.E. Lithium heparin per ml of blood (Sarstedt, Numbrecht, Germany). 
Sterile needles: 24 G (0.55 x 25 mm) for bone marrow aspiration from the femur 
of living mice, 25 G (0.5 x 25 mm) for i.v. injection of cells in mice and flushing of 
bone marrow from prepared bones, and 30 G (0.3 x 13 mm) for i.p. injection of 
avertin (BD Microlance, Drogheda, Ireland).  
Syringes: BD Plastipak 1 ml syringe (BD Biosciences, Palo Alto, CA) for injection 
of cells in mice and Kendall Monoject 3 ml syringes (Tyco Healthcare, UK) for 
bone marrow flushing and plating of CFCs. The stubs of 3 ml syringes were used 
to macerate the spleens and other organs of mice. 
Telleyesnickzky´s solution: 450 ml absolute ethanol + 25 ml glacial acetic acid 
+ 25 ml formaldehyde. 
 
2.2 Mammalian cell lines and prokaryotic cells 
GP+E86:   mouse fibroblast cell line, stable packaging cell line 
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293T:  human embryonic kidney cell line, transient packaging cell  
lines 
Phoenix Eco: 293T mouse cell line, stable packaging cell line 
NIH 3T3:  mouse fibroblast cell line 
32D mouse bone marrow-derived myeloblast cell line, IL-3 
dependent 
BA/F3  mouse bone marrow-derived pro-B cell line, IL-3 dependent 
WEHI-3B  mouse myelomonocytic leukemia cell line, producing IL-3  
K562   human chronic myelogenous leukemia cell line 
Jurkat:  acute T cell leukemia cell line 
HL-60:  acute promyelocytic leukemia cell line  
All cell lines were procured from the American Type Culture Collection (ATCC™, 
Manassas, USA), and from DMSZ GmbH (German collection of microorganisms 
and cell culture, Braunschweig, Germany). 
Escherichia coli epicurian XL1-Blue: subcloning bacterial competent cells 
(Stratagene® La Jolla, CA). 
 
2.3 Oligonucleotides (Metabion, Martinsried, Germany) 
Oligonucleotide  Sequence 5´to 3´ 
EF1a_fw   CAC GAA CAG CAA AGC GAC C 
EF1a_rev   CAC ACG GCT CAC ATT GCA T 
Hoxb4_inter_fw  TGA TCA ACT CAA ACT ATG TCG AC 
Hoxb4_inter_rev  ACT TGT GGT CTT TTT TCC ACT TCA T 
Hoxb4_n_211_s fw CAAGATCTGGTTCCAGAGCCGGCG CAT GAA GTG 
Hoxb4_n_211_s rev CACTTCATGCGCCGGCTCTGG AAC CAG ATC TTG 
Hoxb4_W_144_A fw CGTCGT CTA CCC CGC GAT GCG CAA AGT TCA C 
Hoxb4_W_144_A rev GTGAACTTT GCG CAT CGC GGG GTA GAC GAC G 
Hoxb4_C-del_ fw GTGGAAAAAAGACCACTAGTTGCCCAA CACCAAG 
Hoxb4_C-del_ rev  CTTGGTGTTGGGCAACTAGTG GTC TTTTTTCCA C 
Hoxb4_full lenght_ fw GAG TCA GGG GTC GGA ATA AA 
Hoxb4_full lenght_ rev CCA TCC CCT GCA CTC ACT 
Hoxb4_alternEST_fw CACTCCGCGTGCAAAGAG 
Hoxb4_Bowles_fw  TCT GTC CCC TCG GGC TCC TGC G 
Hoxb4_Bowles_rev  GGC AAC TTG TGG TCT TTT TTC C 
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LM-PCR primers  Sequence 5´ to 3´ 
GFP-A   ACT TCA AGA TCC GCC ACA AC 
GFP-B   ACA TGG TCC TGC TGG AGT TC 
Vectorette primer 224 CGA ATC GTA ACC GTT CGT ACG AGA ATC GCT 
Nested linker primer B TAC GAG AAT CGC TGT CCT CTC CTT 
PstI linker top  CTCTCCCTTCTC-----------GTCCTCTCC TTC CTG CA 
PstI linker bottom GGAAGGAGAGGACGCTGTCTGTCGAAGGTAAGGA 
ACGGACGAGAGAAGGGAGAG 
 
2.4 Plasmids, genes and proteins 
pMSCV-IRES-GFP (MIG): A modified form of the MSCV vector of 6500 bp; it 
contains a bicistronic GFP expression cassette with an internal ribosomal entry 
site (R. Hawley, American Red Cross, Rockville, MD). The selection marker for 
bacterial growth is ampicillin resistance gene. Upstream of the multiple cloning 
site there is the packaging signal (ψ_plus_pack sequence). 
pMSCV-HOXB4-IRES-GFP: the HOXB4 cDNA region encompassing the 
complete coding sequence has been subcloned by blunt-end ligation into the 
HpaI site in the multiple cloning site (MCS) of the MIG vector (kindly provided by 
Dr. K. Humphries, Terry Fox Laboratory, Vancouver, Canada).  
HOXB4-wt: the Hoxb4 gene (2042 bp) is located in the HOXB cluster on 
chromosome 17q21-q22 (44,009,083-44,010,680, NM_024015) and it contains 2 
exons and 1 intron sequences.  
pMSCV-Flag-HOXB4-∆Pro-IRES-GFP: encodes a mutant of Hoxb4 containing 
the 2 exons, a deletion from amino acidic position 78-120, a flag epitope has 
been cloned in frame at the 5’ end and the 5’ and 3’ UTR sequences are missing 
(kindly provided by Dr. K. Humphries, Terry Fox Laboratory, Vancouver, 
Canada).  
 
Protein sequences of generated HOXB4 mutants  
(PBX-ID and HD are underlined): 
Hoxb4-wt     1 MAMSSFLINSNYVDPKFPPCEEYSQSDYLPSDHSPGYYAGGQRRESSFQPEAGFG 55  
Hoxb4∆Pro  1 MAMSSFLINSNYVDPKFPPCEEYSQSDYLPSDHSPGYYAGGQRRESSFQPEAGFG 55   
Hoxb4-Pbx   1 MAMSSFLINSNYVDPKFPPCEEYSQSDYLPSDHSPGYYAGGQRRESSFQPEAGFG 55   
Hoxb4-cDel  1 MAMSSFLINSNYVDPKFPPCEEYSQSDYLPSDHSPGYYAGGQRRESSFQPEAGFG 55   
Hoxb4-HD    1 MAMSSFLINSNYVDPKFPPCEEYSQSDYLPSDHSPGYYAGGQRRESSFQPEAGFG 55    
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56 RRAACTVQRYAACRDPGPPPPPPPPPPPPPPPGLSPRAPAPPPAGALLPEPGQRCEAVSSSPPPP  120 
56  RRAACTVQRYAACRDPGPPPP---------------------------------------------------------------------------------------    76 
56  RRAACTVQRYAACRDPGPPPPPPPPPPPPPPPGLSPRAPAPPPAGALLPEPGQRCEAVSSSPPPP120 
56  RRAACTVQRYAACRDPGPPPPPPPPPPPPPPPGLSPRAPAPPPAGALLPEPGQRCEAVSSSPPPP120 
56  RRAACTVQRYAACRDPGPPPPPPPPPPPPPPPGLSPRAPAPPPAGALLPEPGQRCEAVSSSPPPP120 
 
121 PCAQNPLHPSPSHSACKEPVVYPWMRKVHVSTVNPNYAGGEPKRSRTAYTRQQVLELEKE  180 
77   PCAQNPLHPSPSHSACKEPVVYPWMRKVHVSTVNPNYAGGEPKRSRTAYTRQQVLELEKE  136 
121 PCAQNPLHPSPSHSACKEPVVYPAMRKVHVSTVNPNYAGGEPKRSRTAYTRQQVLELEKE   180 
121 PCAQNPLHPSPSHSACKEPVVYPWMRKVHVSTVNPNYAGGEPKRSRTAYTRQQVLELEKE  180 
121 PCAQNPLHPSPSHSACKEPVVYPWMRKVHVSTVNPNYAGGEPKRSRTAYTRQQVLELEKE  180 
 
181 FHYNRYLTRRRRVEIAHALCLSERQIKIWFQNRRMKWKKDHKLPNTKIRSGGAAGSAGGP  240 
137 FHYNRYLTRRRRVEIAHALCLSERQIKIWFQNRRMKWKKDHKLPNTKIRSGGAAGSAGGP  196 
181 FHYNRYLTRRRRVEIAHALCLSERQIKIWFQNRRMKWKKDHKLPNTKIRSGGAAGSAGGP  240 
181 FHYNRYLTRRRRVEIAHALCLSERQIKIWFQNRRMKWKKDH-Stop  221 
181 FHYNRYLTRRRRVEIAHALCLSERQIKIWFQSRRMKWKKDHKLPNTKIRSGGAAGSAGGP  240 
 
241 PGRPNGGPRAL  251     (27,6 KDa, 18,6% P) 
197 PGRPNGGPRAL  208   (23,4 KDa, 11,6% P) 
241 PGRPNGGPRAL  251   (27,6 KDa, 18,6% P) 
     (24,8 KDa, 18,6% P) 
241 PGRPNGGPRAL  251   (27,6 KDa, 18,6% P) 
 
Refence sequences of HOXB4 (protein accession 
numbers,www.ncbi.nlm.nih.gov): 
Human (NP_076920.1), chimpanzee (XP_001173043.1), dog (XP_851159.1), 
cow (NP_001071582.1), mouse (NP_034589.1), rat (XP_573184.1), chicken 
(NP_990624.1), zebrafish (NP_571193.1). 
pEcopac: A packaging vector coding for the gag, pol, and env viral proteins. 
(Clontech, Palo Alto, CA). 
pGEM®-T Easy Vector: A cloning vector to amplify PCR products, encoding 
beta-lactamase (Promega Corporation, Madison, WI, USA). 
 
2.5 Antibodies 
Name Company Label Dilutions  
Gr-1 BD Pharmingen, Heidelberg PE/APC 1:500 
CD11b (Mac1) BD Pharmingen, Heidelberg PE/APC 1:800 
Sca-1 BD Pharmingen, Heidelberg PE 1:150 
Ter119 BD Pharmingen, Heidelberg PE 1:150 
B220 BD Pharmingen, Heidelberg PE/APC 1:200 
CD4 BD Pharmingen, Heidelberg PE 1:150 
CD117 (c-kit) BD Pharmingen, Heidelberg APC 1:500 
CD8 BD Pharmingen, Heidelberg APC 1:150 
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CD3 BD Pharmingen, Heidelberg PE 1:200 
CD45.1 (Ly 5.1) BD Pharmingen, Heidelberg Biotin 1:200 
CD90.1/Thy1.1 
CD135/Flk-2 
HOXB4 (N-18), 
goat 
BD Pharmingen, Heidelberg 
BD Pharmingen, Heidelberg 
Santa Cruz Biotech. Inc., CA 
APC 
PE 
- 
1:200 
1:200 
1:100 
GFP Molecular Probes Inc., OR - 1:5000 
Anti-FLAG M2 Sigma-Ald. Inc., St Louis, MO - 1:3000 
N-term. FLAG-BAP Sigma-Ald. Inc., St Louis, MO - Ctrl.  
Anti-actin (I-19) Santa Cruz Biotech. Inc., CA HRP 1:200 
Goat Anti-Mouse  Invitrogen, Carlsbad, CA HRP 1:2000 
Anti-Goat Santa Cruz Biotech. Inc., CA HRP 1:500 
Anti-goat Invitrogen, Carlsbad, CA Alexa  Fluor®488
Anti-mouse Invitrogen, Carlsbad, CA Alexa  Fluor®555
 
2.6 Reagents, media and apparatus 
2.6.1. Molecular biology 
Agarose: Molecular biology tested (Sigma-Aldrich, St. Louis, MO). 
Acrylamid-Bisacrylamid: 30% solution (29:1), Rotiphorese® (Roth, Karslruhe, 
Germany) 
Ammonium persulfate: 10% solution in water (Fluka, Buchs, Schweiz). 
Bradford reagent: Bio-Rad protein assay dye (Bio-Rad, Hercules, CA, USA). 
Bromphenol blue: 4X solution for protein loading (Sigma-Aldrich, St. Louis, MO). 
BSA: Bovine serum albumin (NEB, Beverly , MA, USA).  
1,4-Dithiothreitol: or Clelands reagent, antioxidant reagent (Sigma-Aldrich, St. 
Louis, MO). 
EDTA: (ICN Biomedicals, Aurora, OH, USA).  
Enzymes: Ligase, Calf intestine phosphatase, Xho I, KpnI, NdeI, Xba, PmlI, DpnI, 
Eco RI, PstI (New England Biolabs, Beverly, MA). 
Ethidium bromide: stock solution 10 mg/ml (Roth, Karlsruhe, Germany).  
Ethanol, Methanol, and Isopropanol (Merck, Darmstadt, Germany). 
DNeasy mini kit: Genomic DNA extraction kit for small cell numbers (Qiagen 
GmbH, Hilden, Germany). 
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Small-scale plasmid preparation: GFX miniprep kit for isolation of plasmid DNA 
from bacteria (Amersham Biosciences GmbH, Freiburg, Germany) 
Gel Elution of DNA and PCR or DNA clean up: GFX gel elution and PCR 
purification kit for DNA elution from gels and clean up of PCRs (Amersham 
Biosciences GmbH, Freiburg, Germany). 
Propidium Iodide: nucleic acid stain, stock solution 1 mg/ml (Sigma-Aldrich, St. 
Louis, MO). 
Protamine sulfate: (Salamine) from Salmon, cell culture tested, 5 mg/ml stock 
solution (Sigma-Aldrich, St. Louis, MO).  
Protein G-Sepharose: immunoglobulin binding protein (Invitrogen Carlsbad, CA, 
USA). 
 
Southern blot: Microspin S-300 HR columns and Megaprime DNA labeling 
system (Amersham Biosciences GmbH, Freiburg, Germany). 
Pre-hybridization solution: 0.2 g skimmed milk and 2.0 g dextran sulphate were 
dissolved in 17 ml water and 6ml 20 X SSC, 2 ml formamide, 1 ml 20% SDS and 
80 µl 500 mM EDTA were added to the mixture. (All chemicals were individually 
obtained from Sigma-Aldrich, St. Louis, MO). 
Denaturation solution: A solution of 1.5 M NaCl, 0.5 N NaOH in water. 
20X SSC: 175.3 g sodium chloride and 88.2 g sodium citrate were dissolved in 
800 ml deionised water and pH adjusted to 7.0 and the final volume to one liter. 
DNA Crosslinking: GS Gene linker UV chamber (BIO-RAD Laboratories, 
Hercules, CA) 
 
Western blot: ECL Western blotting analysis system (Amersham Biosciences 
GmbH, Freiburg, Germany). 
Gel blotting membrane: Protran® BA 85 (Schleicher und Schnell, Dassel, 
Germany). 
Gel blotting paper: GB003 pore size 0,45 μm (Schleicher und Schnell, Dassel, 
Germany). 
Skim milk powder: (Merck KGaA, Darmstadt, Germany). 
Tween: (Merck KGaA, Darmstadt, Germany). 
Orthovanadate: protein phosphatase inhibitor, stock solution 100 mM (Sigma-
Aldrich, St. Louis, MO). 
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PMSF: phenylmethylsulfonyl fluoride, protein phosphatase inhibitor, stock 
solution 100 mM (Sigma-Aldrich, St. Louis, MO). 
Aprotinin: protease inhibitor, stock solution 10 mg/ml (Sigma-Aldrich, St. Louis, 
MO). 
Acrylamide/bisacrylamide: Rothiphorese® Gel 30% (37.5:1) 
 
Total RNA and genomic DNA isolation: Total RNA isolation reagent (TRIzol®) 
and Genomic DNA isolation reagent DNAzol® (Invitrogen, Carlsbad, CA). 
Alternatively, the RNA has been purified using the RNeasy Mini kit (Qiagen 
GmbH, Hilden, Germany). 
Molecular weight markers: Nucleic acid size standards, 1 kb ladder, 1 kb plus 
ladder and 100 bp ladder (Invitrogen, Carlsbad, CA), Rainbow. 
RT and PCR: Platinum® Taq DNA polymerase kit, Pfu Turbo DNA polymerase, 
ThermoScript™ kit, RT-PCR kit and DNaseI DNA inactivating enzyme kit (all from 
Invitrogen, Carlsbad, CA); PCR soft tubes (0.2 ml) (Biozym Scientific GmBH, 
Hessisch Oldendorf, Germany). 
Real time PCR kit: LightCycler® FastStart DNA Master SYBR green I kit (Roche 
Diagnostics, Mannheim, Germany), LightCycler® Carousel and carousel 
centrifuge (Roche Diagnostics, Mannheim, Germany). 
dNTP mix: 10 mM each of dATP, dTTP, dCTP and dGTP (Invitrogen, Carlsbad, 
CA). 
TEMED: Tetramethylethylenediamine (Bio-Rad, Hercules, CA, USA). 
 
2.6.2 Cell and tissue culture 
Ammonium chloride: RBC lysis buffer, 0.8% NH4Cl, 0.1 mM EDTA (Stem Cell 
Technologies, Vancouver, Canada). 
Ampicillin: stock solution 100 mg/ml in water; working solution 100 μg/ml in LB 
medium (Roth, Kalrsruhe, Germany).  
Hepes Buffered Saline: (HBS) (Invitrogen, Carlsbad, CA).  
Filtration units: Millex syringe driven filter units 0.22 μm and 0.45 μm filters 
(Millipore, Billerica, MA).  
Methylcellulose media: MethoCult® M3434 for the culture of myeloid CFC assays 
(Methylcellulose in Iscove's MDM, Fetal Bovine Serum, Bovine Serum Albumin, 
rh-Insulin, Human Transferrin (Iron saturated), 2-Mercaptoethanol, L-glutamine, 
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rm-Stem Cell Factor, rm-IL-3, rh-IL-6, rh-Erythropoietin) and MethoCult® M3630 
for the pre-B CFC assays (Methylcellulose in Iscove's MDM, Fetal Bovine Serum, 
2-Mercaptoethanol, L-glutamine, rh-IL-7) (Stem Cell Technologies, Vancouver, 
Canada).  
Cell strainer: BD Falcon 40 μm Nylon strainer for macerating the spleen and 
filtering the tissue (BD Biosciences, Palo Alto, CA). 
Cell scrapers: 25 cm sterile cell scrapers (Sarstedt, Newton, NC). 
Cell culture pipettes: Sterile disposable pipettes (2, 5, 10 and 25 ml)(Corning Inc., 
Corning, NY). 
Cell culture plates and dishes: Sterile 96 well, 24 well, 6 well plates (Sarstedt, 
Numbrecht, Germany) 100 mm x 20 mm dishes for adherent cells (Corning Inc., 
Corning, NY), and Petri dishes for suspension cells (Becton Dickinson Labware, 
Franklin Lakes, NJ) 150 mm x 20 mm dishes for adherent cells (Greiner Bione, 
Frickenhausen, Germany). 
Calcium Chloride: solution for transfection, 2.5 M CaCl2 (Sigma-Aldrich®, St. 
Louis, MO) solution in water. 
DMSO: dymethylsulfoxide (Merck, Darmstadt, Germany). 
Hepes Buffered Saline: (HBS) (Invitrogen, Carlsbad, CA). 
Media: Dulbecco’s Modified Eagle’s Medium (DMEM) 4,5 g/l glucose, l-glutamine, 
sodium pyruvate and 3,7 g/l NaHCO3 (PAN biotech GmbH, Aidenbach, 
Germany). 
Fetal Bovine Serum (FBS): 0.2 μm-filtered mycoplasma screened (PAN Biotech 
GmbH, Aidenbach, Germany). 
Dulbecco’s phosphate buffered saline (DPBS): without magnesium and calcium, 
sterile filtered (PAN Biotech GmbH, Aidenbach, Germany). 
Trypan Blue: cell viability stain, 0.4% solution (Sigma-Aldrich®, St. Louis, MO). 
Trypsin – EDTA: 1 X in HBS without calcium and magnesium with EDTA 
(Invitrogen, Carlsbad, CA). 
Penicillin/Streptomycin: Antibiotic solution with 10,000 U/ml Pen G sodium and 
10,000 μg/ml Streptomycin sulfate in 0.85% saline. Used 5 ml per 500 ml medium 
bottle (Invitrogen, Carlsbad, CA). 
Murine cytokines: recombinant m-IL3, m-IL6, m-SCF, m-G-CSF, m-M-CSF and 
m-GM-CSF (lyophilized) (Tebu-bio, Offenbach, Germany). 
Ciprobay®: Ciprofloxacin 400 mg solution, (Bayer AG, Leverkusen, Germany). 
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LB medium: lysogeny broth/Luria-Bertani medium for bacterial culture, pH 7; Agar 
for culture plates, 15g/l (GIBCO-BRL, Grand Island). 
Valproic acid: stock 155 (Sigma-Aldrich®, St. Louis, MO). 
 
2.6.3 Miscellaneous  
X-gal: 5-brom-4-chlor-3-indoxyl-β-D-galactosidase, stock solution 100 mg/ml, 
colorimetric substrate of beta-galactosidase (Roth, Karlsruhe, Germany) 
IPTG: isopropyl-β-D-thiogalactopyranosid, stock solution 0.5 M, lactose analogue 
(Roth, Karlsruhe, Germany) 
Giemsa: Giemsa’s Azure Eosin Methyleneblue solution modified. (Merck KGaA, 
Darmstadt, Germany). 
May-Gruenwald: May-Gruenwald’s Eosin Methyleneblue solution for microscopy 
(Merck KGaA, Darmstadt, Germany). 
Cytospin apparatus: Cytospin 2 Shandon Apparatus (Thermo Electron 
Corporation, USA). 
Cytospin slides: Marienfield pre-cleaned twin frosted slides for fixing single cell 
suspensions and blood smears (Marienfield, Lauda-Königshofen, Germany). 
Cytospin filter cards: ThermoShandon thick white 5991022 filter cards for 
cytospins (Histocom AG, Zug, Switzerland). 
Cytomat medium: mounting medium for confocal microscopy (DAKO, Glostrup, 
Germany). 
Flow cytometry: BD FACS Calibur System (BD Biosciences, Palo Alto, CA). 
Fluorescence Activated Cell Sorting: BD FACS Vantage SE System (BD 
Biosciences, Palo Alto, CA). 
Sequencing mix and apparatus: BigDye Terminator v1.1 Cycle Sequencing Kit 
and the ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA). 
Microscope: Leitz Diavert Inverted Microscope (Ernst Leitz Wetzlar GmBH, 
Wetzlar, Germany). 
BioPhotometer: Eppendorf®, Hamburg, Germany.  
Irradiation source: 137Cs, Gammacell 40, Atomic energy of Canada Limited 
Commercial Products. 
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2.6.4 Software 
 The software used for Flow cytometry and FACS sorting was the 
CellQuest Version 3.1(f) (BD Biosciences, Palo Alto, CA).  
 Calculations of survival curve were performed using Sigma Plot 2001 
Version 7 (SPSS Inc. Chicago, IL).  
 Calculations for the frequency of the competitive repopulating units using 
the L-Calc Limiting dilution analysis software Version 1.1 (StemSoft Inc., 
Vancouver, Canada). 
 The ABI Prism 310 sequencing software (Applied Biosystems, Foster City, 
CA) was used for sequencing and analysis of sequences. 
 The Openlab software 3.0.8 (Improvision Deutschland, Tübingen, 
Germany) was used for visualizing and photographic documentation of cell 
morphology. 
 Vector NTI Advance® 9 (Invitrogen) was used to design cloning strategies. 
 Primers were designed using the Primer3 program, Whitehead Institute, 
Massachusetts Institute for Technology, MA (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). 
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3. Methods 
3.1 Mice maintenance 
Parental strain mice were bred and maintained under standard conditions at the 
animal facility of the Helmholtz Zentrum, Munich. After irradiation and bone 
marrow transplantation the mice were fed with autoclaved chow and supplied 
with autoclaved drinking water containing ciprofloxacin and acetic acid and 
housed in individually vented cage systems. The room temperature was 22±2°C 
in a relative humidity of 50-60% in a 12 hours light-dark cycle.  
 
3.2 Cloning of constructs 
A human Hoxb4 complementary DNA (cDNA) containing the complete Hoxb4 
open reading frame was cloned as an EcoRI fragment and inserted upstream of 
the internal ribosomal entry site (IRES) into a murine stem cell virus (MSCV) 2.1 
vector (from R. Hawley, Rockville, MD) containing the IRES-green fluorescent 
protein (GFP) cassette originally provided by P. Leboulch (Boston, MA). As a 
control, the MSCV vector carrying the IRES-GFP cassette alone was used (GFP 
virus). For proof of protein expression, the Hoxb4 cDNA was subcloned in frame 
3' to the FLAG-site of the pSC plasmid (Clontech, Palo Alto, CA) and then 
subcloned into a MSCV vector. As a control, the MSCV vector carrying the IRES-
GFP cassette alone was used (GFP virus). 
 
3.3 Mutagenesis of Hoxb4 constructs 
Site directed mutagenesis has been performed using PCR primers containing the 
modified sequence in the pre-defined domains. As templates for the mutations 
the Hoxb4-wt and the Hoxb4-∆Proline mutant (kindly provided by K. Humphries, 
Terry Fox Laboratory, Vancouver, Canada) have been used. A forward primer 
containing the point mutation of interest has been designed and used together 
with a reverse primer containing the wild type sequence. The following PCR 
reaction has been performed using the high fidelity Pfu-Polymerase for 12 cycles 
of amplification. After this step, the reaction has been cooled below 37°C and 1 μl 
of DpnI restriction enzyme was added to the reaction and incubated at 37°C for 1 
h.  During this step the DpnI enzyme, which is specific to methylated and hemi-
methylated DNA, digests the parental DNA template but does not digest the 
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mutant-synthesized DNA. As most E.coli strains produce methylated DNA, they 
are not resistant to DpnI digestion. Undigested DNA has then been used to 
transform competent bacterial cells to be amplified and sequenced. 
 
3.4 Transient transfection of packaging cell lines for VCM production   
1.5x106 293T cells were plated in a 15 cm dish and on the following day used for 
transient transfection. 4 hours before transfection the medium was replaced with 
fresh medium. 30 μg plasmid DNA harbouring the gene of interest and 30 μg of 
retroviral packaging construct Ecopac were added to sterile water up to 1 ml. 100 
μl of 2.5M CaCl2 sterile solution were added drop wise to the water-DNA mixture. 
This was added drop wise to a tube containing 1ml of 2X sterile Hepes buffered 
saline solution (pH 7.2). This mixture was gently mixed, incubated at room 
temperature for 3-4 minutes, and finally added drop wise to the medium covering 
the whole plate and without agitating the plates. After 12 hours (the day after) the 
medium was slowly changed and 24 hours later the supernatant has been 
collected for 2 days twice daily. This supernatant containing the newly produced 
viruses was filtered with a 0.45 μm Millipore filter and stored as viral conditioned 
medium (VCM) at –80°C for later use or used directly to transduce cell lines or 
primary murine BM cells. The 293T were after this discharged or lysed for 
western blot anaysis. 
 
3.5 Preparation of high titer stable virus producing cell lines 
5x104 GP+E86 fibroblasts were plated into a 6 well plates one day prior to 
transduction. The day after, medium was removed from these cells and 500 μl or 
1 ml of freshly produced or thawn VCM was layered on top of the cells with the 
addition of protamine sulfate at final concentration of 10 μg/ml. Fresh medium 
was added after 4 hours and the transduction was repeated every 12 hours for 
three-four times. The cells were cultured for two more days to allow GFP 
expression. Green fluorescent cells were separated twice using the fluorescent 
activated cell sorter (FACS), propagated and used as stable virus producing cell 
lines to transduce murine bone marrow cells. Using this protocol, Hoxb4/GFP, 
Hoxb4-∆Pro/GFP, Hoxb4-Cdel/GFP, Hoxb4-HD/GFP, Hoxb4-Pbx/GFP, Hoxb4-
∆Pro-HD/GFP, Hoxb4-∆Pro-Cdel/GFP, Hoxb4-∆Pro-Pbx/GFP, and GFP positive 
GP+E86 cell lines were established and used for experiments. The supernatant 
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of these 100% GFP-positive cells was tested for the amount of virus produced (s. 
below). When the viral titres of bulk cell lines were low, single cells were sorted 
into 96 well plates and after expansion their viral titres determined on NIH-3T3. 
Clones producing highest titres were expanded, frozen and used for experiments. 
 
3.6 Titration of the retroviral conditioned medium (VCM) 
For the titration of produced virus 2x104 NIH-3T3 cells were plated per well in 6 
well plates. The day after the medium was removed and 500 μl of VCM 
containing 10 μg/ml protamine sulfate were added. Fresh medium was added 
after 3-4 hours.  The transfection of the cells with fresh VCM was performed 
every 12 hours (thrice totally). Two days after the last transfection, the cells were 
analysed for GFP expression at the FACS Calibur. The exact calculation of the 
virus concentration in the supernatant of the packaging cell lines (multeplicity of 
infection, m.o.i.) has been calculated with the following formula: %GFP+ cells x 
NIH 3T3 cells plated d0 x 2 = viral particles/ml. 
 
3.7 Culture conditions of cell lines and murine bone marrow cells 
All the cell lines and primary cells used in this work have been cultured under 
standard conditions (5% CO2, 37°C, 96% relative humidity) in a SANYO CO2 
incubator. All the adherent cell lines been cultured in DMEM, supplemented with 
FBS 10% and 1% P/S (Penicillin/Streptomycin). The suspension cell lines have 
been cultured in RPMI, supplemented with FBS 10% and 1% P/S. The murine 
bone  marrow cells have been cultured in non-adherent dishes with DMEM 
supplemented with FBS 15% and 1% P/S in presence of rm-IL3 (6 ng/ml), rm-IL6 
(10 ng/ml), and rm-SCF (100 ng/ml). The cell counts have been performed by 
diluting the cells 1:1 with Trypan Blue and using a Neubauer cell count chamber. 
The cells have been centrifugated in a Rotanta 46 RC centrifuge at 1000 rpm at 
room temperature or at 4°C. The cells have been frozen in FBS:DMSO (9:1) and 
stored in liquid nitrogen.  
 
3.8 Retroviral transduction of primary bone marrow cells 
Donors of primary BM cells were ≥ 8 weeks old (C57BL/6Ly-Pep3b x C3H/Hej) F1 
(PepC3) mice. 150 mg of 5-Fluorouracil (5-FU) were injected per kg of mouse 
body weight to eliminate cycling cells and to enrich for hematopoietic progenitors 
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cells (Fig. 3.8). On the fifth day following 5-FU injection, these mice were 
sacrificed and bone marrow was obtained by flushing several times femurs and 
tibias with 2% serum-supplemented medium. The red blood cells were lysed by 
resuspending them in 0.8% NH4Cl/0.1 mM EDTA solution followed by an 
incubation of 20 minutes on ice. The cells were prestimulated by culturing for 2 
days in DMEM supplemented with 15% FBS and a cytokine cocktail (10 mg/ml 
rm-IL6, 6 ng/ml rm-IL3, and 100 ng/ml rm-SCF). On day 3, suspension and 
adherent cells from primary culture were collected and the transduction was 
started by layering them on top of adherent packaging GP+E86 cell lines (co-
culture). These adherent cell lines were previously irradiated (40 Gy) and plated 
on adherent 150 mm x 20 mm dishes one day prior to the transduction. 10 μg/ml 
protamine sulfate was always added to the medium during viral transduction. 
After 2 days of co-cultivation on the feeder, the BM cells in suspension were 
removed gently without disturbing the adherent monolayer of GP+E86 cell line. 
 
Bone Marrow Transplantation Model
Injection
Ex Vivo Assays
2nd Tx
BM -Aspirations
FACS /ex vivo Assays
Harvest
5-FU BM Transduction Sort
GFP CFU - S Assay
 
Fig. 3.8. Experimental design of bone marrow transduction and transplantation assay.  
 
The bone marrow cells were cultured in DMEM 15% FBS for two more days to 
allow GFP expression. On day 7, GFP positive cells were sorted by FACS 
Vantage and used for bone marrow transplantation or for in vitro experiments. 
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For liquid culture BM cells were maintained in DMEM 15% FBS medium 
supplemented with 10 mg/ml rm-IL6, 6 ng/ml rm-IL3, and 100 ng/ml rm-SCF.  
 
3.9 Bone marrow transplantation and assessment of mice 
As recipients mice ≥ 8 weeks old (C57BL/6J x C3H/Hej) F1 (B6C3) mice were 
used. Prior transplantation they were lethally irradiated (0.8 Gy) in a ventilated 
137Cs Gammacell 40. Transduced bone marrow or bone marrow from leukemic 
mice was injected with or without addition of mock non-transduced freshly 
prepared bone marrow cells intravenously into the tail vein of mice using a sterile 
0.5 x 25 mm needle (Table 3.9). Mice were assessed periodically for signs of 
leukemic symptoms by analysing blood cells obtained from the tail vein using 
sterile scalpels and heparinized capillaries, by bone marrow aspiration from the 
femur of anesthetised animals or by the observance of symptoms that included 
crouching, frizzled body air, paleness in the extremities, heavy breathing and 
disturbed gait. Mice were considered moribund when one of these symptoms was 
starkly visible. The RBCs in the peripheral blood were counted by diluting them 
1:5000 in PBS, while the white blood cells counts were performed by diluting 
whole blood 1:25 in ammonium chloride to lyse RBCs and counting living cells 
after 10 minutes. 
Moribund mice were sacrificed by CO2 asphyxiation and bone marrow was 
isolated as described before. Spleens were dissected and macerated to produce 
single cell suspensions and peripheral blood was drawn with a sterile 0.5 x 25 
mm needle by puncturing the heart immediately after sacrifice. Red blood cells 
(RBCs) from  peripheral blood, bone marrow and spleen were lysed by incubating 
the single cell suspensions in ammonium chloride buffer for 10 minutes at room 
temperature. From BM and spleen cells obtained from primary transplanted mice, 
secondary recipient mice have been transplanted, and from secondary moribund 
mice obtained cells, tertiary mice have been finally transplanted. 
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Table 3.9. Transplantation conditions of experimental mice.  
Experiment no Gene Transduced cells Mock cells 
4421 Hoxb4-wt 112500 0 
4622 H Hoxb4-wt 20000 300000 
4622 B#4 Hoxb4-wt 2000 300000 
3970 Hoxb4-∆Pro 18000000 0 
3860 Hoxb4-∆Pro 630000 0 
4622 I Hoxb4-∆Pro 200000 300000 
4614 B#2, 2nd Hoxb4-∆Pro 1200000 0 
4614 C#1-4, 2nd Hoxb4-∆Pro 1000000 0 
4614 C#5, 2nd Hoxb4-∆Pro 500000 0 
4577, 2nd Hoxb4-∆Pro 1000000 1000000 
4685, 3rd Hoxb4-∆Pro 1000000 2000000 
4670 C GFP 10000 300000 
4670 B GFP 50000 300000 
4670 GFP 100000 300000 
5020 GFP 370000 300000 
5029 GFP 1300000 300000 
5264 Hoxb4-∆Pro-HD 220000 300000 
5331 Hoxb4-∆Pro-HD 300000 300000 
 
3.10 FACS analysis of murine primary cells 
Purified cells from PB, BM, and spleen of transplanted mice were immunostained 
with several fluorescence-conjugated antibodies. Staining was performed in PBS 
containing a 1:200 dilution for each antibody. Samples were incubated for 20 
minutes at 4°C in the dark, and subsequently washed with PBS to remove excess 
of antibody. After centrifugation, cells were resuspended in FACS buffer (2% FBS 
and 2 μg/ml propidium iodide (PI) in PBS). The antibodies used for FACS staining 
were recognizing the following surface antigens: Gr-1, CD11b (Mac-1), Sca-1, 
Ter119, CD4 (all labelled with phycoerythrin, PE, emission 488 nm), and CD11b 
(Mac-1), CD117 (c-kit), B220, Flk2, Thy1.1, and CD8 (all labelled with 
allophycocyanin, APC, emission 633 nm). Fluorescence was detected using a 
FACS Calibur flow cytometer and analysed using the CellQuest software. Dead 
cells were gated out by high PI staining and forward light scatter.  
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3.11 In vitro and ex vivo assays of murine BM cells: proliferation and CFC 
assays 
BM cells were cultured in DMEM supplemented with 15% FBS, 10 mg/ml rm-IL6, 
6 ng/ml rm-IL3, and 100 ng/ml rm-SCF, with or without VPA. The cell counts and 
immunophenotype were assessed after 1 and 2 weeks of proliferation. Myeloid 
and lymphoid differentiation of clonogenic progenitors was analysed by plating 
104-105 cells in methylcellulose supplemented with cytokines (MethoCult® M3434 
for myeloid and MethoCult® M3630 for B-lymphoid differentiation). Re-plating 
was performed every week in appropriate dilutions. 
 
3.12 Cytospin preparation and May-Grünwald-Giemsa staining 
The morphology of cells obtained from liquid culture, CFCs and primary organs of 
transplanted animals was analysed by performing cytospins. Single cell 
suspensions in PBS (2-6x105 cells per 200 µl) were introduced in the cytospin 
apparatus and were permanently fixed on glass slides by centrifugation at 500 
rpm for 10 min. After air-drying, modified Wright-Giemsa staining was performed 
by immersing the slides in an undiluted solution of May-Grünwald stain for 5 min. 
After extensive washing in dH2O the slides were immersed in 1:50 diluted 
Giemsa stain for 1 hour. Slides were dipped in water to remove excess stain 
between the two stainings steps and after the staining procedure and air-dried for 
observance under the inverted light microscope. 
 
3.13 Histological and immunohistochemical analysis 
For histological analysis, the peritoneum of sarificed mice was dissected so as to 
expose all organs and the blood was drained by aspiration from the heart. The 
whole mice and single organs were fixed in an aqueous solution of formaldehyde 
(10% v/v) and sections of selected organs were prepared and haematoxylin-
eosin stained using standard protocols. Immunohistochemical analysis has been 
performed staining the sections with myeloperoxidase antibody (MPO), 
chloracetate esterase (CAE) and other lineage specific antibodies, such as B220, 
CD3, CD11b. 
 
55 
 
                                                                                                 Chapter 3 – Methods 
 
3.14 Delta-colony forming unit-spleen (∆-CFU-S) assay 
Primary BM cells were prepared from F1 donor mice pre-treated with i.v. injected 
5-FU (150 mg/kg) 5 days prior to sacrifice, and were transduced as described in 
3.8 with the different viruses. Cells were highly purified based on expression of 
GFP by using FACS-Vantage. 10-4500 transduced cells were incubated for 1 
week in DMEM supplemented with cytokines cocktail (rm-IL3, rm-IL6, and rm-
SCF) with or without VPA 1 mM. After 1 week the cells were intravenously 
injected into lethally irradiated F1 (B6C3) recipient mice. At day 12 post-injection 
the mice were sacrificed and the spleens were immersed in Telleyesnickzky´s 
solution. After few minutes the ∆-CFU-S were counted as macroscopic white 
colonies visible on the spleens.   
 7 days 12 days 
 
 
5-FU BM    Injection          Spleen colonies 
 
Fig. 3.14. ∆-CFU-S assay. 
 
3.15 Quantification of competitive repopulating units (CRU-assay) 
Primary BM cells from F1 (PepC3) donor mice that had been primed 5 days in 
advance with i.v. injection of 150 gm/kg 5-fluorouracil were transduced (as 
described in 3.8) with the different viruses and cells were highly purified based on 
GFP expression using FACS-Vantage. GFP+ cells have been injected into lethally 
irradiated recipient mice in serial dilutions, in order to calculate the frequency of 
HSCs in the 5-FU BM population that were able to give rise to a normal 
hematopoietic system in recipient mice. 3x105 native mock bone marrow cells 
from a syngeneic mouse were additionally injected for radioprotection. 16 weeks 
post transplantation the mice have been assessed for engraftment (a mouse was 
considered engrafted when >1% of peripheral blood WBCs were GFP+ originating 
from the donor cells). The multilineage engraftment was assessed by measuring 
the chimerism in the WBCs for each lineage (within each lineage, >1% of the 
WBCs originated from the GFP positive transplant) (according to K. Humpries et 
al).The frequency of the hematopoietic repopulating unit was calculated using the 
L-Calc limiting dilution analysis software.  
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3.16 Total RNA / genomic DNA isolation and cDNA preparation 
For the purification of RNA the Trizol method and RNeasy Mini kit (Quiagen) 
were used following the instructions of manufacturers. Each RNA sample was 
treated with DnaseI to remove genomic DNA contaminating the sample according 
to manufacturer´s instructions (Invitrogen). Equal amounts of RNA as quantified 
by spectrophotometer were added to each reaction (in a set) used for cDNA 
synthesis for semi-quantitative PCRs. cDNA was prepared from DnaseI treated 
RNA. First strand cDNA synthesis was done with Thermoscript RT-kit 
(Invitrogen). In 20 μl reaction volume, 1 μg RNA and 50 pmoles of oligo (dT) were 
mixed to a final volume of 11 μl and incubated 10 min. at 65°C. Four μl of 5X first-
strand buffer, 2 μl of DTT 0.1M, 1 μl of 10mM deoxynucleotide triphosphate mix, 
and 2 μl of Thermoscript reverse Transcriptase were added. The samples were 
finally incubated for 1 h at 50°C and used for PCR reactions. Genomic DNA was 
isolated from a minimum of 105 - 107 cells from various murine organs using 
DNAzol® reagent (Invitrogen). The DNA was finally resuspended in sterile 
distilled water and quantified using a Biophotometer (Eppendorf).  
 
3.17 Southern blot 
Southern blot analysis was performed in order to assess proviral integration. 
gDNA was isolated from at least 107 cells from bone marrow, spleen and 
peripheral blood of transplanted mice using DNAzol® reagent. Southern blot was 
performed using standard protocols. DNA was digested overnight with PstI, which 
cuts the proviral DNA once, to release a fragment specific to the proviral 
integration site. After digestion DNA was loaded on a 0.8% agarose gel with 0.5 
μg/ml ethidium bromide. After 5-6 hours of electrophoresis, the DNA was 
depurinated by soaking the gel in 0.2 N HCl for 10 min., and subsequently for 1 h 
in denaturation buffer. After denaturation, DNA was transferred overnight on zeta-
Probe GT membrane by capillary action in 10x transfer buffer. Cross-linking of 
the DNA with the membrane was done by incubating the membrane at 150 mJ in 
a UV gene linker. The probe used was a 700 bp GFP fragment, which was 
digested out from the pEGFP-C1 plasmid and labelled with α-32P dCTP using 
Megaprime DNA labelling system (Amersham). Probe was purified using 
Microspin S-300 HR columns. Hybridization was done with α-32P GFP labeled 
overnight at 62°C. After two rounds of washing, the membrane was dried, 
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covered with a plastic film and placed in a cassette for exposure of the film. The 
film was placed on the membrane in a dark room and the exposure was done at 
variable exposing times between 24 hours and one week, depending on the 
intensity of signal observed.  
 
3.18 Integration analysis: bubble LM-PCR 
Integrated LTR and flanking genomic sequences were amplified and isolated 
using a modification of the bubble LM-PCR strategy (Schessl 2005). 40 pg of the 
genomic DNA from leukemic and normal mice were digested with PstI, and the 
fragments obtained were ligated overnight at room temperature to a double 
stranded bubble linker prior to performing a first PCR (PCR-A) on 10 μl (one-
tenth) of the ligation product using a linker specific Vectorette primer and an LTR-
specific primer. The PCR was performed under the following conditions: one 
cycle at 94°C for 2 minutes, 20 cycles at 94°C for 30 seconds and 65°C for 1 
minute, and one cycle at 72°C for 2 minutes. The bubble linker contains a 30-
nucleotide non-homologous sequence in the middle region that prevents binding 
of the linker primer in the absence of minus strand generated by the LTR-specific 
primer. 1 μl of the PCR-A reaction was used as template for a second nested 
PCR (PCR-B) using an internal LTR-specific primer and the same linker-specific 
Vectorette primer as it was used in PCR-A. 10 μl (one-half) of the final PCR-B 
product was then separated by electrophoresis using 2% agarose TAE gel. 
Individual bands were excised, the DNA fragments purified and cloned into 
pGEMT-easy Vector before sequencing the integration site of the retrovirus in the 
murine genome. BLAST searches were performed using the genome project 
website form the University of California, Santa Cruz (UCSC) 
(http://genome.uscs.edu) to identify the genomic location of the flanking 
sequences. Identified genomic loci were screened using the retroviral tagged 
cancer genes databases (RTCGDmm7) custom track on the UCSC Genome 
browser (August 2005 assembly). 
 
3.19 Western blot 
The protein expression was assessed using the stable transfected GP+E86-
Hoxb4 and the transient transfected 293T-Hoxb4 cell line. 293T cells from an 
80% confluent 15 mm cell culture dish (5-10x107 cells) were transiently 
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transfected with 10 μg of pGFP, pGFP-Hoxb4 and Hoxb4-mutated DNA 
constructs. The cells were lysed using 150 μl RIPA buffer with fresh added 
protease inhibitors and detached using a cell culture scraper. This suspension 
was mixed by inversion and incubated for 30 minutes at 4°C. After sonification, 
the sample was centrifuged at 1400 rpm for 30 minutes. After centrifugation, the 
supernatant was transferred to a new Eppendorf tube and either frozen at –80°C, 
or kept on ice for determination of protein concentration. The Bradford method 
was used for measuring the protein concentration. The assay is based on the 
observation that the absorbance maximun for an acidic solution of Comassie 
Brilliant Blue G-250 shifts from 465 nm to 595 nm when binding to protein occurs. 
Both hydrophobic and ionic interactions stabilize the anionic form of the dye, 
causing a measurable color change. The assay is useful since the extintion 
coefficient of a dye-albumin complex solution is constant over a 10-fold 
concentration range. Within the linear range of the assay (5-25 μg/ml), there is a 
linear correlation between the protein present and the Comassie binding. The 
protein concentration of the sample was determined by comparison to values 
obtained from the measure of the known range of protein standards (here bovine 
serum albumin (BSA) was used). Different albumin dilutions (2.5 μg, 5 μg, 10 μg, 
15 μg, 20 μg, and 25 μg/ml) were further diluted in distilled water to a final volume 
of 800 μl. One μl of cell lysate was diluted in distilled water for the measure. 200 
μl of protein assay solution was added to the tubes. The tubes were incubated at 
r.t. for 15 minutes and the content was further transferred to dedicated cuvettes. 
The determination of the standard curve of the spectrophotometer with distilled 
water and the protein standards was done using the specific program for 
estimation of protein concentration in the spectrophotometer used.  
Total cell extract proteins were separated on a denaturing gel consisting of 14% 
SDS-polyacrylamide Tris-glycine separating gel and a 5% SDS-polyacrylamide 
stacking gel. The concentration of the separating gel was chosen considering the 
size of wt Hoxb4 protein (37kDa) as indicated in molecular protocols (Sambrook, 
1989). The sample was homogenized and diluted 4:1 with 5x loading buffer and 
incubated in a Thermoblock for 10 minutes. Ca. 80 μg proteins were loaded on 
each gel lane. The electrophoresis was performed under 100V for 3 hours at r.t. 
After the electrophoresis, the membrane, the gel and the filter paper were 
equilibrated in transfer buffer for 10 minutes at 95°C. For the blotting, the semi-
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dried system (Trans-blot SD Cell, Bio-Rad) was used. The system was 
assembled putting 3 layers of 0.8 mm filter paper on the bottom and on top of the 
membrane- gel sandwich. The transfer has been performed at constant 250 mA 
at r.t. for 1.5 hours. After the blotting, the membrane has been incubated with 
blocking solution (TBS 5% milk) for at least 1 hour at r.t. Subsequently, the 
membrane has been incubated over night at 4°C in TBS 5% milk containing the 
corresponding first antibody, goat anti-Hoxb4, mouse anti-Flag peptide, or anti-
actin (1:200, 1:3000 and 1:2000 diluted, respectively). The day after, the 
membrane was washed 3 times with TBS 0.05 % Tween to remove the 
unbounded antibody, and incubated with the HRP-labeled secondary antibody, 
anti-goat or anti-mouse (1:500 and 1:2000 diluted, respectively) for 1 hour at r.t.. 
Again the membrane was washed 3 times with TBS 0.1 % Tween and finally 
incubated with the ECL solution for 5 minutes. The bounded antibodies were then 
detected by incubating the membrane with an ECL-film in a dark room for 3-5 
minutes.  
 
3.20 Immunoprecipitation 
Immunoprecipitation (IP) is a method that uses the antigen-antibody reaction 
principle to identify a protein that reacts specifically with an antibody from mixture 
of proteins so that its quantity or physical characteristics can be examined. The 
immunoprecipitation experiments have been performed like previously described 
(Sambrook 1989). The proteins from the cellular or tissue homogenates were 
precipitated in RIPA lysis buffer. After centrifugation the supernatants have been 
incubated with protein A- or G-agarose for at least 3 hours in order to reduce 
background caused by non-specific adsorption of irrelevant proteins to the 
agarose. After centrifugation, the supernatant has been pre-incubated for at least 
1 hour at 4°C with the specific antibody, e.g. anti-Hoxb4. The protein A- or G-
agarose has been then added and the reaction has been incubated at 4°C o.n.. 
After centrifugation, the immunoprecipited proteins were incubated with loading 
buffer at 95°C for 10 minutes, centrifugated and further analyzed by SDS-PAGE 
and immunoblotting to determine their molecular weights and to perform 
semiquantitative analysis of their expression.  
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3.21 Polymerase chain reactions 
The polymerase chain reactions have been performed following standard 
procedures:  10x synthesis buffer 2.5 μl, MgCl2 50mM 0.75 μl, dNTP 10mM 0.5 
μl, primer forward 0.5 μl, primer reverse 0.5 μl, Taq Polymerase 2.5 U/μl 0.25 μl, 
H2O up to 25 μl. PCR conditions: 94°C 2 min., (94°C 30”, specific annealing 
temperature 30”, 68°C 30”) for 35 cycles, 68°C 5 min. To check the expression of 
Hoxb4-wt and Hoxb4-∆Pro, we designed internal primers (Hoxb4_inter_fw, 
Hoxb4_inter_rev), which recognize and amplify 648 bp for Hoxb4-wt and 516 bp 
for Hoxb4-∆Pro. The PCR reaction has been performed as described above with 
the addition of 2x Enhancer solution, using the following conditions: 94°C 2 min., 
(94°C 30”, 59°C 30”, 68°C 30”) for 35 cycles, 68°C 5 min. Alternatively, to check 
the expression of Hoxb4 mutant missing the first 437 bp and the 5´UTR, we 
designed an alternative forward primer (Hoxb4-alternEST_fw) binding from nt 438 
of the CDS in combination with previously reported reverse primer used to check 
the full length sequence. The PCR conditions were the same used for the full 
length. The expected product size was 492 bp. Other primers (Hoxb4_full 
length_fw, Hoxb4_full length_rev) have been designed to check the expression of 
the endogenous full length Hoxb4 in cell lines and patients samples. The PCR 
conditions where: 94°C 2 min., (94°C 30”, 58°C 30”, 68°C 1-2´) for 35 cycles, 
68°C 5 min. Moreover, another set of primers published by Bowles et al have 
been used under the following conditions: 94°C 5 min., (94°C 30”, 55°C 30”, 72°C 
45”) for 35 cycles, 72°C 5 min. The PCR product was 400 bp. 
 
3.22 Immunostaining and confocal laser scanning fluorescence microscopy 
For intracellular localization studies, 293T cells were grown on coverslips and 
transfected with Hoxb4 or FLAG-Hoxb4-∆Proline, FLAG-Hoxb4-Pbx, FLAG-
Hoxb4-HD, FLAG-Hoxb4-cDel plasmids, as described above. After 24 hours, 
cells were fixed with phosphate-buffered saline (PBS) containing 2% 
paraformaldehyde for 10 min, permealized with PBS 0.1% Triton X for 10 min 
and blocked with PBS 10% fetal calf serum (FCS) for 1 h. Coverslips were 
incubated with monoclonal mouse FLAG antibodies (SIGMA) or anti-Hoxb4. 
Following extensive washing with PBS 0.1% Tween, Alexa 555- and Alexa 488-
conjugated secondary -antibodies were added for 1 h. After further washing 
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steps, cells were stained with DAPI and mounted using Cytomat medium (DAKO, 
Glostrup, Denmark). Finally, immunostained samples were analyzed in a 
confocal fluorescence laser scanning system (TCS-SP2 scanning system and 
DM IRB inverted microscope, Leica, Solms, Germany). 
 
3.23 Statistical analysis 
Data were evaluated by using the t test for dependent or independent samples 
(Microsoft EXCEL). Differences of p values <0.05 were considered statistically 
significant. For calculations of frequency of competitive repopulating cells, the L-
CalcTM software was used. Cell numbers were entered as doses, the number of 
mice per cohort as test and the number of engrafted mice as the response for the 
frequency calculation. 
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4. Results 
4.1 Cloning and expression of Hoxb4 constructs 
We sought to determine the effect of constitutive expression of Ho
hematopoietic stem and progenitor cells upon hematopoietic re
lethally irradiated mice. For this purpose, a full length Hoxb
subcloned into a MSCV vector with an IRES driven GFP co-expre
to track transduced cells. This vector has been shown to efficie
hematopoietic stem cells and the GFP co-expression enables
purification of transduced cells (Rawat 2004). In each experiment GFP 
xb4 mutants in 
constitution of 
4 cDNA was 
ssing cassette 
ntly transduce 
 tracking and 
expressing empty vector control transduced cells were used as controls. The 
b4-∆Pro mutant was first cloned in frame 3' to the FLAG-site of the pSC 
plasmid and then cloned into the MSCV vector (Fig 4.1.1, A). 
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Fig. 4.1.1. A schematic representation of the vectors used for bone marro
experiments: A) empty vector control and full length Hoxb4 cDNA flanked by long te
(LTR) sequences. The internal ribosomal entry site (IRES) facil
w transplantation 
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itates co-expression of the GFP. 
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The Hoxb4 DNA binding was abolished introducing the point mu
within helix 3 of the homeodomain (Hoxb4-HD mutant), while the direct Hoxb4-
PBX interaction was inhibited through the W144→G mutation in 
tetrapeptide (Hoxb4-PBX mutant), as described before (Beslu 20
we generated a mutant where at aminoacidic position 222 a stop co
introduced, leading to a truncation of the C terminal sequence 
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Fig 4.1.2. Protein expression of Hoxb4 constructs in 293T cells. A: 293T cells, B:
C: 293T-Hoxb4-wt, D: 293T-Hoxb4-∆Pro; E: 293T-Hoxb4-PBx; F: 293T-Hoxb4-cD
Hoxb4-HD; H: K562. The transduction efficiencies in E, F, and G were 50% lowe
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irradiated recipients normally die of bone marrow failure if injected cells fail to 
engraft the marrow. Following injection of bone marrow cells, it is possible to 
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assess the effects on stem cell activity as well as the leukemogenic ability of 
genes retrovirally inserted into these cells. 
ant of 
d incubating a 
ilutions of the 
 cell lines) or of 
of target cells 
rticles/ml) of the virus-containing 
supernatant. The efficiency of transfection on NIH3T3 cells was on average 
r Hoxb4-Pbx, 50.5% for Hoxb4-
d as described 
 and femurs of 
en lysed with 
tri dishes. The 
r of irradiated 
e different viruses. After the transduction the BM 
cells have been harvested and cultivated for further 48 hours in non-adherent 
Petri dishes to allow the expression of GFP protein. Finally, the cells have been 
then harvested and sorted for GFP expression and used for in vitro and in vivo 
assays. The plots below show the transduction efficiencies obtained in 
representative experiments (Fig. 4.3.1). 
 
4.2 Titration of the viral conditioned medium 
The transduction of the BM cells has been performed using the supernat
packaging cell lines. The efficiency of virus production was teste
defined amount of target cells (5x104 NIH 3T3) with serial d
supernatant taken from liquid culture of 293T (transient packaging
GP+E86 (stable packaging cell line). After 48 h the percentage 
positive for the GFP marker were considered infected and gave a measure of the 
m.o.i. (multiplicity of infection, viral pa
75.5% for GFP control, 60% for Hoxb4-wt, 59% fo
∆Pro, 54.2% for Hoxb4-cDel, and 59.5% for Hoxb4-HD.  
 
4.3 Transduction of primary bone marrow progenitor cells 
The transduction of bone marrow primary cells has been performe
in Chapter 3.8. The cells have been obtained by flushing the tibias
sacrificed 5-FU pre-treated mice. The erythrocytes have be
ammonium chloride and the nucleated cells have been pre-stimulated for 48 
hours in the presence of the cytokine cocktail in non-adherent Pe
cells have been then cultivated for 48-72 hours on a feeder laye
GP+E86 cell lines producing th
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M progenitor 
 type and its 
after retroviral 
CS, the cells have been 
etri dish in 10 
e suspension 
ually adherent 
cells. The cells counts for each mutant are represented in Figure 4.4.1. 
The overexpression of the Hoxb4-wt induced an increase in the cells number of 
4.2fold and a 1.6fold in comparison to the GFP control (p<0.012, n=7) and to the 
Hoxb4-∆Pro mutant (p=0.352, n=5), respective h 
region led to an increase of 2.6fold of harv  in comparison to GFP 
control (p<0.17). The mutation of PBX in
     
 
Fig 4.3.1. Transduction efficiencies of 5-FU enriched BM progenitor cells.  
 
4.4 In vitro assays 
4.4.1 Effect of Hoxb4 and its mutants on liquid expansion of B
cells 
In order to evaluate the effect of the expression of Hoxb4 wild
mutants on the proliferation of bone marrow progenitor cells 
transduction and positive selection for GFP marker by FA
grown in vitro for 1 week. 106 cells have been plated in a 10 cm P
ml medium (DMEM 15% FBS containing SCF, IL3 and IL6). After 1 week the 
cells were harvested by collecting the supernatant containing th
cells, rinsing the dishes and scraping them in order to collect event
ly. The deletion of the proline ric
ested cells
teracting domain (ID) alone and in 
13.627.8 10.8 
28.8 
70.8 
18
80.7 
Hoxb4-wtGFP ctrl Hoxb4-Pbx 
PI
54.2 .9 
GFP
Hoxb4-HD Hoxb4-cDel Hoxb4-∆Pro 
86.2 89 88.7 
PI
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combination with the deletion of the proline rich region led to a de
cell growth (1.69fold, p=0.48 and 2.87fold, p=0.126, respe
compared to the Hoxb4-wt. However, we still reported an increase
of cells harvested when compared to the GFP control (2.48-
p=0.330 and p=0.663, respectively). Moreover, the deletion of the homeodo
alone and in combination with the proline region deletion led t
decrease of cells output when compared to the Hoxb4-wt (5fold
6.2fold, p<0.04, respectively), while it was comparable to the GFP
and 0.68fold decrease, respectively, p>0.7). Interestingly, the dele
terminal region alone or combined with the proline deletion led to a similar
signi
crease in the 
ctively) when 
 in the number 
 and 1.46fold, 
main 
o a significant 
, p=0.094, and 
 control (0.83- 
tion of the C-
 
ficant decrease in cells output in comparison to the Hoxb4-wt (6.4fold, 
lls count was 
e, respectively, 
-PBX, Hoxb4-
 in the absence 
48x108, 3.9x107 
gly, in case of 
∆Pro the incubation with VPA led to a light 
decrease in the number of harvested cells (Hoxb4-∆Pro 1.58x108 vs. 1.32x108 
with VPA, Hoxb4-∆Pro-PBX 8.84x107 vs. 6.66x107, Hoxb4-∆Pro-cDel 5.67x107 
vs. 4.9x107, Hoxb4-∆Pro-HD 4.12x107 vs. 2.05x107cells, n.s.). In summary, the 
proliferative effect induced by VPA was absent when the proline-rich region was 
deleted.  
p=0.075, and 4.5fold, p<0.042, respectively), while the ce
comparable to the GFP control (0.65- and 0.93fold decreas
p>0.7).  
When the cells have been incubated with 1mM VPA for one week, we reported 
an increase of the harvested cells in GFP ctrl, Hoxb4-wt, Hoxb4
cDel and Hoxb4-HD in comparison to the corresponding samples
of VPA (6x107 vs. 1.57x108, 2.5x108 vs. 3.17x108, 1.5x108 vs. 2.
vs. 4.18x107, 5x107 vs. 1.03x108 cells, respectively, n.s.). Interestin
the cells expressing the Hoxb4-
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Figure 4.4.1. In vitro proliferation assay. Initially plated cells: 106. The cells coun
liquid culture with and without VPA are reported. * p<0.05 vs. GFP ctrl; # p<0.
(n=4).  
 
4.4.2 Immunophenotype of in vitro expanded BM progenitor ce
Surface markers Sca-1 and c-kit. After one week of liquid culture 
of FCS, supplemented of IL3, IL6 and SCF, BM cells have been analysed for the 
expression profile of lineage-specific surface markers. 
The percentage of cells positive for the Sca-1 marker was sim
samples and in presence of VPA it was overall increased except fo
harbouring the homeodomain mutation (Hoxb4-HD and Hoxb4-HD
considering the absolute number of cells positive for Sca-1, we reported an 
increase in the number of cells harvested in all the samples in com
GFP control (Hoxb4-wt 6.7fold, Hoxb4-∆Pro 4.8fold), with the 
Hoxb4-∆Pro-PBX and Hoxb4-HD. The incubation with VPA le
increase of Sca-1+ cells in almost all the samples, while we report
in DMEM 15% 
ilar in all the 
r the mutants 
-∆Pro). When 
parison to the 
exception of 
d to a slight 
ed a decrease 
of this subpopulation in Hoxb4-wt, Hoxb4-∆Pro-cDel and Hoxb4-∆Pro-HD 
samples. The deletion of the proline region led in general to a decrease of Sca-1+ 
cells in comparison to the corresponding samples still containing the proline 
region (except for the Hoxb4-HD vs. Hoxb4-∆Pro-HD). Interestingly, the 
combination of VPA treatment with the deletion of the proline region increased 
# 
#
*
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the number of Sca-1+ harvested cells in all the samples, with the exception of 
Ho el, in r co g les without VPA 
ithout the proline deletion (Table 4  and F .1).  
xb4-cD  compa ison to the rrespondin  control samp
and w .4.2.1a ig. 4.4.2
Sample Sca-1 (%) Sca-1+VPA (%) Sca-1 (cells) Sca-1+VPA (cells) 
GFP ctrl 40.92 44.5 2.8 7.43x107  9 x107 
Hoxb4-wt 40.92 49. 1.8 1.85x108  ↓ 
∆Pro 39 50.43 1.37x10 8 
-PBX 26.9 38.28 3.8 8.16x107 
o-PBX 28.9 57.65 2. 5.81x107 
1.12x108 
5.32x107 3.19x107  ↓ 
3.62x107 
1.17x107   ↓ 
. Arrows indicate 
HD. However, 
 control, except 
. The VPA led 
 number of the c-kit+ cells in all the 
s. the corresponding sample ∆Pro-
(4fold inc  vs. wi t VPA  
-rich regi d to a d se in ber o xb4-∆Pro 
-wt (1 ) and 4-∆P vs. H X (5.8fold), while in 
er sampl ncrease s subpo n of ce
c-kit (%) c-kit+VPA (% c-kit (cells) c-kit+VPA (cells) 
 1 8x108 
Hoxb4- 8 2.29x10
Hoxb4 6 5x10  7
Hoxb4-∆Pr 7 72x107 
Hoxb4-cDel 25.65 34.83 6.15x107 
Hoxb4-∆Pro-cDel 53.83 59.55 
Hoxb4-HD 35.07 30.43   ↓ 7.29x106 
Hoxb4-∆Pro-HD 59.5 57.35   ↓ 3.01x107 
Table 4.4.2.1a. Sca-1 positive cells in liquid culture after 1 week (n=3)
comparison with corresponding samples without VPA, respectively. 
 
The proportion of cells positive for c-kit was in almost all the samples lower than 
in the GFP control, except for Hoxb4-∆Pro-cDel and Hoxb4-∆Pro-
the c-kit+ absolute cells numbers were still higher than in the GFP
for Hoxb4-PBX, Hoxb4-∆Pro-PBX, Hoxb4-HD and Hoxb4-∆Pro-HD
to a decrease of the proportion and of absolute
samples v s without VPA, except for Hoxb4-
PBX rease thou ) (Table 4.4.2.1b). The deletion of the
proline on le ecrea the num f c-kit+ cells in Ho
vs. Hoxb4 .4fold in Hoxb ro-PBX oxb4-PB
the oth es it i d thi pulatio lls.  
Sample ) 
GFP ctrl 41 14 1.47x107 .12 3x107 
Hoxb4-wt 11.45 4.09 6.36x107 1.79x107 
Hoxb4-∆Pro 23.98 16.59 4.28x107 2.19x107 
HoxbB4-PBX 11.44 2.39 2.56x107 5.17x106 
Hoxb4-∆Pro-PBX 12.71 15.94   ↑ 4.38x106 1.75x107   ↑ 
Hoxb4-cDel 16.53 3.58 5.74x107 1.18x107 
Hoxb4-∆Pro-cDel 74.46 36.47 6.1x107 2.6x107 
Hoxb4-HD 31.51 5.62 9.96x106 5.98x106 
Hoxb4-∆Pro-HD 73.2 22.9 2.91x107 4.53x106 
Table 4.4.2.1b. C-kit positive cells in liquid culture after 1 week (n=3). Arrows indicate comparison 
with corresponding samples without VPA, respectively. 
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When considering the proportion of cells positive for both Sc
markers, the overexpression of Hoxb4-wt led to a 2.4fold incre
positive harvested cells in comparison to the GFP control (n.s.). T
the proline region led to a decrease of the double positive cells in 
the Hoxb4-wt (1.6fold), while they were still higher than in the GFP control 
(1.5fold). In the GFP control after one week of liquid expansion mo
were mast cells (>70%), while in the Hoxb4-wt and Hoxb4-∆Pro 
higher proportion of immature blasts (30-40%). The VPA treatm
decrease of double positive cells number in the GFP control, Hox
a-1 and c-kit 
ase of double 
he deletion of 
comparison to 
st of the cells 
we detected a 
ent induced a 
b4-wt, Hoxb4-
∆Pro-HD and Hoxb4-cDel, while  
induced a p l increas compa o th nding samples 
t VPA (Tabl .2.1c an 4.4.2.1
 in Hoxb4-∆Pro and in all the remaining samples
VPA artia e in rison t e correspo
withou e 4.4 d Fig. ). 
Sample c-kit/Sca-1 (%) d.p.+VPA (%) d.p. (cells) d.p.+VPA (cells) 
GFP ctrl 15.48 6.93 ↓ 1.88x107 1.28x107 ↓ 
Hoxb4-wt 9.35 4.23  ↓ 4.5x107 1.46x107 ↓ 
Hoxb4-∆Pro 6.4 4.5  ↓ 2.9x107 3.22x107 
Hoxb4-PBX 8.91 6.09  ↓ 7 1.59x10 2.03x107 
Hoxb4-∆Pro-PBX 8.9 10.5 1.27x10  6 8.75x106 
Hoxb4-cDel 9.9 3.5  ↓ 2.6x107 1.49x107 ↓ 
Hoxb4-∆Pro-cDel 32 22.1 ↓ 2.3x10  6 2.5x106 
Hoxb4-HD 21.9 5.3  ↓ 5.5x106 6.6x106 
Hoxb4-∆Pro-HD 49 2 ↓ 6.36x106 6.56x105↓ 
Table 4.4.2.1c. C-kit/Sca-1 double positive cells in liquid culture after 1 week (n
indicate comparison with corresponding samples without VPA, respectively
positive. 
 
In summary, from the analysis of these surface markers, which h
the proportion of more primitive progenitor cells, we noticed that the deletion of
the proline region d
=3). Arrows 
. d.p. = double 
elps to identify 
 
id not dramatically affect the number of Sca1+ cells in 
comparison to the GFP control and the Hoxb4-wt, while this mutation led to an 
increase in the number of c-kit+ cells vs. the Hoxb4-wt. Interestingly, the VPA 
treatment led in general to an increase of Sca-1+ and to a decrease in the c-kit+ 
cells in vitro in comparison to the samples without VPA. However, VPA does not 
significantly affect the proportion of c-kit+ cells in the samples where the proline 
region has been deleted.    
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Figure 4.4.2.1. Immunofluorescence staining of BM progenitor cells after 1 week of liqui
(n=3). A) cell counts; B) cell percentages. 
 
d culture 
BM myeloid cells surface markers Mac-1 and Gr-1. After 1 week o
we analysed the cells for the expression of the myeloid specific surface markers
Mac-1 and Gr-1. The deletion of the proline region did not signific
proportion of Mac-1+ cells, however in the samples harbouring this deletion and 
the double mutations ∆Pro-PBX, ∆Pro-HD, and ∆Pro-cDel we re
f liquid culture, 
 
antly affect the 
ported a clear 
decrease in this myeloid subpopulation when compared to the corresponding 
samples where the proline region was not deleted (Table 4.4.2.1d). In particular, 
this decrease was significant in the Hoxb4-∆Pro-cDel and in the Hoxb4-∆Pro-HD 
(6.2- and 6.85fold, p<0.058 and p< 0.012, respectively) in comparison to the 
corresponding single mutants Hoxb4-cDel and Hoxb4-HD, as well as in 
comparison to the Hoxb4-wt (6fold, p<0.019, and 4.8fold, p<0.025, respectively). 
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In the presence of VPA the number of Mac-1+ cells was lower in the
in Hoxb4-wt, in Hoxb4-∆Pro and Hoxb4
 GFP control, 
-∆Pro-PBX in comparison to the 
corresponding  w  (T .1 samples ithout VPA. able 4.4.2 d).  
Sample Mac-1 (%) Mac-1+VPA (%) Mac-1 (cells) Mac-1+VPA (cells) 
GFP ctrl 38.81 59.32 x108 1.9 1.51x108  ↓ 
Hoxb4-wt  46.97 54.2 2.95x108 1.98x108  ↓ 
Hoxb4-∆Pro 43.15 36.45 2.79x108 2.77x108 ↓ 
Hoxb4-PBX 55.13 49.61 1.13x108 1.18x108 
Hoxb4-∆Pro-PBX 35.69 32.23 1.36x10  7 7.74x106  ↓ 
Hoxb4-cDel 47.42 47.99 2.11x108 2.14x108 
Hoxb4-∆Pro-cDel 7.64 33.36 6.39x105 7.35x106 
Hoxb4-HD 65.79 37.56 2.83x107 3.69x107 
Hoxb4-∆Pro-HD 9.74 30.82 2.09x106 9.58x106 
Table 4.4.2.1d. Mac-1 positive cells in liquid culture after 1 week (n=3). 
comparison with corresponding samples without VPA, respectively. 
 
In the GFP control and in all the samples overexpressing a mutated Hoxb4 t
number of Gr-1+ cells was lower than in the Hoxb4-wt (Table 4.
samples containing the d
Arrows indicate 
he 
4.2.1e). In the 
ouble mutations the number of Gr-1+ cells was lower 
when compared to the corresponding sing ts P control. The 
oid subpopulation, except for 
b4-∆Pro-c nd Ho Pro-HD, in comparison to the corresponding 
 without V reatmen
le mutan  and to the GF
treatment with VPA led to a decrease of this myel
the Hox Del a xb4-∆
samples PA t t.  
Sample Gr-1 (%) Gr-1+VPA (%) Gr-1 (cells) Gr-1+VPA (cells) 
GFP ctrl 25.81 33.1 7. 9.98x107 5 14x107 
Hoxb4-wt  25.36 19.35 2.16x108 9.22x107  ↓ 
Hoxb4-∆Pro 28.88 19.1 2 1.57x108 ↓ 3 x108 
Hoxb4-PBX 29.55 16.23 6.8x107 3.75x107  ↓ 
Hoxb4-∆Pro-PBX 28.96 21.89 9.52x106 6.81x106  ↓ 
Hoxb4-cDel 26.54 20.2 1.37x108 9.84x107  ↓ 
Hoxb4-∆Pro-cDel 14.13 30.87 1.29x106 8.58x106 
Hoxb4-HD 51.97 21.97 1.69x107 7.43x106  ↓ 
Hoxb4-∆Pro-HD 7.1 28.31 2.63x106 9.11x106 
Table 4.4.2.1e. Gr-1+ cells in liquid culture after 1 week (n=3). Arrows indicate comparison with 
corresponding samples without VPA, respectively. 
 
In summary, the overexpression of Hoxb4-wt led to a higher number of myeloid 
cells in comparison to the GFP control (Mac-1+ cells were 2.7fold and Gr-1+ cells 
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were 3fold higher than in the GFP control), and to all the 
combination of the proline region deletion with all the other muta
dramatic decrease in the number of myeloid cells (Mac-1+ cells 
461fold, and 147.5fold less, while Gr-1+ cells were 22.7fold, 167.4fold, and 82
less in the Hoxb4-∆Pro-PBX, Hoxb4-∆Pro-cDel, and Hoxb4-
comparison to the Hoxb4-wt, respectively). On the othe
mutants. The 
tions, led to a 
were 21.7fold, 
fold 
∆Pro-HD in 
r hand, the proline region 
eletion alone, as well as the other single mutations did not significantly affect the 
number of myeloid cells in comparison to the Hoxb4-wt (Fig. 4.4.2.2). 
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Figure 4.4.2.2 Immunofluorescence staining of BM progenitor cells after 1 week of liquid culture. 
A) cells percentages. B) cells counts. 
 
BM cells surface markers Ter-119 and B220. After 1 week of liquid culture, we 
analysed the cells for the expression of the erythroid and lymphoid specific 
surface markers Ter-119 and B220. In the GFP control, in the samples 
harbouring the mutations PBX, HD, cDel alone and combined with the proline 
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deletion we reported a decrease of the Ter119+ cells in comparison
wt and to Hoxb4-∆Pro (21-, 7-, 23-, 48-, 57-, 2.7-, and 57fold,
Moreover, in the presence of VPA, we reported a decrease of the
Hoxb4-wt but not in the GFP control, Hoxb4-∆Pro, Hoxb4-∆Pro-cDe
 to the Hoxb4-
 respectively). 
se cells in the 
l, and Hoxb4-
∆Pro-HD, in comparison to the corres  VPA (Table 
1f, Fig. 4. .).  
ponding samples without
4.4.2. 4.2.3
Sample Ter119 (%) Ter119+VPA (%) Ter119 (cells) Ter119+VPA (cells) 
GFP ctrl 2.54 3.5 1.85x10 6 6 3.68x10
Hoxb4-wt  3.05 0.43 3.97 1.26x106  ↓ x10  7
Hoxb4-∆Pro 4.87 1.79 4.03 5.06x106 x106 
Hoxb4-PBX 5.96 0.26 5.73 7.05x105  ↓ x106 
Hoxb4-∆Pro-PBX 8.15 1.77 1.7 6.61x105  ↓   x106 
Hoxb4-cDel 3.95 0.31 1.45x10  1.08x107 6  ↓ 
Hoxb4-∆Pro-cDel 5.14 12.41 57.07x10  2.46x106 
Hoxb4-HD 5.04 0.45 8.31x105 3.59x105  ↓ 
Hoxb4-∆Pro-HD 2.31 2.97 7.06x105 1.08x106 
Table 4.4.2.1f. Ter-119 positive cells in liquid culture after 1 week (n=3). Ar
comparison with corresponding samples without VPA, respectively. 
 
The number of B220+ cells was similar in the GFP control, Hoxb4-
∆Pro samples. However in other mutant combinations we saw
decrease of these cells when compared to the Hoxb4-wt (Hoxb4-
13.8fold, Hoxb4-HD 57fold, p<0.05) and when compared to the H
(Hoxb4-PBX+VPA 3.3fold, Hoxb4-∆Pro-PBX+VPA 3.4fold, 
cDel+VPA 3.3 fold, Hoxb4-∆Pro-HD+VPA 7fold, p<0.05). The B
Hoxb4-∆Pro-HD+VPA, Hoxb4-∆Pro-PBX+VPA
rows indicate 
wt, and Hoxb4-
 a significant 
∆Pro-cDel 
oxb4-wt+VPA 
Hoxb4-∆Pro-
220+ cells in 
, and in Hoxb4-∆Pro-cDel+VPA 
were 24.3fold ld, ld tl n the Hoxb4-wt 
le, respecti  (p<0.05 e incu with V o a decrease in the 
of B220+  in alm ll the s , exce  Hoxb4-∆Pro-cDel, 
D, and b4-∆Pro  sampl ompar  the corresponding 
samples without the HDACi (Table 4.4.2.1g, Fig. 4.4.2.3.). 
 
, 10.2fo  and 9.9fo  significan y less than i
samp vely ). Th bation PA led t
number  cells ost a amples pt for the
Hoxb4-H Hox -HD es, in c ison with
Sample B220 (%) B220+VPA (%) B220 (cells) B220+VPA (cells) 
GFP ctrl 3.7 3.72 6.61x106 5.73x106 ↓ 
Hoxb4-wt  1.73 0.48 6.78x106 2.29x106  ↓ 
Hoxb4-∆Pro 2.43 1.07 6.07x106 2.56x106  ↓ 
Hoxb4-PBX 1.92 0.36 2.61x106 6.87x105  ↓ 
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Hoxb4-∆Pro-PBX 5.57 2.05 1.63x106 6.64x105  ↓ 
Hoxb4-cDel 0.8 0.24 3.05x106 1.07x106  ↓ 
Hoxb4-∆Pro-cDel 2.32 2.07 4.88x105 6.84x105 
Hoxb4-HD 2.17 0.43 1.18x10  5 3.19 x105 
Hoxb4-∆Pro-HD 2.97 0.95 1.06x10  5 2.79x105 
Table 4.4.2.1g. B220 positive cells in liquid culture after 1 week (n=3)
comparison with corresponding samples without VPA, respectively. 
 
In summary, we observed that the deletion of the proline region led
in the Ter119+ cells in comparison to the samples where th
maintained, while the incub
. Arrows indicate 
 to a decrease 
is region was 
ation with VPA led to a decrease of Ter-119+ and 
B220+ cells in almost all the samples in comparison to the corresponding 
samples without VPA. (Fig. 4.4.2.3). 
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Figure 4.4.2.3. Immunofluorescence staining of BM progenitor cells after 1 week of liquid culture: 
cells percentages. B) cells counts. 
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In conclusion, we reported that the deletion of the proline-rich regi
increase of the Sca-1/c-kit positive cells proportions in compariso
control and to all the samples without this mutation, while this subp
still smaller than in the Hoxb4-wt. In contrast, the myeloid cells
reduced when the proline-rich region was deleted, and this decrease was even 
more pronounced in the presence of VPA. The deletion of proline
affect the number of Ter-119+ and B220+, while the VPA led to a
on leads to an 
n to the GFP 
opulation was 
 counts were 
 region did not 
 decrease of the 
expression of these two markers in almost all the samples. Similarly, the single 
ffect the lineage specificity.  
een cultivated 
to 3 weeks in the presence of the cytokines cocktail (SCF, IL3, IL6). After 3 
eks the cells overexpressing the Hoxb4-wt were almost mast cells, while the 
cells overexpressing the Hoxb4-∆Pro maintained an immature phenotype (Fig. 
4.4.3).     
mutations PBX, HD, and cDel did not significantly a
 
4.4.3 Morphology of in vitro expanded BM progenitor cells  
The 5-FU enriched progenitor cells from BM of donor mice have b
for up 
we
        
 
         
Fig 4.4.3. 5-FU transduced BM cells after liquid culture. Hoxb4-wt after 1 week (A) and 3 weeks 
(C). Hoxb4-∆Pro after 1 week (B) and 3 weeks (D) (100X).   
 
 
 
 
 
A B 
C D 
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4.4.4 Colony forming cells (CFC)-assay in vitro 
5-FU enriched BM progenitor cells have been transduced and sort
marker. 500 GFP+ cells per ml have been plated in semisolid m
mediu
ed for the GFP 
ethylcellulose 
m containing IL3, IL6 and SCF. After 5-7 days the colonies have been 
counted. 
Sample GEMM 
(VPA) [%] 
G (VPA) 
[%] 
GM (VPA) 
[%] 
M (VPA) 
[%] 
BFU-E  
(VPA
Total 
 ) [%] (VPA) 
GFP ctrl 1 (1) 
[0.6] 
15.7 (2) 
[10] 
52 )  (21.3
[33,2] 
39.3 (46) 
[25,1] 
48.5 (82.3) 156.5 
[31] (152.6)  
Hoxb4-wt  3.67 (1) 
[1.6] 
30 (2) 
[13.2] 
28 )  (13.3
[12.4] 
6 60.2)5.8 (  
[29.1] 
99.2 
(119
226.7 
.7) [44] (196.1) 
Hoxb4-
∆Pro 
0.2 (0.2) 
[0.2] 
12.8 (1.1) 
[11.2] 
12 )  (2.5
[10.5] 
25 (24.8) 
[21.8] 
64.5 (99.8) 
[56] 
114.5 
(128.4) 
-PBX 1.2 (0.2) Hoxb4
[0.6] 
17 (1.3) 
[8.1] 
33.3 (22) 
[15.9] 
42.2 (70.5) 
[20] 
116.8 
(101
210.3 
.7) [56] (195.7) 
Hoxb4-cDel  0 (0.7) 
[0] 
17.7 (1) 
[9.6] 
31.7 (31.7) 
[17.1] 
49.3 (55) 
[26.7] 
86.3 (104) 
[46.7
185 
]  (192.3) 
Hoxb4-HD 3.7 (1) 
[1.1] 
78 (2.5) 
[23.6] 
54 (15.5) 
[16.3] 
91.3 (118) 
[27.6] 
104.3 (140) 331.3  
[31.5] (216) 
Table 4.4.4.1. 1°CFC in vitro. 500 freshly transduced 5-FU enriched BM cells ha
methylcellulose containing IL3, IL6 and SCF. After 5-7 days the colonies ha
(n=3). GEMM: granulocyte/erythrocyte/macrophage/megakaryocyte; G: 
granulocyte/macrophage; M: macrophage. [ ]: indicate the % of the total coloni
indicate no. of CFCs in presence of VPA. [] indicate percentages of the total w/o
 
We reported no significant difference in the total number of C
samples in comparison to the GFP control (Table 4.4.4.1, 
However, in all the samples where Hoxb4-wt and its mutants (ex
HD) were overexpressed, we reported an increased proportion of BFU-E c
in comparison to the GFP (44-56% vs. 31%, respectively). 
proportion of GM-CFCs was in all the samples lower than in th
(10.5-17.1% vs. 52%, respectively). The incubation with VPA led to
ve been plated in 
ve been counted 
granulocyte; GM: 
es without VPA. () 
 VPA. 
FCs in all the 
Fig. 4.4.4.1a). 
cept for Hoxb4-
olonies 
Moreover, the 
e GFP control 
 a decrease in 
the total number of CFCs in all the samples except for Hoxb4-∆Pro and Hoxb4-
cDel, in comparison to the corresponding samples without VPA. However in the 
presence of VPA we reported higher percentages of BFU-E colonies in all the 
samples except for Hoxb4-PBX. The Hoxb4-∆Pro led to a decrease in the 
proportion of mature myeloid CFCs (11.2% vs. 13.2% G-CFC, 10.5% vs. 12.4% 
GM-CFC, 21.8% vs. 29% M-CFC, 0.2% vs. 1.6% GEMM-CFCs), while the 
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proportion of BFU-E CFCs was higher (56% vs. 44%) in comparison to the 
rexpressed we 
 and the BFU-
E-CFCs in comparison to the GFP control (Fig. 4.4.4.1b). The VPA led to the 
inversion of the GM/BFU-E CFCs ratio in almost the samples.  
Hoxb4-wt.  
In all the samples where the Hoxb4 and its mutants were ove
reported a clear decrease in the ratio between the G/GM/GEMM/M
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Fig 4.4.4.1a. 1°CFC in vitro. 500 freshly transduced 5-FU enriched BM cells have been plated in 
one ml of methylcellulose containing IL3, IL6 and SCF. After 5-7 days the colonies have been 
counted (n=3). GEMM: granulocyte/erythrocyte/macrophage/megakaryocyte; G: granulocyte; GM: 
granulocyte/macrophage; M: macrophage. 
 
1,0
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2,0
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Fig 4.4.4.1b. 1°CFC in vitro. Ratio between mature myeloid colonies (CFU-G, C
CFU-GEMM) and BFU-E colonies in the presence and in the absence of VPA (n=
 
FU-M, CFU-GM, 
3).  
When the cells harvested from the 1° CFC were replated with a dilution factor of 
1:100, we saw a dramatic increase in the frequency of 2°CFCs in the Hoxb4-
∆Pro in comparison to all the other samples. The incubation with VPA led to an 
increase in the number of 2° CFCs and in particular of the BFU-E CFCs in all the 
samples in comparison to the corresponding samples without VPA (n=2) (Fig. 
4.4.4.1c).  
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he cells collected from the 1°CFC have been replated with a dilution 
colonies have 
the subcellular 
protein, we performed an intracellular immunostaining 
followed by confocal laser scanning fluorescence microscopy. We found that the 
Hoxb4 missing the proline rich region was still localizing in the nucleus as the wild 
type (Fig. 4.4.5). 
Fig 4.4.4.1c. 2°CFC in vitro. T
factor of 1:100 in methylcellulose containing IL3, IL6 and SCF. After 1 week the 
been counted (n=2). 
 
4.4.5 Intracellular localization 
To assess if the deletion of the proline rich region was affecting 
localization of the Hoxb4 
   B  Hoxb4-wt 
  
A
   Hoxb4-∆Pro 
Fig 4.4.5. 293T cells have been transfected with the plasmids of interest. 24 h after transduction 
the cells have been fixed and stained with the anti-Hoxb4 polyclonal antibody or with the anti-
FLAG antibody. A secondary antibody labelled with Alexa Fluor 555 or Alexa Fluor 488 was used, 
respectively. The comparison with the DAPI-stained cells allowed identifying the localization of 
Hoxb4. A: 293T-Hoxb4-wt stained with anti-Hoxb4 antibody. B: 293T-Hoxb4-wt stained with DAPI. 
C: 293T-FLAG-Hoxb4-∆Pro stained with anti-FLAG antibody. D: 293T-FLAG-Hoxb4-∆Pro stained 
with DAPI. 
 
 
 
D C 
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4.5 In vivo assays 
4.5.1 ∆Colony forming unit in the spleen (∆CFU-S) assay  
The number of short-term hematopoietic stem cells in a cell pop
assayed by the colony forming unit in spleen (CFU-S) assay, which
frequency of these cells by the formation of visible colonies in the spleen 12 days
after injection. To investigate the effect of the different mutations 
one week of in vitro expansion, with and without the pre-incuba
bone marrow cells transduced with the different vectors were grow
liquid medium containing SCF, IL3, IL6 with or without VPA (1mM
ulation can be 
 quantifies the 
 
of Hoxb4 after 
tion with VPA, 
n for 7 days in 
), injected into 
lethally irradiated mice, and spleen colony formation was quantified 12 days later 
in sacrificed animals. Colonies can be macroscopically visualized after immersion 
 t e sp en i  Te yesnickzky´s solution (Fig. 4.5.1a).  
 
          B) 
tative example of 
<0.05). When 
erved a 
the Hoxb4-wt 
o mutants still 
mpared to the 
deletion of the 
ase of 75fold 
when compared to the GFP control and to the Hoxb4-wt, respectively (p<0.001). 
In contrast, the mutation of the PBX-interacting domain did not affect ∆CFU-S 
frequency compared to Hoxb4-wt.  
Interestingly, the additional deletion of the proline-rich region in the Hoxb4-HD, 
Hoxb4-cDel, Hoxb4-PBX mutants led to an additional decrease in the ∆CFU-S 
frequencies (135fold, p<0.0001; 13.2fold, p<0.052, and 30fold, p<0.0004, 
        Hoxb4
of h le n ell
 
    A)      
 
 
Fig. 4.5.1a. A) Schematic representation of the ∆CFU-S assay. B) Represen
spleen colonies counted 12 days post injection. 
 
When the Hoxb4-wt was overexpressed we reported a significant increase in the 
∆CFU-S frequency in comparison to the GFP control (2627fold, p
the homeodomain was mutated and the C-terminal region deleted we obs
dramatic decrease in the ∆CFU-S frequency in comparison to 
(136fold and 55.7fold, respectively, p<0.05). However, these tw
GFP 
Injection
induced a significant increase in the ∆CFU-S frequency when co
GFP control (19-and 47fold, respectively, p<0.05). Similarly, the 
proline-rich region led to a significant increase of 35fold and a decre
12 days7 days Spleen 
Colonies 
BM Liquid culture 
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respectively), when compared to the corresponding single mutant
the presence of the double mutants Hoxb4-∆Pro-cDel and Hoxb
reported a non-significant increase and even a decrease of
frequencies, respectively, in comparison to the GFP control (Fig
4.5.1). Indeed, the combination of the proline-rich region deletion with the 
homeodomain mutation, with the PBX-ID mutation, and with t
deletion seemed to act synergistically in decreasing the short-t
cells frequency in
s. Moreover, in 
4-∆Pro-HD, we 
 the ∆CFU-S 
 4.5.1b, Table 
he C-terminal 
erm progenitor 
 this in vivo assay, suggesting that all these regions are 
l of short term 
d the number of colonies 
VPA, but this 
in Hoxb4-∆Pro 
A.  
 of the single 
ficant after the 
U-S frequency 
e, p<0.0001). 
the short-term 
. In contrast, in 
ert the same 
ting stem cells. 
he proline-rich 
 
as significantly 
-cDel (8.5fold) 
omain as well 
as of the proline-rich region might have opposite effects to the HDAC-inhibition 
activity exerted from VPA. Moreover, the VPA pre-incubation of the double 
mutants did not rescue the negative effect of the combined mutations on the 
∆CFU-S frequency observed, when compared to the Hoxb4-wt (Hoxb4-∆Pro-
HD=6129fold, Hoxb4-∆Pro-PBX=18fold, Hoxb4-∆Pro-cDel=88fold decrease vs. 
Hoxb4-wt, p<0.001), suggesting that the proline-rich domain, which may affect 
important for the normal amplificatory effect of Hoxb4 at the leve
repopulating stem cells. 
In all the samples, the pre-incubation with VPA increase
counted when compared to the corresponding samples without 
increase was significant only in the GFP control (6.4fold), and 
(1.87fold), in comparison to the corresponding samples without VP
On the other hand, the decrease of ∆CFU-S observed in case
mutants in comparison to the Hoxb4-wt, was not anymore signi
addition of VPA. Only in case of Hoxb4-∆Pro with VPA the ∆CF
was still significantly lower than in the Hoxb4-wt (40fold decreas
This suggests that the VPA treatment somehow rescued 
progenitor cells proliferation, despite the mutation at the homeodomain, at the 
PBX-binding domain, and at the C-terminal sequence, respectively
the absence of the proline-rich domain the VPA did not ex
amplificatory effect otherwise observed on the short term repopula
When the double mutants harbouring the additional deletion of t
region have been pre-incubated with VPA, the ∆CFU-S frequency was higher
when compared to the double mutants without VPA, but this w
higher only for the Hoxb4-∆Pro-PBX (2.8fold) and in Hoxb4-∆Pro
samples. This suggests that the deletion of the DNA interaction d
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the histone deacetylase activity control regulated by Hoxb4, plays a crucial role in 
the proliferation of ∆CFU-S.  
Sample ∆CFU-S/45.000 cells 
(SEM) 
Fold increase 
vs. GF trl P c
Fold increase 
vs. w
N of 
/o VPA mice 
GFP ctrl   (1.31) - - 11 7
GFP+VPA 44 (12.5) 6.4 6.4 14 
Hoxb4-wt 387 (4857) 2627 - 5 18
Hoxb4-wt+VPA 31125 (15399) 4446 1.69 * 4 
Hoxb4-∆Pro 245 (47.8) 35 - 14 
Hoxb4-∆Pro+VPA 457 (76) 65 1.87 15 
Hoxb4-HD 135 (45) - 2 19 
Hoxb4-HD+VPA 585 (225) 84 4.33 * 2 
Hoxb4-cDel 330 (286) - 3 47 
Hoxb4-cDel+VPA 22500 (20291) 3214 68.2 * 3 
Hoxb4-Pbx 10800 (3836) 1543 - 4  
Hoxb4-Pbx+VPA 11700 (6300) 1671 1.08 * 5 
Hoxb4-∆Pro-HD 0 0 - 10 
Hoxb4-∆Pro-HD+VPA 3 (2.7) 0.43 * 3 * 11 
Hoxb4-∆Pro-cDel 25 (9.6) 3.51 * - 10 
Hoxb4-∆Pro-cDel+VPA 209 (62.5) 30 8.5 9 
Hoxb4-∆Pro-Pbx 362 52 - 11 
Hoxb4-∆Pro-Pbx+VPA 1020 146 2.8 9 
Table 4.5.1. 12 days ∆CFU-S. The ∆CFU-S frequencies/45000 initially plated cells at day 0 for 
each sample are reported. * not significant.  
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Fig 4.5.1b. 12 days ∆CFU-S. The ∆CFU-S frequencies/45,000 initially plated cells at day 0 for 
each sample are reported. * indicate p<0.05 vs. w/o VPA, respectively. 
e model 
on  
een 
 compared, in 
there was no 
onsidering the 
e reported no 
difference in the proportion of GFP+ WBCs in the PB of the different mice 
1.78% in GFP 
, n=3, p>0.1). 
in peripheral 
pheral blood of 
 generated by 
ed. In case of 
 in case of the 
 WBCs in the 
esults, we can 
4 significantly 
, giving rise to 
g the ∆CFU-S, 
n of the short-term repopulating stem cells was less 
pronounced when the proline region was deleted. However, the Hoxb4-∆Pro still 
led to a higher engraftment rate per equal number of injected cells than in the 
GFP control. The chimerism data at this time point originate from serial dilutions 
transplantation experiments, which have been performed in order to evaluate the 
frequency of the HSCs able to give rise to the whole hematopoiesis in recipient 
mice (see paragraph 4.5.2.8). 
 
4.5.2 Hoxb4 BM transplantation experiments in mous
4.5.2.1 Peripheral blood analysis at 4th week after transplantati
4 weeks after transplantation peripheral blood from the tail vein has b
obtained and the blood cells counts at this time point have been
order to estimate the short term engraftment. As expected, 
significant difference in the red blood cells counts in all the mice. C
GFP+ white blood cells arising from a single GFP+ injected cell w
(21.22% in Hoxb4-wt, n=2, vs. 32.33% in Hoxb4-∆Pro, n=2, vs. 1
mice
 
4.5.2.2 The long term engraftment: analysis of chimerism 
blood  
13-16 weeks post transplantation the WBCs isolated from the peri
healthy mice have been analysed. The number of WBCs GFP+
1000 initially injected bone marrow progenitor cells was determin
Hoxb4-wt we obtained 3.68 % of chimerism in the PB (n=19), while
Hoxb4-∆Pro the chimerism was 1.57 % only (n=20) (p<0.031). In the GFP control 
mice the injection of 1000 cells gave rise to 0.11% of GFP+
peripheral blood (n=3, p>0.15) (Fig. 4.5.2.2). Considering these r
conclude that the deletion of the proline-rich region of Hoxb
decreases the in vivo proliferation of bone marrow progenitor cells
a smaller progeny of mature cells in the peripheral blood in comparison to the 
Hoxb4-wt. This is according to what has been observed performin
where the proliferatio
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splantation. The 
FP  WBCs are indicated (Hoxb4-wt n=19; Hoxb4-∆Pro n=20; GFP n=3). 
tion profile in 
 the peripheral 
-1, c-kit, Mac-
se markers as 
Hoxb4-wt, Hoxb4-∆Pro and GFP control mice, indicating that the differentiation 
into mature progeny from the transplanted cells was not perturbed at this time 
point when the Hoxb4-wt and the Hoxb4-∆Pro were overexpressed (Fig. 4.5.2.3).  
Fig. 4.5.2.2. Chimerism in the peripheral blood 13-16 weeks post tran
percentages of G +
 
4.5.2.3 The long term engraftment: analysis of differentia
peripheral blood  
At 13-16th week post transplantation the phenotype of the WBCs in
blood has been analysed. The surface antigens analysed were Sca
1, Gr-1, Ter-119, B220, CD4 and CD8. The FACS analysis of the
well as the morphological analysis did not show significant difference between 
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ice 13-16 weeks 
post transplantation.  
 
4.5.2.4 Overexpression of Hoxb4-∆Pro is associated with acute leukemia in 
transplanted mice 
8-10 weeks old lethally irradiated (850 cGy) recipient mice (C3H-C57Bl/C3H-
PeB) were injected with 1.13x105 to 1.8x107 retrovirally transduced 5-FU 
enriched BM progenitor cells. The recipient mice have been transplanted with 
Fig. 4.5.2.3. Surface markers analysis of GFP+ WBCs from peripheral blood of m
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progenitor cells expressing the following genes: Hoxb4-wt (n=5
(n=9), Hoxb4-∆Pro pre-treated for 1 week with VPA (n=3), Ho
double mutant (n=3), Hoxb4-∆Pro-PBX pre-treated for 1 week w
Hoxb4-∆Pro-HD (n=4) and GFP control (n=3) (Table 4.5.2.4). T
monitored for symptoms of hematological disorders, which included frizzled body
hair, paleness in the extremities and lethargy. The examinatio
symptoms at sacrifice includes the measurement and the morpho
of leukocytes/erythrocytes in the peripheral blood and in the bon
well as th
), Hoxb4-∆Pro 
xb4-∆Pro-PBX 
ith VPA (n=3), 
he mice were 
 
n of leukemic 
logical analysis 
e marrow, as 
e analysis of the spleen (weight and size). Various organs of leukemic 
ical 
 
8.3 d) without 
for irradiation-
 
 these mice, 
 with 0.5-1x106 
 animals. The 
6.5 days post 
died 42.8 days 
in case of a 
cy time of the 
 secondary to 
 suggests 
rexpression of 
multistep process. Few mice have been also 
injected with BM progenitor cells expressing Hoxb4-∆Pro pre-incubated with VPA 
for one week before transplantation. These mice died of leukemia 161 days 
(mean) after transplantation showing a prevalence of myeloid immature cells in 
the organs analyzed (84.6% of WBCs were expressing Mac-1), splenomegaly 
and leukocytosis (3.8x107 WBCs/ml). Apparently, the pre-treatment with VPA did 
not affect the development of the disease. 
mice were fixed in formalin for histopathological and immunohistochem
examinations.
All the Hoxb4-wt mice survived more than 404 days (mean 48
showing any hematopoietic malignancy. One out of 6 mice died 
associated illness. 
The Hoxb4-∆Pro mice died 90-384 days after transplantation (mean 255 d,
p<0.001 vs. Hoxb4-wt) by hematological malignancy. From
secondary syngeneic recipient mice (n=6) have been transplanted
cells obtained from BM or spleen of diseased primary transplanted
mean survival time of these secondary transplanted mice was 6
transplantation. The BM and spleen cells of these secondary transplanted mice 
have been used to transplant tertiary recipient mice (n=4), which 
(mean) after transplantation for the same AML. As expected 
transplantable disease, we observed a shortening of the laten
disease of 3.8fold from primary to secondary and of 1.5fold from
tertiary serial transplantations of recipient animals (Fig. 4.5.2.4c). This
that the disease in primary transplanted mice induced by the ove
Hoxb4-∆Pro probably reflects a 
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All the mice transplanted with Hoxb4-∆Pro overexpressing BM p
died of AML without maturation (Fig. 4.5.2.4a and Fig. 4.5.2.4
progression is often marked by the infiltration of blasts in variou
therefore we assessed sacrificed moribund mice for these sign
histopathological sections of fixed organs followed by immunohistochem
staining. In our model the diffuse neoplastic infiltration was involvin
liver, lymph nodes, lung, heart and kidneys. The infiltration of leuk
the non-hematopoietic organs in general and to the brain in p
striking, highlighting the aggressive nature of the disease. The type
of the cells involved in leukemia can be identified by performing 
immunohistochemical stainings. The myeloperoxidase distinguis
immature cells in acute myeloid leukemia (cell stain positive) and 
lymphoid leukemia (cells stain negative) (Fischbach 1996). Lymph
characteristically negative for myeloperoxidase and chloracetate
rogenitor cells 
b). Leukemia 
s organs and 
s by making 
ical 
g the spleen, 
emic blasts to 
articular was 
 and maturity 
hes between 
those in acute 
oid blasts are 
 esterase. In 
order to determine the nature of the blasts, we performed various stainings of the 
organs from primary leukemic mice. Here we found that the neoplastic cells were 
myeloperoxidase (MPO) positive confirming the diagnosis of acute myeloid 
leukemia without maturation.  
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Fig. 4.5.2.4a. Histological analysis of multiple organs obtained from a represen
mouse, transplanted with cells obtained from the infiltrated spleen of a diseased prim
originally transplanted with Hoxb4-∆Pro expressing BM progenitor cells (Mous
in Fig. 4.5.2.4b, the cells are large with abundant cytoplasm, blastic chroma
nucleolus. There is no myeloid differentiation. In the spleen there are some residual small areas 
of erythropoiesis. In the kidney the neoplastic
tative secondary 
ary mouse, 
e #33). As well as 
tin and prominent 
 cells are identified in the capillary lumens in the 
glomeruli. The type of infiltration in the liver, lung and kidney clearly suggests that the mouse had 
a leukemic phase. The heart has a recent myocardial infarct with neoplastic cell infiltrating the 
myocardial wall. The residual white pulp of the spleen reveals cells that are CD3 and B220 
positive but the tumor cells are negative for these markers.  
 
    
    
         
      
Fig. 4.5.2.4b. Histological analysis of multiple organs obtained from a tertiary mouse, transplanted 
with cells obtained from the infiltrated BM of a secondary diseased mouse, originally transplanted 
with Hoxb4-∆Pro expressing BM progenitor cells (Mouse #36). For description, refer to legend 
Fig. 4.5.2.4a. 
 
Effect of the additional PBX interacting domain (ID) and homeodomain (HD) 
mutations on the survival of Hoxb4-∆Pro leukemic mice. The combination of the 
PBX interacting domain mutation with the deletion of the proline-rich region has 
been investigated by transplanting lethally irradiated recipient mice (n=3) with BM 
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cells overexpressing the double mutated Hoxb4-∆Pro-PBX. These mice d
leukemia 311 days (mean) after transplantation, showing no signif
in comparison to the Hoxb4-∆Pro mice. Moreover, BM cells expre
∆Pro-PBX have been pre-incubated with VPA (1mM) for 
transplanted into three recipient animals. These mice died 338 days (mean, n=3) 
after transplantation. This “intermediate” survival rate of these two 
was not significantly different when compared to the survival
transplanted with HOXB4-wt and to the mice transplanted wit
alone. Moreover, clinical features of these two groups of mice are
Hoxb4-∆Pro-PBX mice showed leukocytosis (1.2x107/ml), myeloid prevalence in 
the peripheral blood (81.32% Mac-1+ WBCs) and moderate splen
mg spleen
ied of 
icant difference 
ssing Hoxb4-
1 week, and 
groups of mice 
 of the mice 
h Hoxb4-∆Pro 
 of note. The 
omegaly (300 
 weight), while the Hoxb4-∆Pro-PBX+VPA mice showed WBCs counts 
the peripheral 
le 4.5.2.4 and 
te ly, in  transp d w o c verexpressing 
Hoxb4-∆Pro-HD  not ob  a lo m e ent, suggesting that 
the stem cell activity as well as for the 
ev t of t mia ob d in th odel. 
(6x106/ml), spleen weight (200mg) and myeloid prevalence in 
blood (60.3% of WBCs) comparable to the GFP control mice (Tab
Fig. 4.5.2.4c). 
In resting the mice lante
served
ith BM pr
ng ter
genitor 
ngraftm
ells o
we did
the interaction with the DNA is essential for 
d elopmen he leuke serve is m
No. Mouse Retroviral 
construct 
GFP+ 
injected 
cells 
Dead n days 
after Tx 
Average d Notes
(p vs wt) 
1  #1 xb4-wt 1.12  x10  404 5 4421 Ho
2  #2 xb4-wt 1.12   4421 Ho x105 416 
3 4622 H #1 xb4-wt 2x1 5  04  Ho 54
4 4622 H #2 xb4-wt 2x1   05  Ho 483
5 4622 H#3 -wt 2x10  5Hoxb4  572 
6 4622 B#4 xb4-wt 2x1 510 
 
 
488.3 
 Ho 0  3
7 3970 A #2 Hoxb4-∆Pro 1.8x107 n.a.  
8 3970 A #3 Hoxb4-∆Pro 1.8x107 279  
9 3970 A #4 Hoxb4-∆Pro 1.8x107 126  
10 3970 A #5 Hoxb4-∆Pro 1.8x107 279  
11 3860 A#1 Hoxb4-∆Pro 6.3x105 n.a.  
12 3860 A #2 Hoxb4-∆Pro 6.3x105 337  
13 3860 B #1 Hoxb4-∆Pro 6.3x105 231  
14 3860 B #2 Hoxb4-∆Pro 6.3x105 90  
15 3860 B #4 Hoxb4-∆Pro 6.3x105 
 
 
 
255 
(p<0.001) 
244  
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16 4622 I #1 Hoxb4-∆Pro 2x105 325  
17 4622 I #3 Hoxb4-∆Pro 2x105 384  
18 4622 F #3 Hoxb4-∆Pro 4 384  2x10
19 ∆Pro- 1.7x  153 3970 B #5 Hoxb4- Pbx 107
2  C Pro- 1.7 0 0 3970  #1 Hoxb4-∆ Pbx x107 47
2  C Pro- 1.7
 
311  
(p=0.080) 
 
1 3970  #3 Hoxb4-∆ Pbx x107 310 
22 3970 B #1 Hoxb4-∆Pro+VPA 2.5x107 154  
23 3970 B #3 Hoxb4-∆Pro+VPA 2.5x107 156  
24 3970 B #4 Hoxb4-∆Pro+VPA 2.5x107 174 
161 
(p<0.0001) 
  
25 3970 C #4 b4-∆Pr
x+VPA 1.8
  Hox
P
o- x107 416 b
26 3970 D #1 b4-∆Pro
x+VPA 1.8x
7 4   Hox -Pb 10 19
27 3970 D #2 b4-∆Pro
VPA 1.8x  
 
338 
0.083) 
 
(p=
 Hox -
Pbx+ 10
7 405 
28 4614 B #2 Hoxb4-∆Pro 1x10  6 50 2nd Tx 
29 4614 C #1 Hoxb4-∆Pro 1x106 54 2nd Tx
30 4614 C #2 Hoxb4-∆Pro 1x106 54 2nd Tx
31 4614 C #3 Hoxb4-∆Pro 1x106 54 2nd Tx
32 4614 C #4 Hoxb4-∆Pro 1x106 82 2nd Tx
33 4614 C #5 Hoxb4-∆Pro 1x10  6 105 
 
66.5 
(p<0.0005 
. 1st Tx) vs
 
 2nd Tx
34 4685 #1 4-∆Pr 1.2 3rd Tx Hoxb o x10  51 6
35 5 #2 4-∆Pr 1.2 42 3rd Tx 468  Hoxb o x106 
36 4685 #3 b4-∆Pr 1.2 43 3rd TxHox o x106 
37 4685 #4 b4-∆Pr 35 
43  
(p<0.0013 
vs. 1st Tx) 
3rd TxHox o 9x106 
38 5264 #2 Hoxb4-∆Pro-HD 2.2x10  5 321 * 
39 5331 #1 Hoxb4-∆Pro-HD 3x105 >331 * 
40 5331 #2 Hoxb4-∆Pro-HD 3x105 >331 
 
327 
* 
GFP 3.7x10
5 >400   41 5020 
42 5029 GFP 1.3x10
6 >400   
43 4951 GFP 1.5x10
6 >400   
Table 4.5.2.4. List of transplanted mice. All the #3970 mice have been injected with cells which 
have been cultivated for 1 week after transduction, with or without VPA. For all the mice a number 
of 5-FU enriched GFP- progenitor carrier cells have been injected (3x105-2x106). The mice 
injected with higher dilutions of BM cells for estimation of the CRU frequencies are not reported. * 
= these animals did not show engraftment.   
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 mice. The animals which died 
ncluded. 
 
a 
Fig. 4.5.2.4. Kaplan-Meier survival curves of Hoxb4 transplanted
shortly after transplantation by irradiation related mortality are not i
 
4.5.2.5 Clinical features of the Hoxb4-∆Pro associated leukemi
Peripheral blood. At sacrifice there was no significant difference
counts in the peripheral blood in almost all the mice. The 1st transplanted Hoxb4-
∆Pro mice did not show anemia signs and the RBCs counts were
normal range. Only in the 2nd mice transplanted with Hoxb4-∆
reported a significant 2.4fold decrease in the RBCs counts in com
GFP control (2.2x109/ml vs. 6.2x109/ml, respectively, p<0.03) (Fig. 
WBCs counts in almost all the mice were higher than the in the GFP c
(range between 1.03fold in the Hoxb4-wt and 68.4fold in 
 in the RBCs 
 almost in the 
Pro cells we 
parison to the 
4.5.2.5a). The 
ontrol 
the Hoxb4-∆Pro mice 
vs. GFP control). This increase was statistically significant in comparison to the 
GFP control (p<0.018) only in the 2nd and in the 3rd Hoxb4-∆Pro transplanted 
mice, as well as in the mice where Hoxb4-∆Pro injected cells have been pre-
treated with VPA before transplantation (3.37x107/ml, 4.33x108/ml and 
3.82x107/ml vs. 6.33x106/ml in GFP control, respectively) (Fig. 4.5.2.5b). 
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Fig. 4.5.2.5a. RBCs/ml in the PB at sacrifice. * significantly lower than in the GFP control 
(p<0.05).  
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Fig. 4.5.2.5b. WBCs/ml in the PB at sacrifice. * significantly higher than in the GFP control 
(p<0.05). 
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Fig. 4.5.2.5c. Spleen weights from transplanted mice. On top of the bars the average of total 
cells/spleen is indicated. *significant difference vs. the GFP control (p<0.05). 
 
Splenomegaly. Enlargement of the spleen mice was a typical feature observed in 
Hoxb4-∆Pro leukemic mice. White spots on the surface of the spleen were 
indicating infiltration with blast colony forming cells, and in some cases 
*
*
7
3.2x109 
5x10
* *
7x10  
4.8x107 
8 7x108 
2x108 
3.9x107 
Spleens weight (mg) 
*
3.2x109 
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parenchymal infarcts derived from leukocytosis were also visible 
The number of cells obtained from the spleen parenchyma was 20
∆Pro 1st Tx, up to 92fold in 2
(Fig. 4.5.2.5c). 
fold in Hoxb4-
nd Tx mice compared to the GFP control mice, while 
in the Hoxb4-wt mice it was normal.  
Immunophenotype of peripheral blood WBCs at sacrifice 
At sacrifice the WBCs have been isolated after lysis of the RBCs w
chloride, and they have been stained with fluorochrome-label
specific for the different lineage markers. The percentages of WB
the single markers are indicated in the tables below. The proportions of Sc
cells in Hoxb4-wt and in Hoxb4-∆Pro was 1.7fold and 1.9fold in comparison to 
the control, respectively (GFP 16.8% of WBCs, Hoxb4-wt 9.4%
8.8%, p=n.s.). In the PB of Hoxb4-∆Pro 3rd transplanted mice 
significant decrease of Sca-1+ cells in comparison to the GFP and H
(p<0.04)(Table 4.5.2.5d). Interestingly, when the double mutant Ho
was overexpressed, we reported a 3fold increase of Sca-1+ cells in comparis
the Hoxb4-wt. In all the mice the proportion of c-kit+ WBCs in the P
than in the GFP control (Hoxb4-wt 5.8fold), and in almost all the
mice the proportion of c-kit+
ith ammonium 
ed antibodies, 
Cs positive for 
a-1+ 
, Hoxb4-∆Pro 
we reported a 
oxb4-wt mice 
xb4-∆Pro-PBX 
on to 
B was higher 
 Hoxb4-∆Pro 
 cells was even higher than in the Hoxb4-wt mice 
4- sed 
ted a significant ease of S and c-kit double positive WBCs in 
the Hoxb4  and to the GFP control (1.31% vs. 0.11% and 
vely) (Fig .5d).  
(1.5-7.7fold). In almost all the samples where Hoxb ∆Pro was overexpres
we repor incr ca-1 
comparison to -wt
0.26%, respecti . 4.5.2
Mice (n) Sca-1 (%) c-kit (%) d.p. (%) 
GFP control (3) 16.76 0.42 0.26 
HOXB4-wt (8) 9.4 2.46 0.11 
HOXB4-∆Pro 1st Tx (8) 8.8 6.18 1.31 
HOXB4-∆Pro 2nd Tx (3) 3.2 18.89 1.05† 
HOXB4-∆Pro 3rd Tx (3) 0.81*† 1.76* 0 
HOXB4-∆Pro+VPA (3) 4.16 7.22 1.2† 
HOXB4-∆Pro-PBX (3) 28.95† 3.61 0.57† 
HOXB4-∆Pro-PBX+VPA (2) 18.45 8.14 0.36 
Table 4.5.2.5d. Sca-1 and c-kit immunostaining of WBCs in the PB of mice at sacrifice. The 
percentages of positive WBCs are indicated. *significant difference vs. the GFP control; 
†significant difference vs. the Hoxb4-wt (p<0.05). 
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 at sacrifice. The 
increase of the 
e GFP control, 
n lower than in 
e Hoxb4-∆Pro 
 the GFP 
Pro 1st Tx and 
n the Hoxb4-wt 
f WBCs in the 
, while it was 
rtion of WBCs 
antly higher in 
 mice (p=n.s.) 
positive WBCs 
th week post 
 d.p. 85.26%) 
and at sacrifice (Mac-1+ 63%, Gr-1+ 49%, and Mac-1+/Gr-1+ d.p. 46.93%), we 
reported a significant over time decrease of 29%, 37%, and 39%, respectively 
(p<0.05). In contrast, in the Hoxb4-∆Pro mice we reported a significant over time 
increase of 45%, 44%, and 43% in Mac-1+, Gr-1+ and double positive, 
respectively (at 16 weeks post transplantation, 43.02%, 29.01%, and 29.23%, vs. 
88%, 73.08%, and 72.09% at sacrifice, respectively) (p<0.00001). We can 
Fig. 4.5.2.5d. Sca-1 and c-kit immunostaining of WBCs in the PB of mice
percentages of positive WBCs are indicated.  
Considering the myeloid compartment, we reported a significant 
Mac-1+ and Gr-1+ WBCs in almost all the mice in comparison to th
while in the Hoxb4-∆Pro-PBX+VPA the myeloid WBCs were eve
the GFP control. The Mac-1+ cells in the Hoxb4-∆Pro 1st Tx, in th
3rd Tx, and in the Hoxb4-∆Pro+VPA were significantly higher than in
control (1.8-, 2-, and 1.7fold, respectively, p<0.05). In the Hoxb4-∆
3rd Tx mice the Mac-1+ WBCs were also significantly higher than i
(p<0.02). The Gr-1 marker was expressed in a similar proportion o
GFP control and in the Hoxb4-wt mice as observed for Mac-1
significantly higher expressed in Hoxb4-∆Pro 2nd and 3rd  mice (1.7fold higher vs. 
Hoxb4-wt, p<0.04; 2fold higher vs. GFP control, p<0.03). The propo
expressing both the Mac-1 and the Gr-1 markers were signific
almost all the Hoxb4-∆Pro mice than in the Hoxb4-wt and the GFP
(Table and Fig. 4.5.2.5e). Interestingly, the proportion of myeloid 
in the PB of Hoxb4-wt mice decreased significantly over time. Comparing the 
proportion of myeloid WBCs in the Hoxb4-wt mice at four
transplantation (Mac-1+ 92.17%, Gr-1+ 85.5%, and Mac-1+/Gr-1+
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conclude that in these two populations of mice there was an opposite 
deve t of myeloi in the P .5.2.5e2lopmen d WBCs B (Fig. 4 ).  
Mice (n) Mac-1 (%) Gr-1 (%) d.p. (%) 
GFP control (3) 49.04 39.23 35.68 
HOXB4-wt (8) 63.07 49.06 49 
HOXB4-∆Pro 1st Tx (8) 88*† 73.08 72.09 
HOXB4-∆Pro 2nd Tx (3) 44.3 90.02*† 39.256 
HOXB4-∆Pro 3rd Tx (3) 96.81*† 82.76*† 60.12 
HOXB4-∆Pro+VPA (3) 84.61* 60.59 60 
HOXB4-∆Pro-PBX (3) 81.32 75.7 67.6 
HOXB4-∆Pro-PBX+VPA (2) 14.21*† 20.68 14 
Table 4.5.2.5e. Mac-1 and Gr-1 immunostaining of WBCs in the PB of mice at sacrifice. The 
percentages of positive WBCs are indicated. * significant difference vs. the GFP control; † 
significant difference vs. the Hoxb4-wt. 
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Fig. 4.5.2.5e. Mac-1 and Gr-1 immunostaining of WBCs in the PB of mice at sacrifice. The 
percentages of positive WBCs are indicated.  
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Fig. 4.5.2.5e2. Mac-1 and Gr-1 positive WBCs from peripheral blood of mice transplanted with BM 
cells overexpressing Hoxb4-wt and Hoxb4-∆Pro. All the differences between the initial value and 
the final value at sacrifice were significant for each marker (p<0.05). 
 
The marker Ter-119 was used to analyse the differentiation into the erythroid 
lineage. We reported a significant decrease of this subpopulation in almost all the 
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mice in comparison to the GFP control (p<0.0002). The B-lymph
antigen B220 was lower expressed in almost all the samples harbo
mutation than in the GFP control and in the Hoxb4-wt (Hoxb4-∆
and 3fold, 2nd Tx=13- and 15fold, 3rd Tx=9.5- and 1
ocytes specific 
uring the ∆Pro 
Pro 1st Tx=2.6- 
0fold lower than in the GFP 
con oxb4-wt, respec  (Table and re 4.5.2.5f). trol and in H tively)  Figu
Mice (n) Ter-119 (%) B220 (%) 
GFP control (3) 83.45† 15.86 
HOXB4-wt (8) 19.09* 18.20 
st Tx (8) HOXB4-∆Pro 1 20.56* 5.92 
nd Tx (3) HOXB4-∆Pro 2 10.05* 1.21 
HOXB4-∆Pro 3rd Tx (3) 6.3* 1.66 
HOXB4-∆Pro+VPA (3) 9.52* 4.85 
HOXB4-∆Pro-PBX (3) 11.96* 5.52 
HOXB4-∆Pro-PBX+VPA (2) 30.92 16.11 
Table 4.5.2.5f. Ter-119 and B220 immunostaining of WBCs in the peripheral blood of mice at 
sacrifice. The percentages of positive WBCs are indicated. *significant difference vs. the GFP 
control; † significant difference vs. the Hoxb4-wt (p<0.05). 
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 at sacrifice. The 
The T-lymphocytes specific marker CD4 wa nificantly lower expressed in 
l the samples comparison  the GFP rol (Hoxb4-wt=3fold, 
Pro 1st Tx=5fol  Tx=11fold  Tx=9.5fold lower than in the GFP 
control, p<0.04). The percentage of T-lymphocytes expressing both markers in 
the peripheral blood was significantly lower in all the samples in comparison to 
the GFP control mice (Table and Figure 4.5.2.5g).  
Fig.4.5.2.5f. Ter-119 and B220 immunostaining of WBCs in the PB of mice
percentages of positive WBCs are indicated. 
 
s also sig
almost al  in  to cont
Hoxb4-∆ d, 2nd , 3rd
Mice (n) CD4 (%) CD8 (%) d.p. (%) 
GFP control (3) 11.4 3.9 0.56 
HOXB4-wt (8) 3.74* 1.54 0.11* 
HOXB4-∆Pro 1st Tx (8) 2.3* 1.95 0.04* 
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HOXB4-∆Pro 2nd Tx (3) 1.07 0.48* 0.03 
HOXB4-∆Pro 3rd Tx (3) 1.21*† 0.8* 0.8 
HOXB4-∆Pro+VPA (3) n.a. n.a. n.a. 
HOXB4-∆Pro-PBX (3) n.a. n.a. n.a. 
HOXB4-∆Pro-PBX+VPA (2) 1.24 0.62 0 
Table 4.5.2.5g. CD4 and CD8 immunostaining of WBCs in the PB of mice at sacrifice. The 
percentages of positive WBCs are indicated. * significant difference vs. the GFP control; † 
significant difference vs. the Hoxb4-wt (p<0.05). 
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at sacrifice. The Fig. 4.5.2.5g. CD4 and CD8 immunostaining of WBCs in the PB of mice 
percentages of positive WBCs are indicated.  
 
Lymphoid/myeloid ratio in PB 
At sacrifice the WBCs from the peripheral blood of diseased mi
stained for lymphoid (CD4, CD8, B220) and myeloid (Gr-1, M
surface markers. In the case of Hoxb4-wt overexpression we reported a reduction 
ce have been 
ac-1, Ter119) 
of the lymphoid proportion when compared to the GFP control (23.5% vs. 67.7 %, 
respectively), while in the mice where the Hoxb4-∆Pro was overexpressed the 
majority of the WBCs were myeloid (lymphoid ≤ 10%, myeloid 90-100%) (Fig. 
4.5.2.5h). This reflects the amplificatory effect of the Hoxb4-∆Pro on the myeloid 
compartment.  
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lack bars indicate Fig. 4.5.2.5h. Lymphoid/myeloid ratio of WBCs of PB at sacrifice. Horizontal b
the medians. 
 
Immunophenotype of bone marrow WBCs at sacrifice 
At sacrifice the bone marrow has been prepared out of the legs bones
analysed for the expression of lineage specific surface markers. 
observation in PB, the Sca-1 marker was expressed at lower leve
3rd Hoxb4-∆Pro transplanted mice (32- and 18fold less, p=n.s.) in
the GFP control mice
 and 
Similarly to the 
l in the 2nd and 
 comparison to 
, while in Hoxb4-wt mice it was similar to the control mice. 
marker was hig expressed e samples overexpressing Hoxb4-wt 
 Hoxb4-∆Pro nd 2nd T ∆Pro-PBX 
mparison to the 
ble 4.5.2
The c-kit her in th
(1.2fold), 1st a x (1.5- and 3.2fold), Hoxb4-
(3.2fold), and in Hoxb4-∆Pro-PBX+VPA (3.6fold, p<0.03) in co
GFP control (Ta .5i). 
Mice (n) Sca-1 (%) c-kit (%) d.p. (%) 
GFP control (3) 5.16 8.72 0.51 
HOXB4-wt (3) 2.08 10.89 1.15 
HOXB4-∆Pro 1st Tx (7) 10.76 13.86 1.64 
HOXB4-∆Pro 2  Tx (2) nd 0.16 28.30 0.03 
HOXB4-∆Pro 3rd Tx (1) 0.44 2.31 0.01 
HOXB4-∆Pro+VPA (3) 2.89 5.58 0.83 
HOXB4-∆Pro-PBX (3) 9.6† 28.29 3.34 
HOXB4-∆Pro-PBX+VPA (2) 15.94 31.61*† 10.52 
Table 4.5.2.5i. Sca-1 and c-kit immunostaining of WBCs in the BM of mice at sacrifice. The 
percentages of positive WBCs are indicated. * significant difference vs. the GFP control; † 
significant difference vs. the Hoxb4-wt (p<0.05). 
 
GFP        HOXB4- HOXB4-∆Pro HOXB4-
∆Pro+VPA 
HOXB4-∆Pro-PBX 
  -VPA     +VPA wt 1st Tx        2nd Tx         3rd Tx 
 97
Chapter 4 - Results 
 
When considering the myeloid compartment, we reported an highe
Mac-1+ cells in almost all the Hoxb4-wt and Hoxb4-∆Pro mice whe
the GFP control mice. In the Hoxb4-wt this increase was 1.4fold
∆Pro (1st, 2nd, 3rd Tx) it was 1.6-, 1.5-, and 1.7fold, respectively, 
∆Pro+VPA 1.4fold higher than in the GFP control (p<0.015). Similarly, the Gr-1 
marke
r proportion of 
n compared to 
, in the Hoxb4-
and in Hoxb4-
r was higher expressed in the Hoxb4-wt (1.5fold), and in Hoxb4-∆Pro mice 
(1st Tx 1.4-, 2nd Tx 1.7 1.6fold  the GFP control (p<0.05) (Table -, 3rd Tx ) than in
4.5.2.5j). 
Mice (n) Mac-1 (%) Gr-1 (%) d.p. (%) 
GFP control (3) 56.28 53.96 53.96 
HOXB4-wt (3) 79.65 79.38 78.16 
HOXB4-∆Pro 1st Tx (7) 90.84* 76.75 74.10 
HOXB4-∆Pro 2  Tx (2) nd 86.86 92.85 81.74 
HOXB4-∆Pro 3rd Tx (1) 97.86 86.5 86 
HOXB4-∆Pro+VPA (3) 76.52 49.09 49 
HOXB4-∆Pro-PBX (3) 60.43 59.3 37.79 
HOXB4-∆Pro-PBX+VPA (2) 33.31† 41.66 29.72*† 
Table 4.5.2.5j. Mac-1 and Gr-1 immunostaining of WBCs in the BM of mice
percentages of positive WBCs are indicated. * significant difference vs. the
significant difference vs. the Hoxb4-wt (p<0.05). 
 
The erythroid lineage was lower represented in the BM pooled ce
 at sacrifice. The 
 GFP control; † 
lls from all the 
mice in com  to the GF l (Hoxb fold, Hoxb4-∆Pro 1st, 2nd 
and as 9-, 44-, and ld, respectively, lower than in the GFP). 
Similarly, the lymphoid marker B220 was lower expressed in the Hoxb4-wt and in 
the nd 3rd Tx mice than in the GFP control mice (3.6-, 4.4-, 
4.4fold, respectively, p=n.s.) (Table 4.5.2.5k). 
parison P contro 4-wt 4.4
3rd Tx it w  20fo
Hoxb4-∆Pro 2nd a
Mice (n) Ter-119 (%) B220 (%) 
GFP control (3) 33.77 8.16 
HOXB4-wt (3) 7.71 2.26 
HOXB4-∆Pro 1st Tx (7) 4.16 7.93 
HOXB4-∆Pro 2nd Tx (2) 0.77 1.84 
HOXB4-∆Pro 3rd Tx (1) 1.69 1.84 
HOXB4-∆Pro+VPA (3) 22.52 15.29 
HOXB4-∆Pro-PBX (3) 10.49 21.21 
HOXB4-∆Pro-PBX+VPA (2) 12.41 7.05 
Table 4.5.2.5k. Ter-119 and B220 immunostaining of WBCs in the BM of mice at sacrifice. The 
percentages of positive WBCs are indicated.  
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Considering the T-lymphoid specific markers, in almost all the H
reported a decrease in the CD4 positive lymphoid population 
Hoxb4-∆Pro 2
oxb4 mice we 
(Hoxb4-wt 3-, 
nd Tx 1.7- and 3rd Tx 2.3fold) in comparison to the GFP control 
(Table 4.5.2.5l). 
Mice (n) CD4 (%) CD8 (%) d.p. (%) 
GFP control (3) 3.47 0.72 0.05 
HOXB4-wt (8) 1.18 0.85 0.07 
HOXB4-∆Pro 1st Tx (8) 8.58 5.28 0.29 
HOXB4-∆Pro 2  Tx (3) nd 2 0.47 0.09 
HOXB4-∆Pro 3rd Tx (3) 1.51 0.9 0.03 
HOXB4-∆Pro-PBX+VPA (2) 2.06 0.37 0.03 
Table 4.5.2.5l. CD4 and CD8 immunostaining of WBCs in the BM of mice
percentages of positive WBCs are indicated.  
 
Interestingly, when the BM WBCs of Hoxb4-wt and of Hoxb4-∆Pro mice were co-
stained with the c-kit and the myeloid markers Mac-1/Gr-1 specific
observed a dramatic increase in the proportion of double positiv
 at sacrifice. The 
 antibodies, we 
e cells (7.14% in 
Hoxb4-wt, 12.3% in the 1st Tx Hoxb4-∆Pro, and 21.4% in the 2nd Tx Hoxb4-∆Pro, 
respectively) in comparison to the GFP control mice (0.8%). The additional co-
staining of the same myeloid markers with Sca-1 antibody did not show 
significant differences between all the samples analyzed (Fig. 4.5.2.5la). 
0
5
Sca-1/Gr-1/Mac-1 ckit/Gr-1/Mac-1
10
15
25
30
35
20
GFP 
HOXB4 wt 
HOXB4 ∆Pro
HOXB4 ∆Pro 2nd Tx
HOXB4 ∆Pro 3nd Tx
 
Fig. 4.5.2.5la. Co-staining of WBCs in the BM of mice at sacrifice. The percentages of positive 
WBCs are indicated.  
 
Immunophenotype of cells obtained from the spleen at sacrifice 
The spleen of dead mice has been mashed and the single cells suspension has 
been stained with the same lineage specific antibodies. The size and the total 
cells numbers are reported above in this paragraph. We observed the same 
immunophenotype as reported in case of the WBCs from BM and PB. In the 
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Hoxb4-wt and the Hoxb4-∆Pro the Sca-1+ cells were 8.8fold and 12
Tx 54-, in the 3rd Tx 68fold) lower than in the GFP control, respectiv
The proportion of c-kit+ cells in the Hoxb4-wt mice was significantly
the GFP control (18% vs. 1.5%, respectively, p<0.024), wh
fold (in the 2nd 
ely (p<0.008). 
 higher than in 
ile in the Hoxb4-∆Pro 
s up to 25fold h r than in the GFP control (Table 4.5.2.5m).  mice it wa ighe
Mice (n) Sca-1 (%) c.kit (%) d.p. (%) 
GFP control (3) 55.5 1.5 0.87 
HOXB4-wt (8) 6.3* 18.12* 2.71 
HOXB4-∆Pro 1  Txst  (8) 4.63* 36.54 0.92 
HOXB4-∆Pro 2nd Tx (3) 1.03*† 38.4 0.83 
HOXB4-∆Pro 3rd Tx (3) 0.81 3.54 0.02 
HOXB4-∆Pro+VPA (3) 28.77 12.77* 3.14* 
HOXB4-∆Pro-PBX (3) 24.44 21.37* 3.93 
HOXB4-∆Pro-PBX+VPA (2) 35.45 48.76* 15.66 
Table 4.5.2.5m. Sca-1 and c-kit immunostaining of WBCs in the spleen of mice
percentages of positive WBCs are indicated. * significant difference vs. the
significant difference vs. the Hoxb4-wt (p<0.05). 
 
The proportion of Mac-1+ cells was also higher in the Hoxb4-wt (7fo
Hoxb4-∆Pro (11fold in th
 at sacrifice. The 
 GFP control; † 
ld, p<0.03), in 
e 1st Tx, 12fold in the 2nd Tx, 13fold in the 3rd Tx, 
p<0.0 nd in Hox -PBX (1 n compa  the GFP control. 
 the proportion -1+ cells w igher in Ho wt (3.6fold), Hoxb4-
, p<0.008 d in the H ∆Pro-PBX (5fold) in comparison to 
008), a b4-∆Pro 0fold) i rison to
Similarly,  of Gr as h xb4-
∆Pro (4-5.6fold ), an oxb4-
the GFP control (Table 4.5.2.5n). 
Mice (n) Mac-1 (%) Gr-1 (%) d.p. (%) 
GFP control (3) 7.3 13.6 1 
HOXB4-wt (8) 50.84* 48.89 47.1* 
HOXB4-∆Pro 1st Tx (8) 79.63* 56.24* 48.67* 
HOXB4-∆Pro 2nd Tx (3) 84.89* 80.98* 69.52* 
HOXB4-∆Pro 3  Tx (3) rd 95.64 76.64 76.17 
HOXB4-∆Pro+VPA (3) 78.05* 44.07 44* 
HOXB4-∆Pro-PBX (3) 76.23 67.46 65.63 
HOXB4-∆Pro-PBX+VPA (2) 18.54 12.08 11.69 
Table 4.5.2.5n. Mac-1 and Gr-1 immunostaining of WBCs in the spleen of mice at sacrifice. The 
percentages of positive WBCs are indicated. * significant difference vs. the GFP control; † 
significant difference vs. the Hoxb4-wt (p<0.05). 
 
The proportion of Ter119+ cells was also lower in all the samples, in comparison 
to the GFP control (Hoxb4-∆Pro 11.5fold lower (p<0.01)). The B220+ cells were 
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similarly less in all the HOXB4 mice in comparison to the GFP con
8fold, 
trol (Hoxb4-wt 
Hoxb4-∆Pro 1st Tx 40-, 2nd Tx 18-, 3rd Tx 13fold lower, p<0.05) (Table 
4.5.2.5o).  
Mice (n) Ter-119 (%) B220 (%) 
GFP control (3) 19.3 52.3 
HOXB4-wt (8) 17.94 6.66* 
st Tx (8) HOXB4-∆Pro 1 1.67* 1.28* 
nd Tx (3) HOXB4-∆Pro 2 3.02 2.91 
HOXB4-∆Pro 3  Txrd  (3) 1.94 4.05 
HOXB4-∆Pro+VPA (3) 9.6 17.43 
HOXB4-∆Pro-PBX (3) 6.41 9.61 
HOXB4-∆Pro-PBX+VPA (2) 2.63 9.75 
Table 4.5.2.5o. Ter-119 and B220 immunostaining of WBCs from the spleen o
The percentages of positive WBCs are indicated. * signifi
 
f mice at sacrifice. 
cant difference vs. the GFP control. 
The T-lymphoid cells specific markers CD4+ and CD8+ were less expressed in 
 as in the Hoxb4-∆  
 in case of cells  PB and B able 4.5.2.5
the Hoxb4-wt as well Pro in comparison to the GFP control, as
observed  from M (T p). 
 
Mice (n) CD4 (%) CD8 (%) d.p. (%) 
GFP control (3) 14.9 8.7 0.1 
HOXB4-wt (8) 2.53 2.01 0.13 
HOXB4-∆Pro 1st Tx (8) 0.72 0.05 0.03 
HOXB4-∆Pro 2nd Tx (3) 3.65 0.93 0.18 
HOXB4-∆Pro 3rd Tx (3) 0.84 2.58 0.05 
HOXB4-∆Pro+VPA (2) n.a. n.a. n.a. 
HOXB4-∆Pro-PBX (3) n.a. n.a. n.a. 
HOXB4-∆Pro-PBX+VPA (2) 1.84 0.27 0.05 
Table 4.5.2.5p. CD4 and CD8 immunostaining of WBCs in the spleen of mic
percentages of positive WBCs are indicated.  
e at sacrifice. The 
 
Interestingly, by performing double stainings for the c-kit/myeloid (Mac-1/Gr-1) 
markers we reported an increased proportion of these double positive cells also 
in the spleen of Hoxb4-wt and Hoxb4-∆Pro mice in comparison to the GFP 
control at sacrifice (Table 4.5.2.5q). In current experiments we are investigating, if 
the leukemic stem cells in this AML model are residing within this subpopulation.  
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Mice (n=2) kit+/Mac-1+/Gr-1+ (%) c-
GFP control  0.82 
HOXB4-wt  6.39 
HOXB4-∆Pro 1  Tx  st 11 
HOXB4-∆Pro 2nd Tx  31.8 
Table 4.5.2.5q. Immunostaining for c-kit, Mac-1 and Gr-1 surface markers of WB
of mice at sacrifice is reported. The percentages of positive WBCs are indicated.
 
In summary, we observed consistently a significant increase of c-k
peripheral blood, bone marrow and spleen of Hoxb4-∆Pro disea
increase of myeloid cells (Mac-1 and Gr-1), and a decrease in the
lymphoid c
Cs in the spleen 
  
it+ cells in the 
sed mice, an 
 proportion of 
ells (B220, CD4, and CD8) in the peripheral blood as well as in the 
ice. The following 
panels show the morphology of cells obtained from representative mice (Fig. 
4.5.2.5i). 
                GFP                                   Hoxb4-wt                           Hoxb4-∆Pro 
spleen, in comparison to the GFP control and Hoxb4-wt m
   PB PB PB
   
   
Fig. 4.5.2.5i. May-Gruenwald stainings of blood smears and cytospin preparations from PB, BM, 
spleen of transplanted mice. Bars: 8 µm, X630. 
 
 
BM BM BM
Spleen Spleen Spleen 
__ 
__ __ __ 
__ 
 __ __
__ __ 
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4.5.2.6 Colony forming cells-assay (CFC) ex vivo 
Long term. 13 weeks post transplantation BM aspiration has b
from GFP control (n=1), Hoxb4-wt (n=2) and from Hoxb4-∆Pro (
20,000 cells/dish have been plated in methylcellulose, to allow
myeloid colonies. At this time point after transplantation we repor
the GFP control, while in the Hoxb4-wt we counted 256 CFCs, and
∆Pro 69 CFCs. In all the samples the presence of VPA (1mM) 
increase in the CFCs frequency (data not shown). Moreover, in th
CFCs were 22,3% G, 26% GM, 22% M, 24% BFU-E, 3% GEMM, 
while in the Hoxb4-∆Pro we reported <1% G, 33% GM, 0.3% M, 58.5% B
and no GEMM/Mek CFCs. In the GFP control we reported 19%
37.5% M, and 12.5% BFU-E CFCs. Analyzing the pooled cells fro
Hoxb4-∆Pro we reported that only 6% and 7.4% 
een performed 
n=1) mice and 
 the growth of 
ted 35 CFCs in 
 in the Hoxb4-
led to a slight 
e Hoxb4-wt the 
and 2.7% Mek, 
FU-E, 
 G, 31% GM, 
m the CFCs of 
of the cells were positive for 
e 60.46% and 
 BM cells have 
ol we reported 
 colonies. We 
ation there is already a reduction of 
 comparison to 
eloid/lymphoid 
control. At this 
∆ w any sign of 
Mac-1 and Gr-1 respectively, while in the GFP control they wer
63.5%, respectively. In the Hoxb4-wt samples 38.2% and 32.9% of the pooled 
cells from CFCs were positive for Mac-1 and Gr-1, respectively.  
In the lymphoid colony forming unit assay (proB) 100,000 primary
been plated in methylcellulose containing IL7. In the GFP contr
39.6 colonies, in the Hoxb4-wt 44.25, and in the Hoxb4-∆Pro 6.5
can conclude that 13 weeks after transplant
the mature myeloid and lymphoid CFCs in the Hoxb4-∆Pro BM in
the Hoxb4-wt and to the GFP control, while in the Hoxb4-wt the my
CFCs counts were similar to the CFCs observed in case of the 
time point the Hoxb4- Pro mice were healthy and did not sho
leukemia, maybe reflecting a pre-leukemic state. 
At sacrifice. At sacrifice we performed the CFC assay from
peripheral blood and spleen cells by plating 100,000 cells into m
containing SCF, IL3 and IL6. In the BM from Hoxb4-∆Pro m
 bone marrow, 
ethylcellulose 
ice we saw a 
dramatic increase of CFCs (1st Tx=2983 CFCs, n=4, 98.3% blast-like colonies; 
2nd Tx=2111 CFCs, n=3, 92.5% blast-like colonies, and 3rd Tx=1296 CFCs, n=2, 
90.7% blast-like colonies), in comparison to the Hoxb4-wt (365 CFCs, n=3, 
46.3% blast-like colonies) and to the GFP control (204 CFCs, n=3, 21.7% blast-
like colonies). In the BM from GFP mice we reported 160 mature myeloid 
colonies (G=31, GM=98, M=19, GEMM=9, MeK=3) per 100,000 plated cells, 
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based on the colony morphology, while in the BM of Hoxb4-wt mic
184 myeloid colonies (G=65, GM=65, M=53, GEMM=2, MeK=0
plated cells. In the BM of 1st Tx Hoxb4-∆Pro mice we reported a 3fo
the number of mature myeloid colonies (51 myeloid CFCs: G=20, 
GEMM=0, Mek=0) when compared to the GFP control (p=0.11), while in the 
Hoxb4-∆Pro 2nd and 3rd tran
e we reported 
) per 100,000 
ld decrease in 
GM=31, M=0, 
splanted mice the myeloid colonies were 158 (G=7, 
GM=36, M=115, GEMM=0, Mek=0) and 120 (G=0, GM=120, M=0, GEMM=0, 
Mek=0), respectively (Fig.4.5.2.6a). 
1,E-01
1,E+03
C
F
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4,E+03
5,E+03
G GM M GEMM Mek Blasts BFU-E total
C
s/
10
0,
00
0 
pl
at
ed
 c
el
l
GFP (n=4) 
s
HOXB4-wt (n=3)
HOXB4∆Pro 1Tx (n=4)
HOXB4∆Pro 2Tx (n=3)
HOXB4∆Pro 3Tx (2)
HOXB4∆Pro+VPA (n=1)
HOXB4∆Pro+PBX (n=1)
HOXB4∆Pro+PBX+VPA (n=1)
 
ated into 
ve been counted. 
ke BFU-
 we reported a 
9 CFCs, n=3, 
 colonies, and 
 the Hoxb4-wt 
 0% 
ce we reported 
0 plated cells, 
wt mice we reported 8.5 myeloid colonies (G=0, 
GM=8.5, M=0, GEMM=0, MeK=1). In the PB of 1st Tx Hoxb4-∆Pro mice we 
reported a similar number of mature myeloid colonies (10 myeloid CFCs: G=0, 
GM=1, M=6, GEMM=1, Mek=2) when compared to the GFP control, while in the 
corresponding 2nd and 3rd transplanted mice the myeloid colonies were 680 (G=0, 
GM=0, M=680, GEMM=0, Mek=0) and 63 (G=0, GM=63, M=0, GEMM=0, 
Mek=0), respectively (Fig. 4.5.2.6b). 
Fig. 4.5.2.6a. 1° CFC from BM of mice at sacrifice. 100,000 BM cells have been pl
methylcellulose containing IL3, IL6 and SCF and after one week the colonies ha
The blast CFCs in GFP control and in Hoxb4-wt appeared more similar to mature CFCs li
E. 
 
When plating 100,000 nucleated cells from PB into methylcellulose
significant increase of CFCs in the Hoxb4-∆Pro mice (1st Tx=25
96.2% blast-like colonies; 2nd Tx=1140 CFCs, n=2, 40.3% blast-like
3rd Tx=369 CFCs, n=4, 82.9% blast-like colonies), in comparison to
(3.8 CFCs, n=2, 0% blast-like colonies) and to the GFP control (1 CFCs, n=3,
blast-like colonies, p=0.26, p=0.009, p=0.001). In PB from GFP mi
1 myeloid colony (G=0, GM=1, M=0, GEMM=0, MeK=0) per 100,00
while in the PB of Hoxb4-
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HOXB4∆Pro 2Tx (n=2)
HOXB4∆Pro 3Tx (n=4)
 
 been plated into 
ve been counted. 
 spleen into 
e Hoxb4-∆Pro 
FCs, n=3, 54% 
 in comparison 
0.11, p=0.016, 
nies, p=0.198, 
d 1.3 myeloid 
ted cells, while 
 (G=7, GM=15, 
en of 1st Tx Hoxb4-∆Pro mice we reported a 
higher number of myeloid colonies (84.1 myeloid CFCs: G=0, GM=81.5, M=2.6, 
GEMM=0, Mek=0) when compared to the GFP control, while in the 
corresponding 2nd and 3rd transplanted Hoxb4-∆pro mice the myeloid colonies 
were 883.3 (G=0, GM=0, M=883.3, GEMM=0, Mek=0) and 2 (G=0, GM=2, M=0, 
GEMM=0, Mek=0), respectively (Fig 4.5.2.6c). 
Fig 4.5.2.6b. 1° CFC from PB of mice at sacrifice. 100,000 WBCs have
methylcellulose containing IL3, IL6 and SCF and after one week the colonies ha
 
Similarly, when plating 100,000 nucleated cells from the
methylcellulose we reported a significant increase of CFCs in th
mice (1st Tx=638 CFCs, n=4, 86.8% blast colonies; 2nd Tx=1920 C
blast colonies, and 3rd Tx=342 CFCs, n=2, 99.4% blast colonies),
to the Hoxb4-wt (35.3 CFCs, n=2, 3% blast colonies, p=0.33, p=
respectively) and to the GFP control (1.3 CFCs, n=4, 0% blast colo
p<0.045, p<0.002). In the spleen from the GFP mice we reporte
colonies (G=0, GM=1.3, M=0, GEMM=0, MeK=0) per 100,000 pla
in the spleen of HOXB4-wt mice we reported 25 myeloid colonies
M=2, GEMM=1, MeK=0). In the sple
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 been plated into 
ted. 
ethylcellulose 
counted. From 
ed 388 2°CFCs per 100,000 replated cells 
from 1°CFC (30% BFU-E and GM mature myeloid/mast cells CFCs). In the 
Hoxb4-wt we counted 819 2°CFCs (42% BFU-E, 32% mast cells CFCs), while in 
the Hoxb4-∆Pro the CFCs counted were 703 (83% blast-like) (n=2) (Fig. 
4.5.2.6d).  
Fig 4.5.2.6c. 1° CFC from spleen of mice at sacrifice. 100,000 WBCs have
methylcellulose containing IL3, IL6 and SCF and after one week the colonies have been coun
 
The 1° CFCs have been harvested, pooled and replated into m
containing IL3, IL6 and SCF. After 1 week the 2°CFCs have been 
the BM of GFP control mice we report
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Fig 4.5.2.6d. 2° CFC from BM of mice at sacrifice. 100,000 cells from 1°CFC have been plated 
into methylcellulose containing IL3, IL6 and SCF and after one week the colonies have been 
counted. 
 
The 2°CFCs from the spleen of GFP mice were only 0.5/100,000 replated cells, 
while in the Hoxb4-wt and Hoxb4-∆Pro we reported 876 and 732 
2°CFCs/100,000 replated cells, respectively. In case of Hoxb4-wt 29% of 2°CFCs 
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were mast cells-CFCs and 69% were mature myeloid CFCs, w
Hoxb4-∆Pro 68% of the 2°CFCs maintained a blast-like morpholo
4.5.2.6e). These results suggest that in the Hoxb4-∆Pro the 
progenitor cells transplanted were maintaining a higher replati
hile in case of 
gy (n=2) (Fig. 
hematopoietic 
ng capacity in 
comparison to the GFP control, and that this was conserved in the progenitor 
cells colonizing the spleen. 
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have been plated 
lonies have been 
rmed the proB-
B-CFCs, while 
B-CFCs (n=3). 
 the same IL7-
 1st and 2nd Tx, 
 
CS staining for 
leen of Hoxb4-
0.17 (1st Tx n=3), and 0 (2nd Tx n=2) proB-CFCs. Moreover, as observed in case 
of the BM from Hoxb4-∆Pro, we reported also from the spleen of these mice the 
growth of blast-like colonies (232 and 242 CFCs in the 1st and 2nd Tx mice, 
respectively). Similarly, from the PB of Hoxb4-∆Pro mice we counted 738 and 
159 blast-like CFCs (2nd and 3rd Tx, respectively), which were able to grow only in 
the presence of IL7, in the absence of normal proB-CFCs (Fig. 4.5.2.6f). In the 
Fig 4.5.2.6e. 2° CFC from spleen of mice at sacrifice. 100,000 cells from 1°CFC 
into methylcellulose containing IL3, IL6 and SCF and after one week the co
counted. 
 
Moreover, from the primary samples mentioned above we perfo
CFCs assay at sacrifice, by plating 100,000 primary cells in IL7-containing 
methylcellulose. In the BM of GFP control mice we reported 53 pro
in the BM cells expressing Hoxb4-wt we counted 13.5 pro
Interestingly, when BM cells from Hoxb4-∆Pro mice were plated in
containing methylcellulose we counted 755.5 and 1172 CFCs from
respectively. Only a small number of these CFCs were effectively proB-CFCs
(49.5 from 1st Tx, n=4, and 0 in 2nd Tx, n=2), as confirmed by FA
B220 and myeloid specific markers (data not shown). From the sp
wt mice we reported 5 proB-CFCs (n=3), while in the Hoxb4-∆Pro there were 
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immunostaining of the cells harvested from these dishes we repor
of the cells were positive for the myeloid markers Mac-1 and G
shown). Taken together these results suggest that the 1°CFCs fro
and PB of Hoxb4-∆Pro leukemic mice were able to grow in the ab
ted that >80% 
r-1 (data not 
m BM, spleen 
sence of IL3, 
IL6 and SCF, and were expressing myeloid markers, while the B-lymphoid 
compartment was displaced. 
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nd spleen of mice at sacrifice. 100,000 cells have been 
onies have 
e blast-like CFCs 
al disease in 
he sequencing 
ase 1 
as common integration site (CIS) in the RTCGD 
database (http://rtcgd.ncifcrf.gov/
Fig 4.5.2.6f. 1°proB-CFCs from BM a
plated into methylcellulose containing IL7 (proB-CFC assay) and 5 days later the col
been counted. Interestingly, in BM and spleen from HOXB4-∆Pro more immatur
were able to grow in the absence of IL3, IL6 and SCF (n=2). 
 
4.5.2.7 Retroviral integration analysis 
The analysis of proviral integration sites demonstrated oligoclon
primary, secondary, and tertiary transplanted mice (Fig. 4.5.2.7). T
of retroviral integration sites in diseased mice (n=7) showed in only one c
site in or near a region described 
) (Akagi, 2004). This site has been found in two 
different mice transplanted with BM cells originating from the same transduction 
experiment. We cannot exclude that a clonal event might be responsible for the 
leukemogenesis in the observed cases. However no proviral recurrent integration 
sites have bee d b 5.2.7)n observe  (Ta le 4. . 
     
  1st Hoxb4-wt mouse no.4 (spleen) 1st Hoxb4-wt mouse no.6 (BM)  
A B 
9kb 
2.2kb 
  9kb 
2.9kb 
  >10kb 
  >10kb 
 49kb 
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Retroviral 
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Gene Description Genomic 
location 
Mouse 
no. 
Hoxb4-wt 9 Intron of Palb2 Partner and localizer of BRCA1 7qF3 4 
Hoxb4-wt Intergenic region - XqA4 2 
Hoxb4-wt 1 Intron AK041797 Murine 3 days neonate thymus 
cDNA° 
5qB3 3 
Hoxb4-wt Intergenic region - 12qA1.2 3 
Hoxb4-wt 2 Intron Bcl9l B-cell CLL/lymphoma 9-like 9qA5.2 3 
Hoxb4-wt Intergenic region - 2qC2 6 
Hoxb4-wt 5 Intron/6 Exon 
Cd68 
CD68 11qB3 6 
Hoxb4-∆Pro 3 Intron of Camk2b* CaM-kinase II subunit beta  11qA1 11† 
Hoxb4-∆Pro Intergenic region  - 17qA3.3 18 
Hoxb4-∆Pro 1 Intron Rreb1 RAS-responsive element-binding 
protein 1 (RREB-1) 
13qA3.3 15† 
Hoxb4-∆Pro 3 Intron of Camk2b* CaM-kinase II subunit beta  11qA1 15† 
Hoxb4-∆Pro Intergenic region - 13qD1 34 
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Hoxb4-∆Pro 3´UTR of AK15123  BM macrophage cD c. NA n.o. 13qD1 34 
Hoxb4-∆Pro  4 Intron EDAR EDAR (ectodysplasin-A receptor)-
associated death 
13qA1 32 
Table 4.5.2.7. Identity of retroviral integration sites in diseased mice. N.o.c.
characterized. *Identified in or near regions (distance ~50 kb) desc
 = not otherwise 
ribed as common integration 
sites (CIS) in the RTCGD database (http://rtcgd.ncifcrf.gov/). ° Hypothetical protein from RIKEN 
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ain advantage 
versus the normal HSCs, or if they preferentially give rise to lineage-limited 
progeny. In case of a leukemic phenotype, it is possible to estimate the frequency 
of the leukemic stem cells (LSCs) in the diseased animals in vivo, by injecting 
serial dilutions of leukemic blasts (bulk or from different subpopulations) 
(Deshpande 2006) obtained from a diseased mouse. The animals are considered 
“engrafted” when they develop the disease. Studying Hoxb4, which is known to 
full-length enriched library. † mice transplanted from same transduction experime
 
4.5.2.8 Effect of the proline-rich region deletion on the CRU fre
assay) 
Hoxb4 is a potent enhancer of primitive hematopoietic cell growth, likely by
increasing self-renewal probability, without impairing homeostatic control of HSC 
population size or the rate of production and maintenance of matur
directly assess the effect of Hoxb4-∆Pro overexpression on ea
hematopoiesis we performed the CRU assay. This assay 
transplantation of limiting numbers of “test” cells into lethally irrad
recipients together with 3 x 105 mock carrier cells. Several cohorts of mice have 
been transplanted with serial dilutions of 5-FU enriched BM p
transduced with GFP, Hoxb4-wt and Hoxb4-∆Pro constructs. The
numbers useful for this purpose in case of Hoxb4 has been determ
previous experiments described by other groups (Antonchuck 2001
A positive engraftment of HSCs was considered when at least 1% of the WBCs in 
the peripheral blood were originating from the transplanted cells. T
of recipients where multilineage hematopoiesis was re-genera
determined at 16th week post transplantation by analysing the GFP
WBCs in the peripheral blood. Moreover, it is possible to determin
chimerism of the WBCs, by calculating the proportion of cells originating from the 
transplants within one lineage compartment, in comparison to the
the cells originated from the normal carrier cells injected originally. In this way it is
possible to compare if the cells under investigation have a cert
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be an important gene in the HSCs fate, and that had never been a
leukemia itself so far in mice and humans, we performed the 
injecting 5-FU enriched progenitor cells, freshly transduced with G
and Hoxb4-∆Pro, and we analysed the mice for engraftment (>1% 
peripheral blood) 16 weeks after the transplantation. Subsequently, the mice 
injected with Hoxb4-∆Pro expressing BM cells developed leukemia
in the previous paragraphs. We transplanted 12 mice with the G
mice with Hoxb4-wt and 18 mice with Hoxb4-∆Pro expressing 
cells. At 16th week post transplantation, we measured the 
GFP+WBCs in the PB of all the mice. Using the L-Calc limiting dilution a
software, we reported a frequency of 1 CRU into 834 for Hoxb4-
into 413 for Hoxb4-∆Pro. 12 mice have been injected with up to 
control cells, but no one showed engraftment. Accordingl
observations, where the GFP CRU frequency was reported to be 
months post transplantation (Antonchuk 2001), we also can postulate that the 
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Table 4.5.2.8a. Serial dilutions of 5-FU enriched BM progenitor cells injected i
The engraftment percentages indicate the WBCs-GFP+ in peripheral blood
transplantation. In Hoxb4-∆Pro mice 200 injected cells were sufficient  to ob
engraftment (chimerism >1% in PB), while in Hoxb4-wt 2000 cells have to be i
engraftment at least in 1 mou
n recipient mice. 
 16 weeks after 
tain a long term 
njected to obtain 
se per cohort. In the GFP control mice 50,000 cells had to be 
ch developed 
rism values in 
when different 
njected cells, 
ected cells, in 
proliferative effect at the level of more differentiated progenitor cells induced by 
Hoxb4 when the proline region was deleted (Fig. 4.5.2.8). 
injected to obtain engraftment. *= averages. Leukemia: the numbers of mice whi
leukemia after 16 weeks are indicated.  
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mbers of injected 
2 days after 
transplantation) and all showed multi-lineage reconstitution. For each lineage the 
proportion of GFP+ transplanted cells has been calculated, and these cells can be 
considered able to reconstitute a lineage, if their proportion within a lineage is 
higher than 1%. We reported that in the Hoxb4-∆Pro mice the proportion of GFP+ 
WBCs in the PB within each lineage was significantly lower in comparison to the 
Hoxb4-wt mice (Table 4.5.2.8b). 
 
 
 
Fig. 4.5.2.8. Engraftment (given as % of WBCs-GFP+ in peripheral blood per nu
cells) 16 weeks after transplantation.   
 
Moreover, all the mice were healthy at this time point (11
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Lineage marker (n) Hoxb4-∆Pro (n=10) Hoxb4-wt (n=12) 
(fold decrease vs. wt) 
Sca-1 26.84 7.45* (3.6) 
c-kit 52.96 35.25 (1.5) 
Mac-1 48.45 21.71* (2.2) 
Gr-1 48.46 27.79* (1.7) 
Ter119 50.47 21.55* (2.3) 
B220 34.56 14.22* (2.4) 
CD4 32.82 13.45* (2.4) 
CD8 22.97 9.15* (2.5) 
Table 4.5.2.8b. The chimerism (proportion of GFP+ cells in %) within each lineage is represented. 
*significant reduction vs. the Hoxb4-wt (p<0.05).  
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Chapter 5 – Discussion  
5. Discussion 
The Hoxb4 is a well-known gene expressed in the most primitive hematopoietic 
stem, embryonic and bone marrow progenitor cells. It has been reported to 
govern central intrinsic cellular pathways implicated in the regulation of cell cycle, 
differentiation, and apoptosis. Hoxb4 activity exerts influence on negative and 
positive regulatory signals, leading to HSCs expansion.  
In the present work we focused on the possible mechanism responsible for the 
benign phenotype observed when Hoxb4 is overexpressed, and on its structural 
regions, which might be vital for the unregulated and aberrant proliferation of the 
HSCs. Using the murine bone marrow transplantation model, we assessed the 
oncogenic potential of human Hoxb4 gene by mutagenesis of its domains. As it 
has been already reported, the single aminoacid mutation in the Pbx-interacting 
domain did not affect dramatically the activity of Hoxb4, while it was shown that a 
single aminoacid within the DNA binding homeodomain is essential for its 
hematopoietic stem and progenitor cells activity (Beslu 2004). In particular we 
focused on the proline rich region (Hoxb4-∆Pro), which has never been so far 
described as a functional domain of this protein.  
By performing in vitro assays we reported that the overexpression of the Hoxb4-
∆Pro mutant slightly reduces the amplification of BM progenitor cells and leads to 
a decrease of the Sca-1/c-kit double positive cells number in comparison to the 
Hoxb4-wt, while it was still higher than in the GFP-control. Similarly, the deletion 
of the proline-rich region led to a slight reduction of myeloid cell counts in 
comparison to the Hoxb4-wt, while we did not observe significant changes in the 
number of cells expressing erythroid and B-lymphoid markers.  
Moreover, Hoxb4-∆Pro did not affect the frequency of 1°CFCs when 
overexpressed in 5-FU-BM cells, while it induced a significant increase in the 
replating capacity of these cells in comparison to the Hoxb4-wt and the GFP 
control. In contrast, its overexpression led to a significant decrease in the 12 
days-∆CFU-S frequency in comparison to the Hoxb4-wt, which may reflect a 
reduced amplificatory potential at the level of short term repopulating progenitor 
cells when the proline region is deleted. However, when we analyzed the 
engraftment rate from the peripheral blood of mice transplanted with BM cells 
overexpressing Hoxb4-wt and Hoxb4-∆Pro at 4 weeks post transplantation we 
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did not observe significant differences. Interestingly, at 13-16 weeks post 
transplantation we could document a significant reduction of circulating 
GFP+WBCs in mice transplanted with Hoxb4-∆Pro overexpressing cells in 
comparison to the mice transplanted with Hoxb4-wt expressing BM cells, despite 
equal numbers of initially transplanted cells. Taken together, deletion of the 
proline rich region seems to impair the capacity of HoxB4 to enhance ST-LSC 
activity. On the other hand it seems to augment serial replating capacity of 
HoxB4, which often is taken as a surrogate marker for the transforming activity of 
a gene. In the CRU assay we reported an increase in the frequency of 
competitive repopulating units when Hoxb4-∆Pro was overexpressed (1 into 413 
vs. 1 into 834 transplanted cells in Hoxb4-wt, p=n.s., while in the GFP control the 
CRU-frequency was < 1 into 666,000). This could reflect that the Hoxb4-∆Pro 
mutant has a differential effect on short – term versus long – term repopulating 
stem cells. Of note, the CRU is an assay designed for normal HSCs and might be 
biased by genes which have leukemogenic potential. Thus, it is difficult to rule out 
that the - in comparison to the Hoxb4-wt - increased CRU activity of the proline 
deleted mutant is not due to its leukemogenic effect, which is not present in the 
Hoxb4-wt.  
Since it has been suggested that the Hoxb4-associated regulatory complex might 
control downstream epigenetic events via binding to CBP / p300 and to histone 
deacetylases, we investigated the effect of HDAC inhibition by incubating the BM 
progenitor cells with the well-known HDACi valproic acid (VPA). When the cells 
were incubated with 1mM VPA for one week, we observed an increase in cell 
number in GFP ctrl, Hoxb4-wt, Hoxb4-PBX, Hoxb4-cDel and Hoxb4-HD in 
comparison to the corresponding samples in the absence of VPA. Interestingly, in 
case of the cells expressing the Hoxb4-∆Pro the incubation with VPA led to a 
slight decrease in cell number, indicating that the effect of HDAC inhibition is at 
least partly dependent on the proline rich region. Considering the surface 
immunophenotype of in vitro expanded cells in the presence of VPA, we reported 
an increase of Sca-1+ and a decrease of c-kit+ cells in comparison to the samples 
without VPA, independently from the deletion of the proline region. This suggests 
that the HDAC-activity could play a role in the proliferation of the committed 
progenitors expressing these surface markers, or may induce the differentiation 
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of progenitor cells in vitro, as it has been reported in case of other solid tumors 
(Göttlicher 2001). 
In the presence of VPA the absolute number of Mac-1+ cells was lower in the 
GFP control and in the Hoxb4-wt in comparison to the corresponding samples 
without the HDACi, while in the Hoxb4-∆Pro, Hoxb4-PBX, Hoxb4-cDel and 
Hoxb4-HD the proportion of mature myeloid cells was not affected by the VPA. 
Moreover, VPA led to a decrease in the total number of CFCs in all the samples 
except for the Hoxb4-cDel, in comparison to the corresponding samples without 
VPA, suggesting that the HDAC inhibition was not affecting the differentiation of 
progenitor cells in vitro. In summary, the VPA did not lead to any significant 
change in the differentiation capacity, while similarly the mutation of the single 
domains of Hoxb4 did not significantly affect the lineage specificity. According to 
recent studies, we reported a proliferative effect of VPA on early progenitor cells 
(Bug 2005, De Felice 2005). Indeed, the pre-incubation with VPA increased the 
12 days ∆CFU-S frequency in all the samples in vivo. This effect has been 
suggested from some authors to be mediated by the induction of the 
endogeneous Hoxb4 expression (Seet 2008), while some others have reported a 
Hoxb4-indipendent VPA-induced expansion of HSCs (Obier 2010). Interestingly, 
while performing murine bone marrow transplantation experiments we reported 
for the first time, that the retroviral induced overexpression of human Hoxb4 
harbouring the deletion of the proline rich region leads to a transplantable acute 
myeloid leukemia in vivo 255 days (mean) post transplantation. In the diseased 
mice the leukemic blasts were infiltrating hematopoietic and non-hematopoietic 
organs, were MPO+, and showed a higher CFCs frequency in ex vivo assays. By 
analysing the retroviral integration pattern we documented no recurring 
integration sites, and this suggests that the leukemic phenotype observed was 
not primarily due to an integration event. We can conclude that the deletion of 
this region converts Hoxb4 into a pro-leukemogenic gene in the murine 
transplantation model. However, the relatively long latency time to disease 
development may reflect the accumulation of further hits collaborating to 
malignant transformation. In this HoxB4-∆Pro-associated AML model the in vitro 
VPA treatment (1 mM for 1 week) of BM progenitor cells prior to transplantation 
did not prevent leukemogenesis. This could reflect on one side the resistance of 
the leukemic stem cells to HDAC inhibition, but on the other side, the treatment 
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schedule used might be not sufficient to suppress leukemogenesis. In previous 
reports it has been reported that the VPA induces the differentiation of 
transformed cells into mature cells (Goettlicher 2001), while it increases the 
number of more primitive normal stem cells without affecting the differentiation. In 
the same way, in 5-FU enriched VPA-treated progenitor cells we did not see any 
significant perturbation of the differentiation of in vitro cultured normal 
hematopoietic progenitor cells. 
VPA has been used in clinical trials for the treatment of acute myeloid leukemia 
and myelodysplastic syndromes. When used as monotherapy or in combination 
with all-trans-retinoic acid, which synergizes with VPA in vitro, VPA led to an 
hematologic improvement in a subset of patients. The application of other 
inhibitors of histone deacetylases alone has been sufficient to reach complete or 
partial remission only rarely (Kuendgen 2007). The effect of the treatment with 
these drugs strictly depends on the biology of the type of cancer, where genetic 
as well as epigenetic changes occur. Some of these epigenetic events, which 
normally are differently regulated during the differentiation, can be absent in 
transformed cells, and this could explain the reduced sensitivity of immature and 
tumor cells to HDACi (Taddei 2005). 
Moreover, Saleh et al have suggested that HOX-PBX complexes may repress 
transcription under certain circumstances, and consistent with this, the binding 
sites of HOX-PBX multimers have been reported to repress reporter gene 
expression in HEK293 cells. Their work offers a mechanistic explanation of the 
repressor function by showing that a corepressor complex, containing the histone 
deacetylases (HDACs) 1 and 3, mSIN3B, and N-CoR/SMRT, interacts with 
PBX1A. They have mapped a site of interaction with HDAC1 at the PBX1 N-
terminus and showed that the PBX partner is required for the normal function of 
the HOX-PBX complex. Additionally, they have shown that the presence of the 
HDAC inhibitor trichostatin A not only inhibits the repression function, but also 
transforms the HOX-PBX complex into a net activator of transcription, and this 
function was demonstrated to be mediated by the recruitment of the coactivator 
CREB-binding protein by the HOX partner (Saleh 2000). Interestingly, Shen et al 
have shown that the HOX proteins inhibit histone acetyltransferase activity of 
CBP in both in vitro and in vivo systems, without being acetylated themselves, 
and this function seems to be independent from the highly conserved PBX-
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interacting domain. In summary, HOX proteins may function without CBP HAT to 
regulate transcription, while they necessitate the interaction with other DNA 
binding molecules like PBX, MEIS, or with other cofactors. On the other hand the 
HOX proteins may inhibit the CBP HAT activity and thus function as repressors of 
gene transcription (Shen 2001).  
Considering these reports and the leukemogenic potential of Hoxb4-∆Pro 
observed in vivo, one possibility could be that the proline region functions as 
HAT/HDAC-interacting domain of Hoxb4. The deletion of this region may then 
prevent the recruitment of co-repressors/activators. So far this region of Hoxb4 
has not been yet well characterized. Further experiments will help to understand 
which molecular interactions of Hoxb4 are perturbed when this region is deleted, 
and from another perspective they will help to decipher the key mechanisms 
which prevent Hoxb4 to act as leukemogenic protein and are responsible for the 
“benign” maintenance of the normal HSC pool. The mild effect exerted by the 
VPA treatment could suggest a predominant mediation of Hoxb4 activity via HAT 
activators. Another explanation could be that VPA induces increased expression 
of endogenous Hoxb4 in cells, in which the gene is already overexpressed by 
retroviral gene transfer.     
 
HDAC inhibitors are known to reduce proliferation and induce differentiation in  
hematological malignacies, like AML and MDS (Bellos 2008). Additionally, in 
ongoing experiments in our laboratory (data not shown) the VPA treatment of 
AML/MDS  NUP98-HOXD13+/Meis1+ cells has been shown to effectively block 
the growth and differentiation of the leukemic blasts. In contrast, in the present 
Hoxb4-∆Pro associated leukemia model, we hypothesize that the interaction with 
the putative partners HDACs/HATs has been perturbed, leading to an inefficient 
antileukemic effect of VPA treatment.  
Moreover, we could argue, that the proline-rich domain of Hoxb4 is modulating a 
determinant downstream control pathways, which could be responsible of the 
benign phenotype of normal HSCs, and may play a crucial role in the 
maintenance of the homeostatic equilibrium of HSCs, which cannot be affected 
by the HDAC inhibition alone. The malignant phenotype observed in our AML 
model was absent when the DNA-interacting domain was mutated. This suggests 
that the DNA-interaction of Hoxb4 is essential for the leukemogenesis. 
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Interestingly, the additional mutation of the PBX-ID did not prevent the Hoxb4-
∆Pro-associated AML, suggesting that the leukemogenesis in this model is 
independent from the interaction with PBX cofactor. 
The significance of a mutation in the proline region of Hoxb4 in human 
leukemogenesis is not yet known, since the detection of such mutation might be 
difficult with the screening methods commonly used, because of the high “GC” 
content in its sequence. Further investigations will allow to determine whether 
any mutation in this N-terminal regulatory region of Hoxb4 is involved in human 
leukemias.  
The identification of new leukemogenic functions of domains such as the proline 
region in Hoxb4 opens novel opportunities such as generating peptidomimetics 
that can antagonize specific protein-protein interaction domains in cultured cells 
and whole animals (Kay 2000).  
Another important aspect that could be elucidated by studying the phenotype 
regulated by the different regions of Hoxb4, is to get more insights about the 
HSCs amplificatory activity of this transcription factor. From previous works of 
Antonchuk et al it has been suggested that a possible way to explain the 
exponential amplification induced by Hoxb4 is the progenitor cells plasticity. The 
dramatic increase in the pool of proliferating progenitor cells could theoretically 
occur via de-differentiation of a committed progenitor into a more primitive, 
multipotent cell. However, the de-differentiation of cells in adult mammals has not 
been clearly and equivocally documented, and at present, no evidence directly 
supports the existence of trans-differentiation or de-differentiation events as 
prove of putative BM progenitor cells plasticity in vivo (Wagers 2004). The 
investigation of the normal function of Hoxb4 will help to clarify the still 
incompletely known fascinating control mechanisms of the stem cell biology. 
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6. Summary 
In the present work structural and functional analyses of a member of the 
Homeobox gene family, Hoxb4, have been performed. These transcription factors 
are highly conserved, and play a determinant role in the development of the early 
hematopoiesis. In particular, Hoxb4 represents a determinant factor, because in 
several experimental reports by using the retroviral gene transfer of Hoxb4 into 
murine and human haematopoietic stem cells (HSC) this transcription factor has 
been shown to amplify HSC (Sauvageau 1994, Buske 2002). To date no 
comprehensive structural / functional analyses of all the potential functional 
relevant domains of Hoxb4 are available. In this work we report the structural and 
functional analysis of relevant domains of Hoxb4. For the first time we showed 
that the deletion of the amino acids 78-120 of Hoxb4 has a leukemogenic effect: 
mice transplanted with bone marrow retrovirally transduced with this Hoxb4 
mutant (Hoxb4-∆Pro) developed acute leukemia after a latency time of 255 days 
(mean, ±96). These data show, that through the loss of its N-terminal proline-rich 
region the Hoxb4 transcription factor turns to an oncogene. The overexpression 
of this mutant led to acute myeloid leukemia with multi-organ infiltration, 
characterized by the expression of myeloid markers as confirmed by FACS and 
immunohistochemical analyses.  
The primary leukemia was transplantable and generated in secondary and 
tertiary transplanted mice a similar acute leukemia after a shorter latency time of 
66.5 (mean, ±22) and 43 days (mean, ±6), respectively. The analysis of the 
retroviral integration profile has shown that this leukemia was oligoclonal.  
The additional deletion of the PBX-interaction domain together with the deletion 
of the proline-rich region did not inhibit the development of leukemia. However, 
the integrity of the DNA-binding was essential for the leukemogenesis induced by 
Hoxb4-∆Pro. In contrast to the leukemogenic effect observed, the deletion of the 
proline-rich region did not affect the differentiation and the proliferation rate of 
short-term repopulating stem cells (CFC assay), as well as the frequency of the 
competitive repopulating units (long term repopulating stem cells) in comparison 
to the Hoxb4-wt (CRU assay). However, the Hoxb4-∆Pro mutant led to a 
significant reduction of the 12 days- ∆CFU-S frequency in comparison to the 
Hoxb4-wt.  
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Since in previous works Hoxb4, as well as other Hox factors, have been 
demonstrated to bind to CBP and the Hox co-factor PBX to bind to histone 
deacetylases (HDACs), we investigated which effect the HDAC inhibitor valproic 
acid (VPA) is exerting on the development of early hematopoietic stem cells. 
Interestingly, VPA has been shown from other authors to amplify human and 
murine HSCs, and this effect was partially explained through the induction of the 
expression of endogenous Hoxb4. With use of functional in vitro an in vivo 
assays we have been able to show that VPA can increase the HSC-amplificatory 
effect of Hoxb4.  In contrast, the incubation of murine BM cells overexpressing 
Hoxb4-∆Pro with VPA did not exert any amplificatory effect on stem cells. This 
suggests a probable involvement of epigenetic events like histone deacetylation 
for the control of the proliferation of early BM progenitor cells mediated by the 
proline region.            
Our findings allow concluding, that the proline region of Hoxb4 is essential for the 
benign amplification of normal HSCs. These results point up, that the further 
analysis of the function of this region could give new insights for the 
understanding of the biology of normal stem cells as well as of leukemogenesis. 
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7. Zusammenfassung 
In der vorliegenden Arbeit wurden Struktur-Funktionsanalysen eines Mitglieds der 
Homeoboxgenfamilie – des Hoxb4 durchgeführt. Dabei handelt es sich um eine 
hochkonservierte Gruppe von Transkriptionsfaktoren, die eine entscheidende 
Rolle in der frühen hämatopoetischen Entwicklung aufweisen. Hoxb4 spielt in 
diesem Zusammenhang eine herausragende Rolle, da in zahlreichen 
Untersuchungen unter Verwendung des retroviralen Gentransfers von Hoxb4 in 
hämatopoetischen Stammzellen der Maus aber auch des Menschen gezeigt 
werden konnte, dass es einen Stammzell-amplifikatorischen Effekt aufweist 
(Sauvageau 1994, Buske 2002). Bislang liegen aber noch keine umfassenden 
Struktur-Funktionsanalysen zu den potentiell funktionell relevanten Domänen von 
Hoxb4 vor. In der vorliegenden Arbeit wurden diese Struktur-Funktionsanalysen 
durchgeführt. Es gelang dabei erstmalig zu zeigen, dass die Deletion der 
Aminosäuren 78-120 des Hoxb4 Proteins einen leukämogenen Effekt hat: 
Mäuse, die mit Knochenmark transplantiert wurden, welches retroviral mit dem so 
mutierten Hoxb4 transduziert wurde, entwickelten nach einer Latenzzeit von 255 
Tagen (Mittelwert, ±96) eine akute Leukämie. Damit zeigen die Daten erstmalig, 
dass durch Verlust der N-terminalen prolinreiche Region der Transkriptionsfaktor 
Hoxb4 zu einem Onkogen wird. Die Mutante induzierte eine akute myeloische 
Leukämie mit Multiorganinfiltration durch leukämischen Blasten, charakterisiert 
durch Expression myeloischer Marker in der FACS Analyse und in der 
Immunhistochemie.  
Die primäre Leukämie war retransplantierbar und generierte in sekundär und 
tertiär transplantierten Mäusen nach einer kurzen Latenzzeit von 66.5 (Mittelwert, 
± 22) bzw. 43 (Mittelwert, ±6) Tagen post transplantationem eine akute Leukämie 
gleichen Phänotyps. Die Analyse des retroviralen Integrationsprofils zeigte, dass 
die Leukämie oligoklonaler Natur war.  
Die zusätzliche Deletion der PBX-Interaktionsdomäne zusammen mit der 
Deletion der prolinreichen Region konnte die Entwicklung der Leukämie nicht 
verhindern, andererseits war die Bindung an die DNS für die Hoxb4-∆Pro 
induzierte Leukämogenese entscheidend. Im Gegensatz zu dem leukämogenen 
Effekt bewirkte die Deletion der prolinreichen Region keine Änderung der 
Differenzierung und der Proliferationsrate von Kurzzeit-repopulierenden 
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Stammzellen (CFC assay), sowie der Frequenz kompetitiv-repopulierender 
Einheiten (langzeit-repopulierender Stammzellen) im Vergleich zum Hoxb4-
Wildtyp. Nur die 12 Tage-∆CFU-S Frequenz in vivo war durch die Expression von 
dem Hoxb4-∆Pro Mutant im Vergleich zu Hoxb4-wt signifikant reduziert.  
Aufgrund von vorhergehenden Arbeiten, in denen gezeigt wurde, dass Hoxb4 wie 
andere Hox Faktoren an CBP bzw. den HOX Ko-faktor PBX1 an Histon 
Deacetylasen (HDACs) bindet, untersuchten wir, ob der HDAC-Inhibitor 
Valproinsäure (VPA) einen Einfluss auf die durch den Hoxb4-wt bzw. durch die 
Hoxb4 Mutante induzierten Effekte auf die frühe hämatopoetische 
Stammzellentwicklung hat. VPA wurde von anderen Autoren gezeigt, eine 
Amplifizierung von humanen und murinen HSZ zu bewirken, wobei dieser Effekt 
teilweise durch die Induktion der endogene Hoxb4-Expression erklärt werden 
konnte (Seet 2008). Unter Verwendung funktioneller in vitro und in vivo Analysen 
gelang es uns zu zeigen, dass VPA den bekannten Stammzell-amplifikatorischen 
Effekt des Hoxb4-wt sogar noch verstärken konnte. Im Gegensatz hierzu, führte 
die Inkubation von Mausknochenmarkzellen, die Hoxb4-∆Pro überexprimierten, 
mit VPA nicht zu einer Verstärkung des Stammzell-amplifikatorischen Effektes. 
Dies könnte auf eine Bedeutung von epigenetischen Faktoren im Rahmen der 
Zellproliferation früher hämatopoetischer Vorläuferzellen hinweisen.   
Unsere Ergebnisse zeigen, dass die Prolinregion des Hoxb4 für die normale 
stammzellamplifikatorische Wirkung von Hoxb4 essentiell ist. Die Daten 
unterstreichen, dass die weitere Analyse der Wirkungsweise der Prolinregion von 
Hoxb4 sowohl für ein besseres Verständnis der normalen Stammzellbiologie als 
auch der möglichen leukämischen Transformation von großer Bedeutung ist.  
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Creation of fusion genes by balanced chromosomal translocations is
one of the hallmarks of acute myeloid leukemia (AML) and is consid-
ered one of the key leukemogenic events in this disease. In
t(12;13)(p13;q12) AML, ectopic expression of the homeobox gene
CDX2 was detected in addition to expression of the ETV6-CDX2 fusion
gene, generated by the chromosomal translocation. Here we show in
a murine model of t(12;13)(p13;q12) AML that myeloid leukemogen-
esis is induced by the ectopic expression of CDX2 and not by the
ETV6-CDX2 chimeric gene. Mice transplanted with bone marrow cells
retrovirally engineered to express Cdx2 rapidly succumbed to fatal
and transplantable AML. The transforming capacity of Cdx2 de-
pended on an intact homeodomain and the N-terminal transactiva-
tion domain. Transplantation of bone marrow cells expressing ETV6-
CDX2 failed to induce leukemia. Furthermore, coexpression of ETV6-
CDX2 and Cdx2 in bone marrow cells did not accelerate the course of
disease in transplanted mice compared to Cdx2 alone. These data
demonstrate that activation of a protooncogene by a balanced
chromosomal translocation can be the pivotal leukemogenic event in
AML, characterized by the expression of a leukemia-specific fusion
gene. Furthermore, these findings link protooncogene activation to
myeloid leukemogenesis, an oncogenic mechanism so far associated
mainly with lymphoid leukemias and lymphomas.
The molecular dissection of balanced chromosomal translo-cations in patients with acute leukemia has greatly advanced
our knowledge of the pathogenesis of this disease, demonstrating
that chromosomal translocations often affect genes that regulate
hematopoiesis. Chromosomal translocations involve mainly two
mechanisms that lead to malignant transformation: deregulation
of the expression of a protooncogene by juxtaposition of a potent
enhancer or promoter elements or creation of a fusion gene
(1–3). Although both mechanisms are found in lymphoid leu-
kemia or lymphoma, formation of a fusion gene predominates in
acute myeloid leukemia (AML). In fact, to date, there are no
experimentally confirmed instances in which the transcriptional
deregulation of a protooncogene is the key leukemogenic event
in a fusion gene-positive AML.
The oncogenic potential of fusion genes has been well docu-
mented experimentally. However, emerging data, mostly from
murine in vivo models, have demonstrated that many of these fusion
genes are not able to induce leukemia on their own. This observa-
tion suggests an important role for other genetic alterations that
cooperate with fusion genes in patients with AML (4–6). The
intriguing differences in the oncogenic potential of fusion genes are
well documented for the large family of chimeric genes involving the
ets transcription factor ETV6, located at 12p13. ETV6 is one of the
genes most frequently involved in chromosomal translocations.
Chromosomal translocations affecting the ETV6 locus have been
reported with40 different partners (7). Fusion partners of ETV6
can be phosphotyrosine kinases (PTK) or transcription factors and
genes of unknown function, dividing ETV6 fusion genes into two
distinct groups. Fusions of ETV6 with PTKs such as PDGFRB,
JAK2, ABL1, ABL2, or NTRK3 create highly leukemogenic proteins
in murine experimental models (8–12). In the group of ETV6-
transcription factor fusions, the N-terminal portion of ETV6 is fused
to the partner gene in most cases, retaining (e.g., ETV6-AML1) or
losing the pointed domain (e.g., ETV6-CDX2, ETV6-MDS1EVII)
(13–15). Although data about the leukemogenic potential of this
group of fusion genes are still limited, extensive analyses of the most
frequent ETV6 chimeric transcription factor, ETV6-AML1, failed to
show any major transforming activity in a transgenic or bone
marrow (BM) transplantation mouse model (16, 17). Based on
these data, expression of an ETV6-transcription factor fusion might
not be sufficient to induce disease. Indeed, recent evidence cor-
roborates that ETV6 acts as a tumor suppressor gene and that, in
almost all cases of ETV6AML1-positive acute lymphoblastic leu-
kemias, there is a deletion or loss of expression of the nonrear-
ranged ETV6 allele (18, 19). Furthermore, several chromosomal
translocations involving the ETV6 locus associated with myeloid
malignancies such as t(4;12), t(5;12), or t(12;17) do not form any
functional fusion gene at all, pointing to a key variant oncogenic
mechanism in these cases (20, 21). In this regard, the
t(12;13)(p13;q12) associated with the ETV6-CDX2 fusion gene in
human AML is of notable interest. The translocation breakpoint
leaves the CDX2 gene intact, and expression of both the fusion gene
and full-length CDX2, normally restricted to intestinal epithelial
cells, was observed in leukemic cells, thus raising the possibility that
ectopic expression of CDX2 is the key pathogenic event (14).
To clarify this particular issue and to gain insight into alter-
native mechanisms of transformation in patients with AML and
ETV6 rearrangements, we established a mouse model for
t(12;13)(p13;q12) human AML. We demonstrate that ectopic
expression of Cdx2 is the key transforming event that induces
fatal AML in transplanted mice. In contrast, expression of the
ETV6-CDX2 fusion protein is unable to induce leukemia.
Furthermore, we show that the transforming potential of Cdx2
depends on the integrity of its DNA-binding domain and the
N-terminal domain of Cdx2. Our data point to a previously
uncharacterized mechanism of leukemogenesis in patients with
AML, in which a balanced chromosomal translocation contrib-
utes to malignant transformation by activating the expression of
a protooncogene, a mechanism so far associated mainly with
lymphoid leukemias or lymphomas (3).
Materials and Methods
cDNA Constructs and Retroviral Vectors. cDNAs of ETV6-CDX2 and
Cdx2 (93% overall and 98% identity in the homeodomain between
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; YFP, yellow fluorescent
protein; CFU-S, colony-forming unit–spleen; PB, peripheral blood.
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the human and murine proteins) were kindly provided by D. G.
Gilliland (Division of HematologyOncology, Harvard Medical
School, Boston) and N. Cross (Department of Haematology,
Hammersmith Hospital, London). A histidine-tagged version of
ETV6-CDX2 was constructed by ligating a PCR product of the
fusion gene in frame to the 3 end of the histidine epitope of the
pCDNA6V5-His A plasmid (Invitrogen), Cdx2 mutants were
created that were previously shown to inactivate a putative PBX1
interacting motif (W167A-Cdx2) (22) or to inactivate the DNA-
binding homeodomain (N51S-Cdx2) (23) by using the QuikChange
XL Site-Directed Mutagenesis Kit (Stratagene). The Cdx2 mutant
lacking the first 179 N-terminal amino acids, which are deleted in
the ETV6-CDX2 fusion, was generated and histidine tagged by PCR
following standard procedures (N-Cdx2) (4). For retroviral gene
transfer into primary BM cells, the different constructs were
subcloned into the multiple cloning site of the modified murine
stem cell virus (MSCV) 2.1 vector (4) upstream of the internal
ribosomal entry site (IRES) and the enhanced GFP or yellow
fluorescent protein (YFP) gene. As a control, the MSCV vector
carrying only the IRES-enhanced GFP cassette was used.
Production of high-titer helper-free retrovirus was carried out
following standard procedures by using the ecotropic packaging cell
line GPE86 (4). The number of provirus integrants was deter-
mined by EcoRI digestion and full length integration by NheI
digestion, followed by Southern blot analysis using standard tech-
niques (24). Protein expression of the ETV6-CDX2, Cdx2, and Cdx2
mutant plasmids was documented by Western blotting using stan-
dard procedures. Membranes were probed with an antihistidine
monoclonal antibody (Sigma) for ETV6-CDX2 and the N-Cdx2
mutant or with an anti-CDX2 monoclonal antibody (kindly pro-
vided by DCS Innovative, Hamburg, Germany) for expression of
the Cdx2, W167A-Cdx2, and N51S-Cdx2 mutants (25) (Fig. 1).
In Vitro Assays. Cell proliferation was assessed in DMEM supple-
mented with 15% FBS10 ng/ml mIL-66 ng/ml mIL-3100 ng/ml
murine stem cell factor (standard medium) (Tebu-bio, Offenbach,
Germany). Differentiation of clonogenic progenitors was analyzed
by plating cells in methylcellulose supplemented with cytokines
(Methocult M3434, StemCell Technologies, Vancouver). IL-3-
dependent cell populations expressing Cdx2 or coexpressing ETV6-
CDX2 and Cdx2 were established in vitro directly after sorting in
DMEM15% FBS with IL-3 alone (6 ng/ml). The differentiation
capacity of cultured cells was tested in DMEM15% FBS supple-
mented with granulocyte colony-stimulating factor 100 ng/ml or
macrophage colony-stimulating factor 10 ng/ml (R & D Systems)
and all-trans retinoic acid at 1 M final concentration. After 5 days,
the morphology was determined by Wright–Giemsa-stained cyto-
spin preparations (4, 25).
Mice and Retroviral Infection of Primary BMC. Parental strain mice
were bred and maintained at the GSF animal facility. Donors of
primary BM cells were 12-wk-old (C57BL6Ly-Pep3b  C3H
HeJ) F1 (PepC3) mice, and recipients were 8- to 12-wk-old
(C57BL6JC3HHeJ) F1(B6C3) mice. Primary mouse BM cells
were transduced as described (4). For transduction, cells were
cocultured with irradiated (40 Gy) ETV6-CDX2GFP or Cdx2
YFP GPE86 producers or with a mixture of 40–50% Cdx2YFP
and 50–60% ETV6-CDX2GFP producers in cotransduction
experiments.
Colony-Forming Unit–Spleen (CFU-S) Assay. Primary BM cells from
F1(PepC3) donor mice treated 4 days previously with 5-fluorouracil
were transfected with the different viruses, and retrovirally trans-
duced cells were highly purified based on expression of GFP or YFP
by using a FACSVantage (Becton Dickinson). Transduced cells
were cultured 7 days in standard medium. The day 0 equivalent of
2.5–3  104 cells was injected into lethally irradiated F1(B6C3)
recipient mice. The recovery of CFU-S cells was quantified by
determining the number of macroscopic colonies on the spleen at
day 12 postinjection after fixation in Telleyesnickzky’s solution.
BM Transplantation and Assessment of Mice. Recipient F1(B6C3)
mice (8–10 wk old) were irradiated with 850 cGy from a 137Cs
-radiation source. FACS-purified transduced BM cells, or a de-
fined ratio of transduced and untransduced cells was injected into
the tail vein of irradiated recipient mice. Peripheral blood (PB) or
BM cell progeny of transduced cells were tracked by using the GFP
or YFP fluorescence (26). The lineage distribution was determined
by FACS analysis as described (4): phycoerythrin-labeled Gr-1,
ScaI, Ter-119, CD4, and allophycocyanin-labeled Mac1, cKit, B220,
or CD8 antibodies were used for analysis (all PharMingen). For
histological analyses, sections of selected organs were prepared and
hematoxylineosin-stained by using standard protocols.
RT-PCR. Expression of Hoxa9 and Meis1 was assayed by RT-PCR in
Sca-1–Lin cells sorted from a mouse repopulated with Cdx2
expressing BM cells or a control animal. Total RNA was isolated
by using Trizol reagent (GIBCOBRL) and treated with DNase I
(amp grade) to remove contaminating genomic DNA. First-strand
cDNA was synthesized from 1 g of total RNA by using the
thermoScript RT-PCR system (all reagents from Invitrogen).
Equal amounts of cDNA originating from 50 ng of starting RNA
were loaded to assess transcription levels. Intron-spanning primer
pairs were selected to avoid amplification of contaminating
genomic DNA. The annealing temperatures were 58°C and 60°C for
Meis1 and Hoxa9, respectively. The number of PCR cycles for each
gene was chosen to stop the reaction in the linear phase of
amplification (25 cycles for m-2 microglobulin, 35 cycles for Meis1
and Hoxa9).
Statistical Analysis. Data were evaluated by using the t test for
dependent or independent samples (Microsoft EXCEL). Differences
with P values  0.05 were considered statistically significant.
Fig. 1. (a) Retroviral vectors used to express ETV6-CDX2, Cdx2, and the different
Cdx2 mutants in murine BM. IRES, internal ribosomal entry site. (b) Western blot
analysisofcellularextracts fromNIH3T3orE86cells transfectedwiththedifferent
constructs. The molecular mass is indicated.
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Results
Ectopic Expression of Cdx2 Causes AML in Transplanted Mice. To
analyze whether expression of the t(12;13)-associated ETV6-CDX2
fusion gene andor the ectopic expression of the homeobox gene
Cdx2 is able to transform early murine hematopoietic progenitors
in vivo, we generated MSCV-based retroviral constructs and doc-
umented full-length protein expression by Western blotting (Fig. 1).
Murine hematopoietic progenitors constitutively expressing ETV6-
CDX2 or Cdx2 were highly purified by FACS based on GFP or
YFP expression, respectively, and injected into lethally irradiated
recipient mice directly after sorting (3–3.5  105 and 2–3.6  105
cells per mouse for Cdx2 and ETV6-CDX2, respectively).
Mice transplanted with BM cells expressing Cdx2 became mor-
ibund after a median of 90 days posttransplantation (n 18) (Fig.
2). Diseased mice were characterized by cachexia, shortness of
breath, and lethargy when they were killed for further analysis. In
striking contrast, mice transplanted with ETV6-CDX2-expressing
cells did not succumb to terminal disease (n 9) (Fig. 2). Diseased
Cdx2 mice were characterized by elevated peripheral white blood
count (WBC) (3.8-fold) with up to 48  106 circulating WBC per
milliliter. Furthermore, moribund mice were anemic, with a 5-fold
decrease in peripheral erythrocyte count (P 0.001) (Table 1). All
Cdx2 mice analyzed (n  7) suffered from splenomegaly, with an
average spleen weight of 0.6 g (range 0.4–0.9; P  0.01 compared
to control animals) (Table 1). More detailed hematological analyses
demonstrated that animals suffered from AML with a high per-
centage of blasts in the BM (42% 6), PB (14% 3), and spleen
(35% 5) (n 8; P 0.01 compared to the control animal) (Table
1). Furthermore, leukemic mice showed multiple organ infiltration
with blast cells. Thirty percent of the blasts expressed CD34 but
were negative for N-acetyl-chloroacetate esterase, periodic acid
Schiff reagent, and terminal deoxynucleotidyltransferase, as shown
by immunohistochemistry, consistent with an undifferentiated my-
eloblastic phenotype of the disease (Fig. 3). Immunophenotypic
Fig. 2. Survival curve of mice transplanted with BM cells expressing Cdx2 (n
18), ETV6-CDX2 (n 9), or coexpressing Cdx2 and the fusion gene (n 13). The
control group was injected with BM infected with the GFP empty retrovirus (n
7). The survival time of secondary recipient mice, transplanted with BM from
diseased primary Cdx2 or ETV6-CDX2 and Cdx2 recipients, is indicated.
Table 1. Hematological parameters of experimental mice
Mouse no.
Retroviral
construct
Day of
death
RBC per ml
109
WBC per ml
106
Spleen weight,
mg
BM
% blasts
Spleen
% blasts
PB %
blasts
Lymphoidmyeloid
ratio in PB
1 GFP 90 6 4.5 150 0 0 0 5:1
2 GFP 90 4.8 3.2 200 0 0 0 2:1
3 GFP 90 5.0 3.6 200 0 0 0 2:1
1* Cdx2 128 1.0 3.2 400 28 21 8 0.5:1
2* Cdx2 79 2.0 37 650 40 35 12 0.4:1
3* Cdx2 52 0.7 9 600 38 30 15 0.2:1
4* Cdx2 116 0.4 48 nd ND 60 14 0.4:1
5* Cdx2 37 0.6 5 400 25 22 5 0.3:1
6* Cdx2 171 0.8 24 900 71 48 18 0.3:1
7* Cdx2 192 1.1 10 800 60 41 30 0.5:1
8* Cdx2 84 0.4 28 400 32 24 8 0.8:1
1*  168 1.0 3.2 400 25 18 3 0.6:1
2*  230 1.1 8 500 45 30 10 0.1:1
3*  151 0.2 8 600 58 37 16 0.4:1
4*  237 1.5 24 300 25 18 5 0.6:1
5*  187 0.5 25 900 50 43 8 0.3:1
1 ETV6-CDX2 375 6.5 2.4 160 10 8 0 0.3:1
2 ETV6-CDX2 375 5 3.2 200 25 15 0 0.4:1
3 ETV6-CDX2 375 5.2 6 180 15 9 0 2:1
*, diseased; , ETV6-CDX2 and Cdx2; RBC, red blood cell count; WBC, white blood cell count; ND, not determined.
Fig. 3. Histological analysis of diseased Cdx2 mice. (a) BM [hematoxylineosin
(H&E)]. Immunohistochemistry of the BM (200) for N-acetyl-chloroacetate es-
terase (400) (b) and CD34 expression (640) (c). Histology of the spleen H&E
(25) (d) and Giemsa staining (640) (e) and liver with perivascular infiltration
(200) (f ). Cytospin preparations from PB (g), BM (h), and spleen (i) (all1,000).
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characterization of PB, BM, and spleen in diseased mice confirmed
the predominance of myeloid Mac1 and Gr-1 cells (84%  10
and 73%  15 in the PB, 65%  14 and 53%  14 in the spleen,
respectively; n 4) compared to the GFP control mice (Mac1 and
Gr-1 cells 47%  5 and 25%  3 in the PB, 14%  9 and 10%
 1 in the spleen, respectively; n 4). Furthermore, diseased mice
were characterized by a greatly reduced normal B220 lymphoid
population in the spleen and PB compared to controls (1.8%  1
vs. 35%  8 and 1.3%  0.5 vs. 46%  21 in the PB and in the
spleen, respectively; n  4) (Fig. 4a). Mice transplanted with
Cdx2-expressing BM cells were characterized by a 19-fold increased
frequency of clonogenic cells in the PB and a100-fold increase in
the spleen compared to the control as quantified by ex vivo CFC
assays (248 vs. 13 clonogenic cells per 1 106 cellsml in the PB and
1,400 clonogenic cells vs. 13 per 1  106 cellsml in the spleen,
respectively) (n  3). Twenty-eight percent (3) of these clono-
genic progenitors were not able to terminally differentiate and
formed blast colonies in methylcellulose with high serial replating
capacity (data not shown).
The Cdx2-induced AML was transplantable and all lethally
irradiated mice (n  11) injected with BM cells of diseased Cdx2
animals died within 24 days posttransplantation (Fig. 2). Analysis of
the clonality of the disease by Southern blot analysis demonstrated
different intensities and patterns of proviral signals in the different
hematopoietic organs consistent with an oligoclonal nature of the
disease (Fig. 4b).
To analyze whether the ETV6-CDX2 fusion caused subtle per-
turbations in hematopoietic development, healthy animals (n  3)
were killed 44 wk after transplantation with ETV6-CDX2-
expressing BM cells. Interestingly, two of three animals showed an
expansion of the mature neutrophil compartment in the PB with an
inversion of the lymphoidmyeloid ratio (Table 1) and 87% and
68% Mac1Gr1 cells in the GFP-positive compartment. Fur-
thermore, spleens from all mice were infiltrated with terminally
differentiated myeloid cells (86%  0.9 Gr1Mac1 cells). How-
ever, none of the animals suffered from anemia, splenomegaly, or
the emergence of a blast population in the PB (Table 1). Thus,
ETV6-CDX2 was able to induce a myeloproliferation without
causing disease but failed to induce leukemic transformation.
In addition, 13 mice were transplanted with a mixture of ETV6-
CDX2, Cdx2, and Cdx2 and ETV6-CDX2 coexpressing cells, con-
taining between 1.9–4.5  104 Cdx2 and ETV6-CDX2 cells and
4,000 Cdx2 cells per mouse. The addition of Cdx2 and ETV6-
CDX2 coexpressing cells did not accelerate the course or change the
phenotype of the disease compared to only Cdx2-expressing cells.
All animals succumbed to AML, and the leukemic population
consisted of Cdx2- and ETV6-CDX2-coexpressing or Cdx2-
expressing cells in all mice analyzed (n  4) (Fig. 2). These data
indicate that aberrant expression of the wild-type Cdx2 gene is
crucial for malignant transformation in this model.
The Transforming Potential of Cdx2 Depends on the N-Terminal
Transactivation Domain and the Intact Homeodomain. In an effort to
characterize the contribution of different motifs of Cdx2 to the
transforming capacity of the gene, three different mutants were
designed: a mutant inactivating the homeodomain (N51S-Cdx2), a
Cdx2 mutant with an inactivating mutation in the putative PBX1-
interacting motif (W167A-Cdx2), and a mutant lacking the N-
terminal portion of Cdx2, which is not present in the ETV6-CDX2
fusion (N-Cdx2). Protein expression of the mutants was con-
firmed by Western blot analysis (Fig. 1b). Expression of wild-type
Cdx2 and W167A-Cdx2 in primary bone marrow cells rapidly
induced the outgrowth of IL-3-dependent cell populations in liquid
cultures. The cells showed blast morphology, were GrMac1-
positive, and had lost their differentiation capacity when incubated
with macrophage colony-stimulating factor, granulocyte colony-
stimulating factor, or all-trans retinoic acid (data not shown).
Furthermore, mice transplanted with 1  106 of these cells devel-
oped leukemia 8 wk posttransplant in contrast to mice injected with
nontransduced or GFP-expressing control cells. Cells expressing
Fig. 4. (a) Flow cytometry from a representa-
tive leukemic Cdx2 mouse from PB, BM, and
spleen in comparison to a GFP control animal.
Cells were stained for the myeloid markers Gr1
and Mac1 and the lymphoid marker B220. The
proportion of positive cells within the GFP com-
partment is indicated. (b) Southern blot analyses
of genomic DNA from BM, PB, and spleens of
representative leukemic Cdx2 mice. Genomic
DNA was digested with EcoRI, which cuts once in
the provirus, to determine the number of provi-
rus integrants. Signals with different intensity,
indicating the presence of different leukemic
clones, are indicated. Full-length provirus inte-
gration was documented by digestion with NheI,
which cuts only in the LTRs of the provirus.
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ETV6-CDX2, the N-Cdx2, or the N51S mutant as well as the
control cells were not able to form blast cell populations in vitro.
When colony formation was tested, Cdx2-positive cells generated a
higher number of primary CFC in methylcellulose compared to
GFP (76 22 vs. 41 20 per 500 initially plated cells, respectively;
n  5; P  0.02). Furthermore, Cdx2-positive colonies contained
	10 times more cells per colony than the controls (33  103 vs.
3.9 103 per colony, respectively; n 5; P 0.004). The expression
of the other constructs did not change the size or number of
colonies compared to the control. To investigate the effect of the
different mutants on primitive hematopoietic cells, cells infected
with the different viruses were injected into lethally irradiated mice
after 7 days of in vitro culture, and spleen colony formation was
quantified 12 days after injection in killed mice (CFU-S assay).
Cdx2 expression as well as expression of the W167A-Cdx2 mutant
induced a significant10-fold increase in the yield of day 12 CFU-S
compared to the GFP control (n  8; P  0.0001). In contrast,
deletion of the N-terminal portion of Cdx2 (n  5) or inactivation
of the homeodomain (n 5) resulted in complete loss of the Cdx2
activity in these assays. ETV6-CDX2 (n  6) did not show any
increase in CFU-S compared to the GFP control (Fig. 5a).
The Expression of Hoxa9 and Meis1 Is Not Increased by Ectopic
Expression of Cdx2. Given the role of Cdx2 as an upstream regulator
of Hox gene expression, we asked whether Cdx2 would perturb
expression of leukemogenic homeobox genes such as Hoxa9 or
Meis1. First, expression of Hoxa9 and Meis1 was determined by
RT–PCR in the 32D cell line transduced with the Cdx2, the
ETV6-CDX2, or the GFP virus. Compared to the control, Cdx2 did
not increase expression of Hoxa9 or Meis1 (data not shown). In
addition, Sca
lin-differentiated cells were recovered and highly
purified from a mouse transplanted with Cdx2-expressing BM cells
and a control animal, a cell population with normally no detectable
expression of Hoxa9 and Meis1 (27): specific amplification products
were not detectable by RT-PCR after 25 cycles in both experimen-
tal arms. Amplification products could be detected after 35 cycle
but without considerable differences in the intensity between
Cdx2-transduced and control cells (Fig. 5b). Thus, ectopic expres-
sion of Cdx2 was not associated with up-regulation of Meis1 or
Hoxa9 in this model system.
Discussion
The formation of fusion genes with oncogenic properties by
balanced chromosomal rearrangements is considered one of the
crucial steps for leukemic transformation in patients with AML.
By using the murine BM transplantation model, we now provide
direct evidence that the ectopic expression of the protooncogene
Cdx2 and not the expression of the fusion gene ETV6-CDX2 is
the key transforming event in t(12;13)(p13;q12)-positive AML.
Activation of protooncogenes by balanced chromosomal trans-
locations is a well-known oncogenic mechanism in lymphoid
leukemias or lymphomas but has, to our knowledge, not been
functionally demonstrated for AML and translocations involving
ETV6 (3). In addition, these data present evidence that the
homeobox gene and Hox gene upstream regulator Cdx2, which
so far has been linked to intestinal metaplasia and colon cancer
(28), is highly leukemogenic when aberrantly expressed in he-
matopoietic progenitor cells.
Cdx2 belongs to the large group of homeobox genes, which were
originally described as master regulators of embryonic body devel-
opment. The Cdx genes and their homologues caudal in Drosophila
and Xcad in Xenopus belong to the ParaHox cluster, which is
considered an ancient paralog of the Hox gene cluster (29).
Although the Cdx genes show similarities to the 5-located
Abdominal-B like genes of the Hox gene cluster, they possess a Pbx
recognition motif, a characteristic of 3-located Hox genes (30). Cdx
genes play a key role in the homeobox regulatory network, acting
as upstream regulators of several Hox genes (30, 31). Thus, per-
turbation of Cdx2 might be linked to critical alterations in down-
stream Hox genes that are central regulators of normal early
hematopoietic development in the adult with a distinct expression
profile in human and murine early progenitor cells (27, 32, 33).
Gene expression profiling of acute leukemias using DNA microar-
ray technology linked aberrant expression of Hox genes such as
HOXA9, HOXA10, and of the nonclustered homeobox gene MEIS1
to leukemogenesis (34–37). Retrovirally enforced expression of
these genes induced severe perturbations of normal hematopoietic
development in human and murine experimental models (24, 38).
Altered expression of several Hox genes might be one of the reasons
for the strong oncogenic potential of Cdx2 (30, 39–42). However,
RT–PCR analyses in the 32D cell line model and in Sca
lin BM
population of a Cdx2 repopulated mouse did not indicate gross
up-regulation of Meis1 and Hoxa9 by Cdx2. However, this does not
exclude that perturbation of other Hox genes might play a role in
the transformation process initiated by ectopic Cdx2 expression.
Of note, perturbed expression of Hox genes such as HOXA9 or
HOXA10 in hematopoietic progenitor cells is not able to induce
frank AML in transplanted mice after a short latency time but
requires collaboration with the Hox co-factor MEIS1. In striking
contrast, constitutive expression of Cdx2 rapidly caused leukemia in
recipient mice. The underlying cause for the difference in the
leukemogenic activity between Cdx2 and HOXA9 or HOXA10 is
not known. But, in contrast to HOXA9 and HOXA10, which are
normally expressed at high levels in progenitor cells, CDX2 is not
expressed in hematopoietic cells (14). Thus, ectopic expression of
CDX2 in leukemia patients might result in the activation of de novo
downstream pathways, which are normally silent in early blood
development.
Despite the differences in the oncogenic potential, many of the
in vitro and in vivo hematopoietic effects induced by Cdx2 are highly
reminiscent of the effects of retrovirally overexpressed hematopoi-
etic HOX genes as well as leukemia-specific fusion genes such as
NUP98-HOXD13 with regard to the impact on short-term repop-
ulating CFU-S or clonogenic progenitors (4, 38, 43). The striking
similarities of the phenotypes induced by the over-expression of
Fig. 5. (a) Total number of d12 CFU-S colonies derived per culture initiated with
1105 cells transduced with the different viruses after 1 wk in liquid culture. The
median is indicated. (b) Expression of Meis1 and Hoxa9 analyzed by RT-PCR in
Sca
lin BM cells isolated from a Cdx2 mouse or a control mouse. The number of
PCR cycles for each gene was chosen to stop the reaction in the linear phase of the
amplification (25 cycles for m-2 microglobulin, 35 cycles for Meis1 and Hoxa9).
C, control; Cdx, Cdx2.
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homeobox genes of the Hox cluster and of Cdx2 as a member of the
ParaHox complex (29) point to a high level of functional redun-
dancy among homeobox proteins in hematopoiesis.
The hematopoietic activity of Cdx2 strictly depended on its intact
homeodomain, implicating that DNA binding of Cdx2 is essential
for its transforming activity. Furthermore, deletion of the Cdx2
N-terminal portion resulted in a complete loss of activity in our
assays. Of note, it was demonstrated that the N-terminal part of
Cdx2 is necessary for transcriptional activation of Hox genes,
supporting the concept that activation of downstream Hox genes is
a potential key mechanism of Cdx2-induced transformation (44).
Furthermore, it was demonstrated that the transcriptional activity
of CDX proteins depends on the interaction of the p38 mitogen-
activated protein kinase and the N-terminal transactivation domain
of Cdx2 (45). As a consequence, N-terminal deletion would dimin-
ish the transactivation capacity of CDX2. Importantly, the ETV6-
CDX2 fusion gene lacks the N-terminal portion of CDX2, presum-
ably hampering its capability to transactivate target genes. This
would explain the obvious discrepancy in the oncogenic potential
between Cdx2 and the ETV6-CDX2 fusion gene; this is supported
by our data, which demonstrate a complete loss of activity when this
N-terminal portion of Cdx2, which is not present in the ETV6-CDX2
fusion gene, is deleted in the N-Cdx2 mutant. Notably, mice
transplanted with BM cells expressing the chimeric gene developed
myeloproliferation after a long latency time but without any clinical
symptoms. These data indicate that, despite the loss of the N-
terminal portion, the fusion gene is able to perturb hematopoietic
development, although to a significantly lesser extent than full-
length Cdx2. However, it cannot be excluded from our experiments
that the first 54 amino acids of ETV6, which are fused to CDX2, are
responsible for or at least contribute to the observed disturbances
of hematopoiesis. Taken together, our data propose a model in
which the chromosomal translocation t(12;13)(p13;q12) causes
AML by inducing the ectopic expression of CDX2. The mechanism
of transcriptional induction is not precisely known, but it was
demonstrated that the chromosome 13 breakpoint lies upstream of
the CDX2 gene. Therefore, one possible explanation for the ectopic
expression of CDX2 could be that the translocated protooncogene
might now be under the control of one of the two alternative ETV6
enhancerpromoters, located between exons 2 and 3 of ETV6 (14).
Intriguingly, it was recently shown that the homeobox gene GSH2
and IL-3 are ectopically expressed in patients with AML and the
translocations t(4;12)(q11–12;p13) and t(5;12)(q31;p13), respec-
tively. Both translocations involve ETV6 but do not create any
functional fusion genes (20). This observation suggests that activa-
tion of protooncogenes is a more common phenomenon in ETV6-
associated leukemias than previously thought. Taking into consid-
eration that several AML-associated fusion genes are not
leukemogenic on their own, it is tempting to speculate that activa-
tion of protooncogenes by chromosomal rearrangements might be
quite a widespread mechanism in myeloid leukemogenesis. This
hypothesis is supported by observations in AML cases not affecting
ETV6, in which expression of the putative protooncogene EVI1 is
activated by juxtaposition to the enhancer sequences of the ribo-
phorin-I gene in patients with AML and 3q21 alterations (46). Our
data provide compelling evidence that myeloid leukemogenesis can
be initiated by this mechanism and emphasize the relevance of
protooncogene activation for the development of AML.
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The	molecular	characterization	of	leukemia	has	demonstrated	that	genetic	alterations	in	the	leukemic	clone	
frequently	fall	into	2	classes,	those	affecting	transcription	factors	(e.g.,	AML1-ETO)	and	mutations	affecting	
genes	involved	in	signal	transduction	(e.g.,	activating	mutations	of	FLT3	and	KIT).	This	finding	has	favored	
a	model	of	leukemogenesis	in	which	the	collaboration	of	these	2	classes	of	genetic	alterations	is	necessary	for	
the	malignant	transformation	of	hematopoietic	progenitor	cells.	The	model	is	supported	by	experimental	
data	indicating	that	AML1-ETO and	FLT3	length	mutation	(FLT3-LM),	2	of	the	most	frequent	genetic	altera-
tions	in	AML,	are	both	insufficient	on	their	own	to	cause	leukemia	in	animal	models.	Here	we	report	that	
AML1-ETO	collaborates	with	FLT3-LM	in	inducing	acute	leukemia	in	a	murine	BM	transplantation	model.	
Moreover,	in	a	series	of	135	patients	with	AML1-ETO–positive	AML,	the	most	frequently	identified	class	of	
additional	mutations	affected	genes	involved	in	signal	transduction	pathways	including	FLT3-LM	or	muta-
tions	of	KIT and	NRAS.	These	data	support	the	concept	of	oncogenic	cooperation	between	AML1-ETO	and	a	
class	of	activating	mutations,	recurrently	found	in	patients	with	t(8;21),	and	provide	a	rationale	for	therapies	
targeting	signal	transduction	pathways	in	AML1-ETO–positive	leukemias.
Introduction
The cloning of recurring chromosomal translocations and, increas-
ingly, the molecular characterization of point mutations in patients 
with acute leukemia have substantially contributed to the under-
standing of the pathogenesis of this disease. In acute myeloid leu-
kemia (AML), chromosomal translocations most frequently target 
transcription factors involved in the regulation of normal hema-
topoietic differentiation, whereas point mutations often affect 
genes involved in signal transduction pathways associated with cell 
proliferation (1–3). The systematic analyses of genetic alterations 
in patients with AML have demonstrated that genetic lesions of 
more than 1 transcriptional regulator, such as AML1-ETO (RUNX1-
MTG8), HOX fusion genes, or PML-RARA, rarely occur in the leuke-
mic clone. Similarly, patients with concurrent mutations of FLT3, 
KIT, or NRAS are rare. However, there are numerous examples in 
which fusion genes are identified together with activating muta-
tions of receptor tyrosine kinases, exemplified by PML-RARA and 
the FLT3 length mutation (FLT3-LM), which occur together in up 
to 35% of all patients with t(15;17)–positive AML (4).
These observations have favored a model of pathogenesis of acute 
leukemia in which the 2 groups of genetic alterations, 1 affecting 
transcriptional regulation and hematopoietic differentiation, the 
other altering signal transduction cascades associated with cell pro-
liferation, collaborate in inducing acute leukemia (5). This concept 
is supported by experimental data demonstrating that AML1-ETO, 
one of the most frequent fusion genes in AML, is not able, on its 
own, to induce leukemia in experimental in vivo models but requires 
additional mutations in yet unknown genes for induction of hema-
tological disease. In a conditional AML1-ETO murine model, for 
example, only mice treated additionally with N-ethylnitrosourea 
(ENU) developed AML as well as T cell lymphoblastic lymphoma, 
whereas untreated AML1-ETO mice showed only minimal hemato-
poietic abnormalities (6). Similar observations were reported from 
an hMRP8–AML1-ETO transgenic mouse model, which developed 
AML as well as T–acute lymphoblastic leukemia/lymphoma (T-ALL/
lymphoma) only after ENU mutagenesis (7), and from a murine BM 
transplantation model inducing constitutive expression of AML1-
ETO in hematopoietic progenitor cells by retroviral gene transfer 
(8). In a recent report, mice targeted to express AML1-ETO in the 
HSC compartment developed a nonlethal long-latency myeloprolif-
erative syndrome but failed to develop acute leukemia (9).
To test the hypothesis of oncogenic cooperation between differ-
ent classes of mutations, we analyzed a series of 135 patients with 
AML1-ETO–positive AML for the occurrence of activating muta-
tions involving signal transduction pathways (FLT3-LM, FLT3D835, 
KITD816, NRAS codon 12/13/61). Because almost one-third of all 
AML1-ETO–positive patients had such activating mutations, we 
asked whether AML1-ETO would be able to collaborate with 1 of 
Nonstandard	abbreviations	used: ALL, acute lymphoblastic leukemia; AML, acute 
myeloid leukemia; B6C3, C57BL/6J × C3H/HeJ (mice); CBF, core-binding factor;  
CFU-S, colony-forming spleen unit(s); cy, cytoplasmic; ENU, N-ethylnitrosourea; 
FLT3-LM, FLT3 length mutation; GSF, National Research Center for Environment 
and Health; IRES, internal ribosomal entry site; KD, kinase dead; LTR, long-terminal 
repeat; MSCV, murine stem cell virus; PepC3, C57BL/6Ly-Pep3b × C3H/HeJ (mice); 
VCM, virus-containing medium; YFP, yellow fluorescent protein.
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these alterations to induce leukemia. Here we demonstrated that 
retrovirally engineered coexpression of AML1-ETO and FLT3-LM 
potently synergizes to trigger the development of aggressive leu-
kemia in a murine transplantation model.
This model will allow valuable insights into the pathogenesis 
of core-binding factor (CBF) leukemias and demonstrates, for 
the first time to our knowledge, the functional collaboration of 
AML1-ETO with a class of activating mutations frequently found 
in patients with t(8;21)–positive leukemia.
Results
AML1-ETO occurs frequently together with activating mutations involving 
signal transduction pathways in patients with AML. In order to charac-
terize genetic alterations that occur together with the AML1-ETO 
fusion gene in AML, 135 patients with AML1-ETO (93 male, 42 
female; median age 50.9, range 15.8–89.1) were screened for activat-
ing mutations in the receptor tyrosine kinases FLT3 and KIT as well 
as in NRAS (KITD816, NRAS codon 12/13/61). Patients included 118 
with newly diagnosed AML, 4 in first relapse, and 13 classified as 
having therapy-related AML. Activating mutations were detected in 
38 patients (28.1%) and included mutations in the receptor tyrosine 
kinase FLT3 or KIT (25 patients in total) or in NRAS (13 patients). In 
contrast, no MLL-PTD (partial tandem duplication) mutations were 
detected in 87 samples subjected to this analysis (Table 1). These 
data demonstrate that genetic alterations occurring with the AML1-
ETO fusion gene frequently affect signal transduction pathways.
AML1-ETO cooperates with FLT3-LM in inducing acute leukemia in trans-
planted mice. To test the functional significance of the association of 
AML1-ETO with mutations involving critical signal transduction 
cascades, we used the murine BM transplantation model. Murine 
stem cell virus–based (MSCV-based) retroviral constructs carrying 
the AML1-ETO cDNA upstream of an internal ribosomal entry site–
green fluorescent protein (IRES-GFP) cassette or the FLT3-LM cDNA 
upstream of an IRES–yellow fluorescent protein (IRES-YFP) cassette 
were generated to transduce and track hematopoietic cells expressing 
AML1-ETO (GFP+), FLT3-LM (YFP+), or both AML1-ETO and FLT3-
LM (GFP+/YFP+) in vitro and in vivo (Figure 1). In order to investigate 
the impact of expression of AML1-ETO or FLT3-LM individually on 
primary primitive hematopoietic progenitor cells, we performed the 
colony-forming spleen assay (CFU-S). BM cells transduced with the 
AML1-ETO/GFP or FLT3-LM/YFP vector or both vectors were highly 
purified 96 hours after the start of infection by FACS. Their ability 
to form spleen colonies (day 0 equivalent) was measured by trans-
plantation of transduced cells after purification into lethally irradi-
ated recipient mice and quantification of spleen colony formation 
12 days after injection. Constitutive expression of FLT3-LM did not 
increase the CFU-S content compared with the GFP control. In con-
trast, AML1-ETO increased the CFU-S content 3.1-fold compared 
with the control (P < 0.002). Strikingly, coexpression of FLT3-LM 
together with AML1-ETO increased CFU-S numbers a further 2.1-
fold for a net increase of 6.5-fold CFU-S compared with the control 
(P < 0.013), thus demonstrating functional collaboration of these 2 
genetic alterations in enhancing the CFU-S frequency (Figure 2A). In 
an effort to characterize the domains responsible for the collabora-
tion of the 2 aberrations, an FLT3-LM and an AML1-ETO mutant 
were generated: the FLT3-LM mutant with loss of its kinase activ-
ity (kinase dead [KD]) (FLT3-LM-KD) and the AML1-ETO mutant 
with an L148D point mutation in the Runx1 domain of AML1-ETO 
(AML1-ETO-L148D), previously reported to lack DNA-binding 
activity. Expression of the constructs was tested by Western blot and 
FACS analysis, and FLT3-LM-KD was also tested for autophosphory-
lation as a surrogate marker for kinase activity and for its capacity 
to induce IL-3–independent growth in Ba/F3 cells (Figure 1, B, D, F, 
and G). Of note, AML1-ETO-L148D was not able to collaborate with 
FLT3-LM. Furthermore, the collaboration between AML1-ETO and 
FLT3-LM was dependent on the kinase activity of FLT3, as FLT3-
LM-KD did not collaborate with the fusion gene (Figure 2A). Inhibi-
tion of the kinase activity of FLT3-LM by the protein tyrosine kinase 
(PTK) inhibitor PKC412 was tested in a ∆CFU-S assay after 48 hours 
of incubation with the inhibitor. The compound induced a 62% 
reduction of the day 0 equivalent of the CFU-S frequency (42 versus 
16 per 1 × 105 initiating BM cells) of cells cotransfected with FLT3-LM 
and AML1-ETO compared with the untreated control, whereas the 
CFU-S frequency of cells infected with the GFP control vector was 
unchanged by the inhibitor (Figure 2B).
To further assess the potential collaboration of AML1-ETO with 
FLT3-LM, we carried out  long-term BM transplantation stud-
ies using BM transduced with AML1-ETO or FLT3-LM alone or 
with both together. Over an observation period extending to 20.6 
months, no disease developed in recipients of BM singly transduced 
with AML1-ETO (3 × 105 to 4 × 105 highly purified GFP+ cells; n = 9) 
or FLT3-LM (7 × 104 to 2 × 105 highly purified YFP+ cells together 
with 3 × 105 to 1 × 106 nontransduced helper cells; n = 9). To obtain 
mice engrafted with AML1-ETO/FLT3-LM–coexpressing BM cells, 
mice were injected with a mixture of GFP+/YFP+ cells (range 1 × 103 
to 5.5 × 104 cells) and nontransduced normal BM cells  (range 
2.3 × 105 to 1.9 × 106). All recipients of doubly transduced BM (n = 11 
from 5 independent experiments) succumbed to an aggressive acute 
leukemia after a median latency time of 233 days post-transplan-
tation (Figure 3). These mice were engrafted with GFP/YFP–coex-
pressing cells that were positive for AML1-ETO and FLT3-LM tran-
scripts in the RT-PCR analysis (Figure 1C). At diagnosis the mice 
were moribund, cachectic, and short of breath and suffered from 
splenomegaly (median spleen weight 441 mg) (Table 2). Peripheral 
blood and BM contained a high proportion of blasts, and peripheral 
blood wbc counts were highly elevated in 5 of 11 animals (range 
2 × 106 to 430 × 106 cells/ml) compared with the GFP control (range 
3.5 × 106 to 9 × 106) (Table 2), consistent with a diagnosis of acute 
leukemia. Additionally, mice were anemic, with a 45% reduction in 
erythrocyte counts compared with the mean count in the control.
Coexpression of AML1-ETO and FLT3-LM causes both acute myeloblas-
tic and lymphoblastic leukemia. In 7 animals the morphology of the 
blasts was myeloblastic (Figure 4A), whereas 4 animals were char-
acterized by a lymphoblastic cell population (Figure 4, B and C, 
and Table 2). In 2 of the 7 animals with AML (mice nos. 16 and 24) 
the blast population was accompanied by a dominant mast cell 
Table 1
Genetic alterations in patients with AML1-ETO rearrangement
	 No.	of	patients	 No.	of	patients		
	 analyzed	 with	mutation		
	 	 detected
FLT3-LM 135 11 (8.1%)
FLT3D835 135 3 (2.2%)
KITD816 135 11 (8.1%)
NRAS codon 12/13/61 135 13 (9.6%)
FLT3, KIT, or NRAS mutation 135 38 (28.1%)
MLL-PTD 87 0
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population with fine metachromatic granulation in the panop-
tic staining (Figure 4A). The BM and spleen were infiltrated with 
up to 80% and 80% blasts, respectively, in the mice with AML and 
up to 85% and 95%, respectively, in the mice suffering from ALL 
(Table 2 and Figures 4 and 5).
In order to determine more precisely the immunophenotype of the 
leukemic population, flow cytometric analyses from BM cells were 
performed. Seven animals suffered from AML with a Gr-1/Mac-1– 
positive cell population in the transduced compartment, which 
coexpressed Sca-1 (45.2%, range 19–73%). Of note, in 4 of the 7 ani-
mals with AML, coexpression of CD4 was detected in 21%, 27%, 31%, 
and 32% of BM cells (animals nos. 15, 16, 22, and 23, respectively; 
Table 2). Three mice suffered from B-lymphoblastic leukemia, with 
90.4% of the transduced cells expressing B220 (range 85–97%) and 
lacking expression of myeloid antigens (Gr-1–positive 1.5%, range 
0.4–2.3%; Mac-1–positive 1.7%, range 1.4–1.9%). One animal devel-
oped T cell leukemia, with coexpression of CD4 and CD8 (99% 
CD8+, 86% CD4+ in the transduced compartment) and expression 
of Sca-1 in 76% of all cells (Figure 4C). Histological tissue sections 
and immunohistochemistry were performed in 2 diseased mice with 
AML, including 1 of the animals with an increase in mast cells in 
the peripheral blood (mouse no. 16). Both animals showed multiple-
organ infiltration into hematopoietic and nonhematopoietic organs 
with effacement of the normal follicular architecture of the spleen 
(Figure 5, D and E [right side]) and an infiltration with leukemic blasts 
in the liver and spleen (Figure 5, A–D and F). Immunohistochemistry 
Figure 1
Schematic diagram and analysis of expression of different constructs. (A) Retroviral constructs for expression of AML1-ETO and of the AML1-ETO-
L148D (31, 47), FLT3-LM, and FLT3-LM-KD mutant proteins. The GFP vector served as a control. AE, AML1-ETO; LTR, long-terminal repeat; RHD, 
runt homology domain; TAF110, TATA-binding protein–associated factor 110; HHR, hydrophobic heptad repeat; ZNF, zinkfinger; TM, transmem-
brane; JM, juxtamembrane; PTK, protein tyrosine kinase; KI, kinase insert. (B, C, and E) Western blot analysis of cellular extracts from GP+ E86 
and NIH 3T3 cells transfected with the different constructs (the molecular mass is indicated). Kasumi cells served as a positive control. (D) a-pTyr 
plot demonstrating phosphorylation of FLT3-LM and FLT3-WT but not of FLT3-LM-KD. (F) FACS analysis of Ba/F3 cells transduced with the FLT3 
constructs. (G) Growth of IL-3–dependent Ba/F3 cells infected with the different constructs. (H and I) Flow cytometry and RT-PCR analysis of cells 
coexpressing FLT3-LM/YFP and AML1-ETO/GFP, isolated from a representative leukemic mouse. FL, FLT3 ligand; PB, peripheral blood.
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confirmed the diagnosis of AML: blasts were positive for myeloper-
oxidase but showed differentiation into more mature myeloid cells 
with positivity for chloracetatesterase (mouse no. 14; Table 2 and 
Figure 5, B, C, and F). In the second mouse with AML, infiltration of 
organs with cells expressing mast cell–specific tryptase and CD117 
could be confirmed in the primarily and secondarily transplanted 
mouse, indicating the presence of a malignant infiltrating mast cell 
population in this animal (mouse no. 16).
The leukemias were readily transplantable and had the same his-
tomorphology within 106 days after transplantation (median sur-
vival 68 days, range 57–106 days; n = 5) (Figure 3 and Figure 5, G–O). 
Southern blot analyses of BM from leukemic mice revealed modest 
numbers of proviral integrations, consistent with double infection 
and monoclonal or, at most, oligoclonal disease (Figure 6A). Mono-
clonal or oligoclonal disease is consistent with the relatively small 
transplant doses used but could also reflect a possible contribution 
of retroviral insertional mutagenesis to the transformation process. 
To further explore this latter possibility, 10 retroviral integration 
sites were subcloned and sequenced from 4 leukemic mice; all 10 sites 
were unique, and thus there was no indication of a common integra-
tion site associated with the leukemic transformation. Moreover, 5 
sites were intergenic or not linked to known genes. The remaining 
sites were in introns in a 5′ to 3′ orientation most likely to lead to 
gene knock down rather than activation (Figure 6B and Table 3).
Since we observed coexpression of CD4 in leukemic cells of the 
majority of mice who developed AML in our model, we analyzed 
expression of CD4 and cytoplasmic (cy) CD3 in patients with 
AML1-ETO–positive AML; 17 of 52 patients analyzed (32.7%) and 
39 of 50 patients analyzed (78%) were positive for CD4 or cyCD3, 
respectively. Furthermore, 31 of 52 patients (59.6%) expressed the B 
cell antigen CD19, 27 of 52 patients cyCD22 (51.9%), and 38 of 39 
patients cyCD79a (97.4%) (Figure 7). There was no difference in the 
extent of coexpression of lymphoid antigens in AML1-ETO–posi-
tive AML with additional activating mutations of FLT3, KIT, and 
NRAS (n = 14) versus cases without this class of mutations (n = 38) 
(data not shown). This indicates that coexpression of lymphoid 
and myeloid antigens in myeloblastic leukemia, which is detected 
in the murine model, is a common characteristic in patients with 
AML1-ETO–positive AML.
Discussion
The translocation t(8;21)(q22;q22), which generates the AML1-ETO 
fusion gene, is one of the most frequent chromosomal translocations, 
detected in 12% of all AML patients and in up to 40% of FAB-M2 
AML patients (10, 11). The translocation targets AML1 (RUNX1), a 
member of the RUNX family characterized by a DNA-binding Runt 
domain at the amino terminus that is retained in the fusion gene 
(12). This domain is necessary for DNA binding and heterodimer-
ization of AML1 with CBFB, the non–DNA-binding subunit of the 
complex. As predicted by the discovery that the AML1 gene is rear-
ranged in human hematopoietic disease, the AML1/CBFB complex 
was shown to be a key regulator of definitive hematopoiesis, and loss 
of either of these genes resulted in embryonic lethality with complete 
lack of definitive HSCs (13). In addition, it was recently reported that 
AML1+/– adult mice suffer from a 50% reduction of long-term repopu-
lating stem cells (14). Although it is yet not fully understood how the 
Figure 2
Analyses of CFU-S frequencies. (A) Primary BM cells retrovirally trans-
duced with GFP, AML1-ETO, AML1-ETO-L148D, FLT3-LM, or FLT3-
LM-KD vectors or with combinations of the different vectors were isolated 
by FACS 48 hours after infection and injected into lethally irradiated mice 
to assess initial (day 0) CFU-S numbers. CFU-S frequency per 1 × 105 
initiating BM cells was determined in 3 independent experiments. The 
number of analyzed mice and the P value compared with the GFP con-
trol are indicated. (B) CFU-S frequency of primary BM cells infected 
with GFP or with both AML1-ETO and FLT3-LM and treated with the 
inhibitor PKC412 for 48 hours compared with untreated controls.
Figure 3
Survival of transplanted mice. Survival curve of mice transplanted with 
BM cells expressing AML1-ETO (n = 9), FLT3-LM (n = 9), or GFP (n = 12), 
of mice transplanted with marrow cells coexpressing AML1-ETO and 
FLT3-LM (n = 11), and of secondarily transplanted mice (n = 5).
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AML1-ETO fusion gene contributes to leukemogenesis, it is thought 
that 1 key mechanism is the suppression of AML1- and C/EBPa-
dependent activation of genes responsible for myeloid development 
(15, 16). Perturbation of hematopoiesis by expression of AML1-ETO 
results in an increase in the replating capacity of murine clonogenic 
progenitors and in the growth of primitive human progenitor cells in 
vitro (6, 17). Furthermore, in vivo and ex vivo analyses demonstrated 
alterations in the differentiation pattern and proliferative capacity of 
murine hematopoietic cells expressing the fusion gene (8, 9, 18, 19). 
However, numerous murine in vivo models documented that AML1-
ETO on its own is not able to induce leukemia (6, 7, 9, 18, 19). The 
observation that AML1-ETO as a single factor is nonleukemogenic 
is further supported by findings that nonleukemic AML1-ETO–
expressing progenitor cells can be isolated from healthy individuals 
as well as AML patients in remission, which suggests that additional 
mutations in these AML1-ETO–positive progenitors are necessary 
for the transformation into leukemia-initiating cells (20–22). The 
importance of collaborating genetic events in the pathogenesis of 
AML1-ETO–positive leukemias has indeed been shown in different 
murine models, such as a conditional AML1-ETO murine model as 
well as an hMRP8–AML1-ETO transgenic mouse model. Only mice 
treated additionally with ENU developed AML or T cell lymphoma 
(6, 7). Furthermore, retrovirally expressed AML1-ETO induced myelo-
blastic transformation in vivo only in a background deficient in the 
IFN-regulatory factor IFN consensus sequence-binding protein (18). 
These data strongly suggest that genetic alterations cooperating with 
AML1-ETO play a role in inducing leukemia. 
In order to characterize genetic alterations that potentially col-
laborate with AML1-ETO, we screened 135 patients with AML for 
activating mutations of signal transduction pathways or mutations 
affecting the MLL gene. Whereas MLL-PTD mutations, which exem-
plify genetic alterations involved in transcriptional regulation, were 
not found at all, 28% of the patients were positive for activating 
mutations such as FLT3-LM, FLT3D835, KITD816, or NRAS. The 
frequent coexistence of such mutations with AML1-ETO fits well 
in the model of leukemogenesis in which the collaboration of 2 
classes of genetic alterations, 1 affecting transcription factors asso-
ciated with hematopoietic differentiation, the other affecting signal 
transduction pathways associated with cell proliferation, is neces-
sary for the malignant transformation of hematopoietic progenitor 
cells (3). Using the murine BM transplantation model, we obtained 
direct evidence for a functional collaboration of AML1-ETO with 
FLT3-LM in inducing leukemia, supporting the aforementioned 
model of leukemogenesis. Furthermore, these data demonstrate 
the collaboration of the 2 most frequent genetic alterations in AML, 
providing an important model for the understanding of both the 
AML1-ETO–positive and the FLT3-LM–positive leukemias.
Of note, 4 of 7 AML mice reported here expressed the T cell anti-
gen CD4. Although the mechanisms underlying the coexpression 
of myeloid and lymphoid antigens in AML1-ETO–positive myeloid 
leukemia are not clear, one possibility is that in this AML subtype 
an early progenitor cell with a lineage-overlapping mixed phenotype	
is the target of leukemogenic transformation, as recently proposed 
for hematological malignancies (23). Of note, it was recently demon-
strated that, in AML1-ETO–positive leukemia, evidence of lineage 
overlap is not restricted to the expression of cytoplasmic or surface 
antigens but extends to the transcriptional apparatus, since PAX5 
is selectively expressed in one-third of patients with t(8;21) AML in 
Table 2
Hematological parameters of analyzed experimental mice
Mouse		 Retroviral		 Day	of		 rbc/ml	 wbc/ml		 Spleen	size		 Spleen	weight		 BM		 Spleen		 PB		
no.	 construct	 sacrifice	 	×	109 ×	106 (mm)	 (mg)	 %	blasts	 %	blasts	 %	blasts
1 GFP  ND 4.8 7.6 ND ND 1 0 0
2 GFP  ND 6.4 8.1 ND ND 0 0 0
3 GFP  90 7 5 14 × 4 51 2 0 0
4 GFP  ND 5.4 9 ND ND 0 0 0
5 GFP  689 5.6 4.5 15 × 4 78 0 0 0
6 GFP  721 7.25 3.5 ND ND 3 0 0
7 AE 444 6 13 13 × 3.5 63 8 0 0
8 AE 479 3.1 15 14 × 4 60 11 0 0
9 AE 493 5.7 6.9 14 × 4 82 2 0 0
10 AE 615 5 7.6 16 × 5 117 14 0 0
11 FLT3-LM 88 4.5 10 15 × 4 95 4 ND 0
12 FLT3-LM  ND 4.5 13 ND ND 2 ND 0
13 FLT3-LM  ND 5.6 8.3 ND ND 1 ND 0
14A AE/FLT3-LM 233 ND 23 27 × 7 600 80 52 20
15A AE/FLT3-LM 100 0.85 26.5 19 × 6 166 48 80 75
16A AE/FLT3-LM 612 1.7 12.5 14 × 4 118 20 50 25
17B AE/FLT3-LM 84 ND 430 24 × 9 572 80 22 60
18B AE/FLT3-LM 84 4.4 3.3 21 × 7 270 85 43 62
19B AE/FLT3-LM 94 7.7 7.2 12 × 4 ND 85 20 95
20B AE/FLT3-LM 96 3.8 60 21 × 6 310 40 95 60
21A AE/FLT3-LM 269 4 2 28 × 9 650 38 62 30
22A AE/FLT3-LM 303 2.6 10 15 × 3 200 24 76 38
23A AE/FLT3-LM 304 2.6 2.5 29 × 10 1,400 27 55 78
24A AE/FLT3-LM 359 2.5 35 28 × 9 760 39 77 64
AAML; BALL. PB, peripheral blood; ND, not determined; AE, AML1-ETO.
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contrast to all other cytogenetically defined AML subtypes (24). Fur-
thermore, both myeloblastic and lymphoblastic leukemias of B and 
T cell type developed in this model of AML1-ETO and FLT3-LM coop-
eration. This observation was also reported in other murine models: 
in a conditional AML1-ETO murine model, mice treated additionally 
with ENU developed AML as well as T cell lymphoblastic lymphoma, 
although most of the T cell neoplasms did not express the fusion 
gene (6). Similar observations were reported from an hMRP8–AML1-
ETO transgenic mouse model, which developed AML as well as 
T-ALL/lymphoma after ENU treatment (7). In addition, expression 
of AML1-ETO might contribute to the lymphoid phenotype of the 
leukemias in our model, as it was reported that FLT3-LM is able to 
induce a long-latency T cell lymphoma–like disease in the C57BL/
C3H background (25). However, the association of FLT3-LM with a 
lymphoid disease seems to depend on the genetic background of the 
mouse strain, as FLT3-LM induced a myeloproliferative syndrome in 
BALB/c mice (26). In our model, also using the C57BL/C3H back-
ground, constitutive expression of FLT3-LM alone did not induce any 
perturbation of the hematopoietic development in vivo; this result 
was also recently reported in a mouse model of collaboration of 
FLT3-LM with MLL-SEPT6 using the C57BL/6 strain (27).
Of note, overexpression of FLT3 and activating FLT3 mutations 
are associated with ALL in humans, in particular in cases of ALL 
with hyperdiploidy or MLL rearrangement, characterized by a primi-
tive B cell or a mixed lymphoid-myeloid phenotype (28–30). The 
observations that ETV6-PDGFBR, which already by itself causes 
a lethal myeloproliferative syndrome in transplanted mice, induc-
es exclusively a myeloblastic leukemia when coexpressed with 
AML1-ETO might point to the importance of the collaborating 
partner for the phenotype of the induced leukemia (31). Another 
possible explanation for the development of lymphoid malignan-
cies in our model is that, in individual mice, lymphoid-commit-
ted stages of differentiation were hit by the retrovirus, resulting 
in lymphoblastic leukemia in these animals. This would poten-
tially be a key difference from the human situation, in which 
both AML1-ETO and FLT3-LM are already present in the HSC 
pool (21, 32). An important question is whether the results were 
influenced by retroviral insertional mutagenesis. Most of the leu-
kemic animals were transplanted with a low transplant dose and 
then suffered from monoclonal or oligoclonal disease. Although 
the number of retroviral integration events was low in the mice, 
insertional mutagenesis might have contributed to the leukemo-
genesis. However, analyses of the retroviral integration sites in the 
diseased animals showed integration into intergenic regions or 
introns of genes, more likely resulting in their knock down than 
in their activation. These data suggest that retroviral insertional 
mutagenesis might not play the key part in disease development, 
an issue that might be more accurately addressed in mouse mod-
els expressing AML1-ETO from an endogenous promoter. The 
long latency of the leukemias, even of secondary disease, however, 
strongly argues that additional secondary in vivo genetic events 
in the animals contributed to disease development.
To our knowledge, this is the first functional evidence of a leu-
kemogenic collaboration of AML1-ETO with a complementary 
class of mutation, recurrently found in patients with t(8;21). It 
facilitates our understanding of acute leukemias associated with 
2 of the most frequent genetic alterations in this disease. Further-
more, our experimental data support recent reports that show 
the functional relevance of activating mutations in patients with 
CBF leukemias [AML1-ETO or CBFB-MYH11] by demonstrating 
a significantly shortened overall and event-free survival for AML1-
ETO–positive leukemias harboring activating mutations of FLT3 
or KIT compared with those without these mutations. In contrast, 
RAS mutations did not affect the treatment outcome (S. Schnittger, 
unpublished observations) (33, 34). In line with these findings, it 
was recently shown that in patients with AML1-ETO–positive leuke-
mia, most leukemic cells at diagnosis additionally harbored muta-
tions in KIT, whereas in 3 patients analyzed in complete remission, 
only the fusion gene, but not the KIT mutation, could be detected 
by PCR; this strongly supports the concept of a stepwise develop-
ment of disease involving 2 collaborating genetic aberrations (35). 
These observations encourage the systematic screening of activating 
mutations in patients with CBF leukemias in prospective clinical 
trials to evaluate more precisely their prognostic impact, and they 
form a rationale to consider treatment strategies targeting the signal 
transduction apparatus in this AML subtype.
Methods
Patient samples. BM samples from 135 adult patients with newly diagnosed 
AML — de novo AML (n = 118), secondary AML after treatment of a previ-
ous malignancy (n = 13), and AML at relapse (n = 4) — were analyzed. The 
diagnosis of AML was performed according to the French-American-Brit-
ish criteria and the WHO classification (36, 37). Cytomorphology, cyto-
chemistry, cytogenetics, and molecular genetics were applied in all cases 
Figure 4
Immunophenotype and morphology of hematopoietic cells recovered from 
leukemic mice. The plots show representative FACS profiles from BM cells 
in comparison with cells from GFP control animals, with indication of the 
proportion of positive cells within the GFP+/YFP+ compartment. The pho-
tographs show cytospin preparations (H&E; magnification, ×630) from 
peripheral blood (A, right image; B and C) and from BM (A, left image). 
(A) AML with a dominant mast cell population (marked by arrows) (mouse 
no. 16). (B) B-ALL (mouse no. 17). (C) T-ALL (mouse no. 20).
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as described below. Both animal and human studies were approved by the 
Ethics Committee of Ludwig Maximilians University and abided by the 
tenets of the revised World Medical Association Declaration of Helsinki 
(http://www.wma.net/e/policy/b3.htm).
Cytogenetic and FISH analysis. Cytogenetic analyses were performed using 
standard techniques. For FISH, a commercially available AML1-ETO probe 
was used according to the manufacturer’s instructions (Vysis Inc.) (38).
PCR. Molecular genetic analysis for AML1-ETO (38), MLL-PTD (39), FLT3-
LM (4), NRAS mutations, FLT3D835, and KITD816 (40) in patient samples was 
performed as has been described previously (41).	In leukemic mice, expression 
of AML1-ETO and FLT3-LM was assessed by RT-PCR in animals transplanted 
with BM cells coexpressing AML1-ETO/GFP and FLT3-LM/YFP. Preparation 
of cDNA was performed as previously described (41). For AML1-ETO the prim-
er forward 5′-ATGACCTCAGGTTTGTCGGTCG-3′ and the primer reverse 
5′-TGAACTGGTTCTTGGAGCCTCCT-3′ (corre-
sponding to positions nucleotide 395 and nucleo-
tide 633 of GenBank accession number D13979, 
respectively) were used; for FLT3-LM the primer 
forward 5′-GCAATTTAGGTATGAAAGCCAGC-
3′ and the primer reverse 5′-CTTTCAGCATTTT-
GACGGCAACC-3′  (corresponding to positions 
nucleotide 1,704 and nucleotide 1,920 of GenBank 
accession number NM_004119, respectively) were 
used. The annealing temperature was 57°C. The 
number of PCR cycles for each gene was chosen 
to stop the reaction in the linear phase of ampli-
fication (35 cycles for AML-ETO and FLT3-LM). 
The integrity of the RNA in all samples was con-
firmed by mβ-2 microglobulin RT-PCR.
For the linker-mediated PCR (LM-PCR), inte-
grated long-terminal repeats (LTRs) and flank-
ing genomic sequences were amplified and then 
isolated  using  a  modification  of  the  bubble 
LM-PCR strategy  (42, 43). Aliquots of  the cell 
lysates from leukemic mice were digested with 
PstI or Ase (New England Biolabs Inc.), and the 
fragments were ligated overnight at room tem-
perature  to  a  double-stranded  bubble  linker 
(5′-CTCTCCCTTCTCGAATCGTAACCGTTCG-
TACGAGAATCGCTGTCCTCTCCTTG-3′ and 5′-
ANTCAAGGAGAGGACGCTGTCTGTCGAAGG-
TAAGGAACGGACGAGAGAAGGGAGAG-3′). 
Next, a first PCR (PCR-A) was performed on 10 µl 
(one-tenth) of the ligation product using a linker-
specific Vectorette primer (5′-CGAATCGTAACC-
GTTCGTACGAGAATCGCT-3′) (Invitrogen Corp.) 
and an LTR-specific primer (LTR-A: 5′-CAACACA-
CACATTGAAGCACTCAAGGCAAG-3′) under the 
following conditions: 1 cycle of 94°C for 2 min-
utes, 20 cycles of 94°C for 30 seconds and 65°C 
for 1 minute, and 1 cycle of 72°C for 2 minutes. 
The bubble linker contains a 30-nucleotide nonho-
mologous sequence in the middle region that pre-
vents binding of the linker primer in the absence 
of the minus strand generated by the LTR-specific 
primer. A 1-µl aliquot of the PCR-A reaction (one-
fifteenth) was then used as a template for a second 
nested PCR (PCR-B) using an internal LTR-specific 
primer  (LTR-B:  5′-GAGAGCTCCCAGGCTCA-
GATCTGGTCTAAC-3′) and the same linker-spe-
cific Vectorette primer as was used in PCR-A, with the following conditions: 
1 cycle of 94°C for 2 minutes, 30 cycles of 94°C for 60 seconds and 72°C for 
1 minute, and 1 cycle of 72°C for 2 minutes. Ten microliters (one-half) of 
the final PCR-B product was electrophoresed using 2% agarose tris-acetate-
EDTA gel. Individual bands were excised and purified using the QIAEX 
II Gel Extraction Kit (QIAGEN) and then cloned into PCR2.1 (Invitrogen 
Corp.) before sequencing of the integration site of the retrovirus.
Multiparameter flow cytometry. Immunophenotypic analyses were per-
formed as previously described (44). The following combinations of anti-
bodies were used: CD34/CD2/CD33, CD7/CD33/CD34, CD34/CD56/
CD33, CD11b/CD117/CD34, CD64/CD4/CD45, CD34/CD13/CD19, 
CD65/CD87/CD34, CD15/CD34/CD33, HLA-DR/CD33/CD34, CD4/
CD13/CD14, CD34/CD135/CD117, CD34/CD116/CD33, CD90/CD117/
CD34, CD34/NG2(7.1)/CD33, CD38/CD133/CD34, CD61/CD14/CD45, 
Figure 5
Histological analyses of leukemic mice. (A–F) Histological analyses of AML (mouse no. 14). 
Original magnifications: A–C, ×200; inset in C, ×1,000; D and right side of E, ×250; inset in D, 
×650; left side of E, ×400; F, ×400. (G–O) Histological analyses of AML with a dominant mast 
cell population (mouse no. 16). (G–L) Primary recipient. (M–O) Secondary recipient. Original 
magnifications: G and M, ×100; H, J, and N, ×200; I, K, and O, ×400; L, ×600. Mast cells with 
metachromatic granulation in the Giemsa stain are indicated by an arrow. MPO, myeloperoxi-
dase; CAE, N-acetyl-chloroacetate esterase.
research article
2166	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 115      Number 8      August 2005
CD36/CD235a/CD45, CD15/CD13/CD33, CD9/CD34/CD33, CD38/
CD34/CD90, CD34/CD79a/CD19, TdT/cyCD33/cyCD45, myeloper-
oxidase/lactoferrin/cyCD15, TdT/cyCD79a/cyCD3, and TdT/cyCD22/
cyCD3. All antibodies were purchased from Beckman Coulter Inc., except 
for CD64 and CD15 (Medarex Inc.), CD133 (Miltenyi Biotec), and myelo-
peroxidase and lactoferrin (CALTAG Laboratories). For the analysis of 
cytoplasmic antigens, cells were fixed and permeabilized before staining 
with FIX & PERM (CALTAG Laboratories). Multiparameter flow cytom-
etry analysis was performed with a FACSCalibur flow cytometer (BD).
The purity of all samples was 80–100%. Furthermore, immunophenotyp-
ing was performed with triple staining in all cases as indicated above, test-
ing simultaneous expression of myeloid and lymphoid antigens to exclude 
contaminating normal lymphoid cells.
In mice, immunophenotypic analysis of single-
cell suspensions from BM, spleen, and peripheral 
blood was performed by flow cytometry (FACS-
Calibur cytometer; BD) using PE-labeled Sca-1, 
Gr-1, Ter-119, and CD4 antibodies and allophy-
cocyanin-labeled Mac-1, Kit, B220, and CD8 anti-
bodies (all from BD Biosciences — Pharmingen), 
as previously described (45). The surface expres-
sion of the FLT3-LM construct and the FLT3-
LM-KD mutant of Ba/F3 cells was confirmed 
by FACS analysis (Figure 2B) using anti–human 
CD135–PE mAb (BD) and an isotype-matched 
IgG1-PE control (Beckman Coulter Inc.).
cDNA constructs and retroviral vectors. For retro-
viral gene transfer into primary BM cells, AML1-
ETO cDNA was subcloned into the multiple clon-
ing site of the modified murine stem cell virus 
(MSCV) 2.1 vector (41) upstream of the enhanced 
GFP (EGFP) gene and the internal ribosomal entry 
site (IRES). The FLT3-LM cDNA was subcloned 
into the identical MSCV vector construct carrying 
the enhanced YFP (Figure 1A). The MSCV vector 
carrying only the IRES-EGFP cassette was used as 
a control. The cDNA of FLT3-LM was kindly provid-
ed by D.G. Gilliland (Harvard Medical School, Bos-
ton, Massachusetts, USA) and contained a 28–amino 
acid duplicated sequence (CSSDNEYFYVDFREYEY-
DLKWEFPRENL) inserted between amino acids 610 
and 611. The AML1-ETO cDNA was provided by S.W. 
Hiebert (Vanderbilt University School of Medicine, 
Nashville, Tennessee, USA).
The  FLT3-LM-KD mutation  K672R  (a  point 
mutation of Lys644 to Arg that disrupts an ion pair 
with Glu661 that is critical for nucleotide binding 
in FLT3-WT; ref. 46), and the L148D AML1-ETO 
point mutation (31, 47) to prevent AML1-ETO DNA 
binding, were generated from the full-length human 
FLT3-LM cDNA and the AML1-ETO cDNA, respec-
tively, using the QuikChange Site-Directed Muta-
genesis Kit (Stratagene) according to the manufac-
turer’s instructions. The correct sequences of the 
constructs were confirmed by complete nucleotide 
sequencing, and expression was proved by Western 
blot and FACS analysis (Figure 1).
Cell culture. Gag-pol and envelope (GP+ E86) packag-
ing cells, NIH 3T3 cells, and 293T cells were grown in 
DMEM with 10% FBS and 1% penicillin/streptomy-
cin in a humidified incubator at 37°C and 5% CO2. Primary murine BM cells 
were plated in transplant medium consisting of DMEM supplemented with 
15% FBS, 1% penicillin/streptomycin, 6 ng/ml IL-3, 10 ng/ml IL-6, and 100 
ng/ml SCF (tebu-bio GmbH). IL-3–dependent Ba/F3 cells stably expressing 
the empty vector alone, FLT3-WT, FLT3-LM, and FLT3-LM-KD were seeded 
at a concentration of 0.05 × 106 per milliliter in the presence or absence of IL-3 
and FLT3 ligand, as described previously (48). At 72 hours, viable cells were 
counted in a standard hemacytometer after staining with trypan blue.
Retrovirus production. High-titer helper-free retrovirus was produced with 
the constructs above by individual cotransfection of each construct with 
Ecopac (Cell Genesys Inc.) into 293T cells using calcium chloride precipita-
tion. The retrovirus was subsequently collected in the conditioned medium. 
Figure 6 
Analysis of proviral integrations. (A) Southern blot analysis of genomic DNA from differ-
ent primary mice and a secondary recipient to detect clonal proviral integrations. DNA was 
digested with EcoRI, which cuts once in the proviral sequence, and blots were hybridized to 
a GFP/YFP probe. The mouse numbers are indicated (corresponding to those in Table 2). 
S, spleen; PB, peripheral blood; sec. of 21, second mouse of 1° mouse no. 21. (B) Bubble 
PCR analyses of retroviral integration sites in diseased mice. The bands (A–I) were isolated, 
subcloned, and sequenced. A description of the PCR products is given in Table 3. Asterisk 
indicates resolution as 2 unique bands after subcloning and sequencing of integration sites.
Table 3
Identity of retroviral integration sites in diseased mice
LaneA	 PCR		 Gene	 Protein		 Chromosome	 Mouse		
	 productA	 	 family	 	 no.
2 A 1 Intergenic  17qE3 15
 A 2 Intron 1 of Rnf8 alias AIP37 Ring finger  17qA3 
  and 5 kbp 3′ of Pim1 protein 8
3 B  Intergenic  15qE2 16
 C Intron 1 of Ptp4a3 Protein tyrosine  15qD3 
   phosphatase 4a3
4 D Hypothetical gene  10qC2 12
 E Intron 3 of GATA Transcription  6qD1  
   factor
5 F Intergenic  18qD3 
 G Intron 4 of SF3b Splicing factor  8qE1
   subunit b3
6 H Intergenic in intron   3qF1 18
  of hypothetical gene
 I Intergenic in intron   16qA1  
  of hypothetical gene
ALanes and PCR products according to Figure 6B.
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To optimize transduction efficiency, the virus-containing medium (VCM) 
of different constructs was used to transfect GP+ E86 cells to establish sta-
ble packaging cell lines, or to directly infect 5-FU–mobilized BM cells in the 
case of FLT3-LM. Ba/F3 cells were transfected with the different constructs 
as previously described (48, 49).
Mice and retroviral infection of primary BM cells. Parental-strain mice were 
bred and maintained at the GSF animal facility. Donors of primary BM 
cells  [(C57BL/6Ly-Pep3b × C3H/HeJ) F1  (PepC3) mice] and recipient 
mice [(C57BL/6J × C3H/HeJ) F1 (B6C3)] were more than 8 weeks old. Pri-
mary mouse BM cells were transduced as previously described (41). For 
transduction of AML1-ETO, cells were cocultured in transplant medi-
um with AML1-ETO/GFP producer cells irradiated with 40 Gy of 137Cs 
γ-radiation. For infection with the FLT3-LM virus, BM cells were cultured 
in FLT3-LM/VCM, supplemented with cytokines (IL-3, IL-6, and SCF), to 
achieve optimal transduction efficacy. For coinfection with the FLT3-LM 
and AML1-ETO retroviruses, BM cells were cultured on a mixture of 30–50% 
AML1-ETO/GFP and 50–70% FLT3-LM/YFP producer cells in transplant 
medium or FLT3-LM/VCM supplemented with IL-3, IL-6, and SCF. Retro-
viral transfection of primary BM cells with the AML1-ETO mutant L148D 
and the FLT3-LM-KD mutant was performed as described for FLT3-LM, 
by cultivation of the BM in VCM supplemented with IL-3, IL-6, and SCF. 
All transductions were performed with the addition of 5 µg/ml protamine 
sulfate. Infected cells were highly purified (FACSVantage; BD) based on 
expression of GFP (for AML1-ETO alone), expression of YFP (for FLT3-
LM alone), or coexpression of GFP and YFP (for AML1-ETO/FLT3-LM 
cotransduction) before transplantation.
BM transplantation and assessment of mice. FACS-purified transduced BM 
cells or ratios of transduced and nontransduced cells (if less than 3 × 105 
transduced cells per recipient were available) were injected into the tail vein 
of 8- to 10-week-old irradiated recipient F1 (B6C3) mice (800 cGy from a 
137Cs γ-radiation source). Peripheral blood or BM cell progeny of transduced 
cells were tracked using the GFP and/or YFP fluorescence in vivo (41). For 
transplantation of secondary mice, 1 × 106 to 2 × 106 cells of diseased pri-
mary animals were injected into the recipients after 800 cGy irradiation.
CFU-S and ∆CFU-S assay. 5-FU–mobilized primary BM cells  from F1 
(PepC3) donor mice were retrovirally transduced with AML1-ETO; AML1-
ETO-L148D; FLT3-LM; FLT3-LM-KD; both AML1-ETO and FLT3-LM; 
both AML1-ETO and FLT3-LM-KD; or both AML1-ETO-L148D and 
FLT3-LM. Cells transfected with the empty GFP vector served as control. 
Successfully transduced cells were isolated 48 hours after termination of 
infection by FACS (FACSVantage; BD). To assess initial (day 0) CFU-S 
numbers, purified cell populations were injected into lethally irradiated 
F1 (B6C3) recipient mice 96 hours after the start of infection (45). To 
study the effect of the selective protein tyrosine kinase inhibitor PKC412 
on double-positive cells, freshly sorted cells were cultured in transplant 
medium with 0 and 100 nM PKC412. After 48 hours, the cells were injected 
into lethally irradiated mice as described above, and the day 0 equivalent of 
the CFU-S frequency was calculated for both experimental groups. In this 
∆CFU-S assay the base-line frequency of CFU-S is lower than in the CFU-S 
assay. The recovery of CFU-S cells was quantified by determination of the 
number of macroscopic colonies on the spleen at day 12 postinjection	after 
fixation in Telleyesniczky’s solution.
Southern blot. Genomic DNA was isolated from BM, spleen, and peripheral 
blood of diseased mice with DNAzol as recommended by the manufacturer 
(Invitrogen Corp.). Southern blot analysis was performed as previously 
described (45). DNA was digested with EcoRI and probed with a 32P-labeled 
GFP/YFP DNA. Hybridizing bands were visualized by autoradiography.
Western blot. Protein expression of AML1-ETO, AML1-ETO-L148D, FLT3-
LM, and FLT3-LM-KD was demonstrated by Western blotting using stan-
dard procedures (41). Membranes were probed with an anti-ETO polyclonal 
goat antibody and an anti-FLT3 polyclonal rabbit antibody (Santa Cruz 
Biotechnology Inc.). Protein expression of FLT3-LM showed 2 bands, as 
previously reported: in detail, the FLT3 receptor occurs in 2 different forms 
due to glycosylation that can be resolved in SDS-PAGE gradient gels — a 
158- to 160-kDa membrane-bound protein that is glycosylated at N-linked 
glycosylation sites in the extracellular domain and an unglycosylated 130- 
to 143-kDa protein that is not membrane bound (50–52). Phosphorylation 
of FLT3 was tested by Western blot using 293T cells that were starved for 12 
hours at 37°C, 5% CO2. After cell harvesting and lysis, 300 µg of the lysates 
was immunoprecipitated with polyclonal rabbit anti-FLT3 antibody (s-18; 
Santa Cruz Biotechnology Inc.). Immunoprecipitates were analyzed by 
SDS-PAGE with mouse monoclonal anti-phosphotyrosine antibody (PY-99; 
Santa Cruz Biotechnology Inc.) and reprobed with anti-FLT3 antibody.
Histology. For histological analyses, sections of selected organs were pre-
pared and stained at the Academic Pathology Laboratory, GSF (Munich, 
Germany), using standard protocols, as previously described (41). The mast 
cell–specific tryptase and the CD117 antibody were purchased from Dako-
Cytomation. All the tumors were histopathologically classified according 
to the Bethesda proposals for classification on nonlymphoid and lymphoid 
hematopoietic neoplasms in mice (53, 54).
Statistical analysis. Data were evaluated using the 2-tailed Student’s 
t  test for dependent or independent samples (Microsoft Excel 2002, 
Microsoft Corp.). Differences with P values less than 0.05 were consid-
ered statistically significant.
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Figure 7
Expression of lymphoid antigens on 52 samples of patients with AML1-
ETO–positive AML, determined by immunophenotyping. Samples 
were defined as negative for expression of cytoplasmic antigens when 
less than 10% of the cells stained with the antibody, and as negative 
for expression of surface antigens when less than 20% of the cells 
stained with the antibody (shaded areas).
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Summary
A challenge for the development of therapies selectively targeting leukemic stem cells in acute myeloid leukemia (AML) is
their similarity to normal hematopoietic stem cells (HSCs). Here we demonstrate that the leukemia-propagating cell in mu-
rine CALM/AF10-positive AML differs from normal HSCs by B220 surface expression and immunoglobulin heavy chain rear-
rangement. Furthermore, depletion of B220+ cells in leukemic transplants impaired development of leukemia in recipients.
As in the murine model, human CALM/AF10-positive AML was characterized by CD45RA (B220)-positive, IG DH-JH rear-
ranged leukemic cells. These data demonstrate in a murine leukemia model that AML can be propagated by a transformed
progenitor with lymphoid characteristics, which can be targeted by antibodies that do not crossreact with normal HSCs.Introduction
For most cancers, the cell that propagates tumor growth and is
thought to play a key role in recurrence of disease is unknown.
The study of normal and malignant hematopoiesis has formed
a roadmap for the detailed analysis of the concept of the tu-
mor-initiating cell and has demonstrated that, in leukemia, the
malignant clone is organized in a hierarchy in which only a small
subpopulation of cells—the leukemic stem cells (LSCs)—are
able to initiate and propagate the disease (Hope et al., 2004).
In AML most studies indicate that malignant transformation tar-
gets cells within the hematopoietic stem cell compartment.
However, more recent data demonstrated that multipotentialCANCER CELL 10, 363–374, NOVEMBER 2006 ª2006 ELSEVIER INC. Dprogenitors or more committed myeloid progenitors can also ac-
quire leukemic stem cell properties when transformed by appro-
priate oncogenes (Cozzio et al., 2003; So et al., 2003). These re-
ports clearly demonstrated that cells other than hematopoietic
stem cells can be the target of fully transforming oncogenes,
which are characterized by their ability to transfer self-renewal
potential to committed stages of differentiation (Huntly et al.,
2004; Jamieson et al., 2004). The identification of leukemic
stem cell properties is a key step for an improved understanding
of the biology of acute leukemias and might also have clinical im-
plications: because of its essential role for the initiation and
maintenance of the leukemic clone, a curative therapeutic strat-
egy should be able to eradicate the LSC in the diseased patients.S I G N I F I C A N C E
The identification of tumor stem cells is one of the major goals of cancer research. We report on a murine model demonstrating that
myeloid malignancies such as acute myeloid leukemia can be propagated by a transformed progenitor with lymphoid characteris-
tics. These data extend our previous knowledge about leukemia stem cell candidates in acute leukemia and indicate that leukemia-
propagating cells in AML might differ from the myeloid blast population as well as from the normal hematopoietic stem cell in their
surface antigen profile. These findings suggest that such leukemic stem cell candidates can be targeted with antibodies that spare
the normal stem cell pool. This may pave the way for innovative antibody-based therapeutic strategies in this disease.OI 10.1016/j.ccr.2006.08.023 363
A R T I C L EAt the same time, such a strategy should spare normal hemato-
poietic stem cells (HSCs) to avoid intolerable therapy-associ-
ated stem cell toxicity. However, the major challenge for the de-
velopment of such therapeutic approaches is the often striking
similarity between leukemic and normal HSC, e.g., with regard
to their cell surface markers (Reya et al., 2001; Warner et al.,
2004). The limitations of the therapeutic tools available today
are well known: although standard chemotherapy is highly effec-
tive in inducing remissions in patients with AML, the majority of
patients finally relapse and succumb to this disease (Hiddemann
et al., 2005). One of the reasons for treatment failure is that even
dose-intensive conventional chemotherapy is not able to effi-
ciently target the LSC, demonstrated, for example, by the obser-
vation that patients in morphological complete remission harbor
CD34+/CD382 progenitor cells with the leukemia-specific ge-
netic alteration in their bone marrow (Feuring-Buske et al.,
1999). A major step toward the development of stem cell-tar-
geted AML therapies would be the identification of key differ-
ences between normal HSCs and the LSC. It has been reported
that the LSC differs from its normal counterpart by the expres-
sion of CD90 or the interleukin-3a receptor, and in a preclinical
NOD/SCID mouse model a diphtheria toxin (DT) human interleu-
kin 3 fusion protein (DT388IL3) was able to selectively kill LSCs in
patients with different subtypes of AML (Blair et al., 1997; Feur-
ing-Buske et al., 2002; Jordan et al., 2000).
The recent reports demonstrating that acute leukemias can
also arise from transformed committed progenitor cells might
improve the chances to define biological differences between
the LSC and the HSC (Huntly et al., 2004; So et al., 2003). How-
ever, leukemic stem cell candidates such as multipotent progen-
itor cells (MPPs) might be difficult to distinguish from normal
HSCs, although first strategies were established in mice to dis-
criminate MPPs from long-term repopulating stem cells by im-
munophenotype (Forsberg et al., 2005; Morrison et al., 1997).
In this report we present experimental evidence that acute mye-
loid leukemia can be propagated by a transformed progenitor,
which differs from normal hematopoietic stem cells by surface
expression of B220 and immunoglobulin heavy chain (IG
DH-JH) rearrangement. We established a murine model of
CALM/AF10 (C/A)-positive acute myeloid leukemia using the
bone marrow transplantation model and retroviral gene transfer
to constitutively express the fusion gene in hematopoietic pro-
genitor cells. The established model well predicted our findings
in patients withC/A-positive AML, who showed a cell population
expressing CD45RA, the human homolog of B220. This human
CD45RA+ cell population displayed IG DH-JH rearrangements,
was positive for the fusion gene as detected by fluorescence in
situ hybridization (FISH), and was able to form CFU-blast colo-
nies in vitro. In these patients the fusion gene is formed by the
translocation t(10;11) (p13;q14), which involves the CALM gene
(associated with clathrin-mediated endocytosis) and AF10 (a
putative transcription factor). This fusion gene is found in a vari-
ety of leukemias, which are all characterized by a very poor prog-
nosis (Dreyling et al., 1998). Of note, the malignant phenotypes
associated with C/A span AML, undifferentiated leukemia, acute
lymphoblastic leukemia, and T cell lymphoma, thus making it
appealing to determine the nature of the leukemic stem cell
candidate(s) in C/A-positive disease. The results of this study
demonstrate in a murine leukemia model that a transformed
progenitor cell population with lymphoid characteristics can
play a key role in propagating C/A-positive AML.364Results
CALM/AF10 induces acute myeloid leukemia in mice
To test the impact of constitutive expression of C/A on murine
hematopoietic development, we employed the murine bone
marrow (BM) transplantation model. The fusion gene was ex-
pressed in a murine stem cell virus (MSCV)-based retroviral con-
struct carrying the C/A cDNA upstream of an internal ribosomal
entry site (IRES)-green fluorescence protein (GFP) cassette that
has been shown to efficiently transduce hematopoietic stem
and progenitor cells (Figures S1A–S1C in the Supplemental
Data available with this article online).
All mice (n = 13) transplanted with highly purified GFP+ C/A
transduced cells (median retroviral transduction efficiency of
5.7, range 1.2%–16.4%) with or without nontransduced helper
cells developed a disease after a median of 110 days posttrans-
plantation (range 46–366) (Figure 1A) and suffered from ca-
chexia, lethargy, and shortness of breath. Detailed analyses of
the hematopoietic compartments showed a more than 10-fold
elevated white blood cell count in the peripheral blood (PB)
of all animals with a median of 4.9 3 107 cells/ml (range 3.2–
8.5 3 107) compared to the GFP control (median 0.48, range
0.32–0.8 3 107) (p < 0.002). Furthermore, mice were anemic,
with a 7.3-fold reduced median red blood cell count of 0.75 3
109 cells (range 0.6–1.253 109) versus 5.53 109 (range 4.8–73
109) in the control mice (p < 0.0001), and suffered from spleno-
megaly (Table 1). Panoptic staining of PB smears and cytospin
preparations of BM and spleen cells revealed an accumulation
of blasts accounting for medians of 32%, 40%, and 39%, re-
spectively, of all cells (Table 1; Figure 1B). The spleen showed
a massive infiltration with myeloid cells (median of 86.9%
Mac1+ cells [range 72.8%–91.1%] versus 12% in the control
[range 7%–26.5%] and 62.5% Gr1+ cells [range 40%–76.2%]
compared to 9.5% in the control [range 7.5%–11.3%]) (Fig-
ure 1B). Histological sections demonstrated infiltration of blasts
in multiple nonhematopoietic organs, including the brain (Fig-
ure 1C). Immunohistochemistry showed positivity of the blasts
for myeloperoxidase (MPO) and chloracetate esterase and
negativity for B220 and CD3, indicating the myeloid nature of
the population (Figure 1D). Taken together, the mice suffered
from acute myeloid leukemia according to the Bethesda pro-
posal for classification of nonlymyphoid and lymphoid hemato-
poietic neoplasms in mice (Kogan et al., 2002; Morse et al.,
2002).
Transplantation of BM cells of leukemic mice into secondary
recipients (n = 22) rapidly induced leukemia with the same char-
acteristics after a median of 15 days (range 14–21 days) post-
transplantation (Figure 1A). Bone marrow aspirations of anes-
thetized primary recipients 8 weeks posttransplantation did
not show any myeloproliferative or lymphoproliferative syn-
drome before the onset of leukemia (n = 5). Analysis of proviral
integration sites demonstrated oligoclonal disease in primary
and secondary mice (Figure S2). Sequencing of the retroviral in-
tegration sites (n = 18) in the diseased mice showed 10 out of 18
sites in or near regions described as common integration sites
(CIS) in the RTCGD database (http://rtcgd.ncifcrf.gov/) (Akagi
et al., 2004). No recurrent integration sites or any association
of the leukemic phenotype with individual proviral integrations
were observed (Table S1). In summary, these data demon-
strated that constitutive expression of CALM/AF10 induced
short-latency AML in transplanted animals.CANCER CELL NOVEMBER 2006
A R T I C L EFigure 1. CALM/AF10 induces transplantable AML
A: Survival curve of mice transplanted with BM cells expressing CALM/AF10 (n = 13, originating from five independent sets of transduction experiments). The
control group was transplanted with BM infected with the GFP empty retrovirus (n = 6). The survival time of secondary recipient mice, transplanted with BM
from diseased primary CALM/AF10 mice or tertiary recipient mice injected with BM from leukemic secondary mice, is indicated. C/A, CALM/AF10.
B: Cytospin preparations from PB, BM, and spleen and immunophenotype of the spleen of a representative leukemic CALM/AF10 mouse in comparison to
a GFP control animal. Cells were stained for the myeloid markers Gr1 and Mac1 and the lymphoid markers B220, CD4, and CD8. The proportion of positive
cells within the GFP+ compartment is indicated; the CD4/CD8 costaining was gated for GFP+ cells. BM, bone marrow; PB, peripheral blood. Scale bar, 10 mm.
C: Histological analysis of diseased CALM/AF10 mice. Blast infiltration in the different organs is shown (brain, intestine, glomerular and tubular areas of the
kidney, sinusoidal and portal areas of the liver, spleen, and lungs) Scale bar, 100 mm; scale bar in inset picture of spleen, 25 mm.
D: Histochemical and immunohistological analysis of the spleen and liver of a diseased CALM/AF10 mouse. Anti-B220 (Da and Db) and anti-CD3 staining
(Dc) of spleen sections and hematoxylin-eosin (Dd), CAE (De), MPO (Df), and anti-CD3 staining (Dg) of liver sections. MPO, myeloperoxidase; CAE, N-acetyl-
chloroacetate esterase. Scale bars, 100 mm in Db–Dg, 25 mm in Da, 50 mm in Dd.CALM/AF10-induced leukemia is propagated by
a transformed B220+, immunoglobulin DH-JH
rearranged progenitor cell
More detailed analyses of the leukemic BM population (GFP+
cells) revealed that, in addition to a majority of cells expressing
myeloid markers (MM) (Mac1+ cells, 82.9% [68.6]; Gr1+ cells,
86.4% [63.7]), there was a small B220+/MM2 cell population
in all animals obtained from five independent sets of experi-
ments, which accounted on average for 6.7% (62.1%) of theCANCER CELL NOVEMBER 2006cells, comparable to the proportion of these cells in control
mice (on average 9.4% 6 3%). An average of 26.0% (68.6)
and 32.5% (613.2) of the BM cells coexpressed B220 with
Mac1 or B220 with Gr1, respectively (n = 4) (B220+/MM+). Highly
purified cells of the B220+/MM2 population had an immature,
blast-like appearance, whereas the B2202/MM+ population in-
cluded blasts as well as terminally differentiated myeloid cells
(Figure 2A). Interestingly, all three subpopulations, including
the cells expressing solely the MMs Mac1 or Gr1, showed DJ365
A R T I C L ETable 1. Hematological parameters in representative experimental mice
Mouse no.
Retroviral
construct
Day of
sacrifice RBCs/ml 3 109 WBCs/ml 3 107
Spleen
weight (mg)
Percent
BM blasts
Percent spleen
blasts
Percent
PB blasts
IgH DJ
rearrangement
1 C/A 10 0.75 3.5 700 30 32 27 ND
2 C/A 78 0.75 5.0 400 40 30 33 +
3 C/A 85 0.6 8.5 250 65 60 61 +
4 C/A 121 0.82 5.2 300 38 38 31 +
5 C/A 85 0.6 4.8 200 78 40 ND +
6 C/A 86 1.25 3.2 400 ND 42 32 +
7a C/A 67 4 2.5 240 32 29 33 +
8a C/A 98 2.65 ND 350 36 ND 28 2
9 GFP 90 6 0.45 150 0 0 0 ND
10 GFP 157 4.8 0.32 200 0 0 0 ND
11 GFP 85 5 0.36 200 0 0 0 ND
12b GFP ND 4.8 0.76 ND 1 0 0 ND
13 b GFP ND 6.4 0.8 ND 0 0 0 ND
14 GFP 90 7 0.5 51 2 0 0 ND
C/A, CALM/AF10; ND, not determined; RBC, red blood cell; WBC, white blood cell; BM, bone marrow; PB, peripheral blood.
aMice were injected with highly purified B220-negative progenitor cells with IgH in germline configuration.
bDetermined by bone marrow aspiration and bleeding of the mouse.rearrangements of the heavy chain of the IgH locus, indicating
that the myeloid population originated from DJ rearranged cells
(Figure 2A). The bulk leukemic population isolated from dis-
eased mice showed unlimited IL3-dependent growth in vitro
and retained its characteristic phenotype with appearance of
the B220+/MM2 as well as the B220+/MM+ and the B2202/
MM+ population (n = 3).
To determine whether the growth potential differed between
the three subpopulations, single cells of the B220+/MM2,
B220+/MM+, and the B2202/MM+ population were sorted
and tested for their proliferative capacity: strikingly, only the
B220+/MM2 population displayed high clonal proliferative po-
tential at the single-cell level, with a mean seeding efficiency
of 29.3% compared to 1% in the other two populations
(Figure 2B). When competitive transcriptional profiling of highly
purified B220+/Mac12 and B2202/Mac1+ cells was performed
by cDNA microarray analysis, 944 genes out of a total of 3643
present genes were differentially expressed between the two
populations. The gene categories, which were significantly
overrepresented in the B220+/Mac12 cells, comprised genes
linked to mitosis and S phase, to response to DNA damage, to
translation, and to DNA repair and replication. In contrast, the
B2202/Mac1+ cells showed overrepresentation of genes be-
longing to the categories cell death, cell communication, and
actin cytoskeleton organization, reflecting the profound differ-
ences in the transcriptome and the proliferative status between
the two populations (http://www.ncbi.nlm.nih.gov/geo/; GEO
accession number GSE5030) (Figure 2C). Importantly, a single
B220+/MM2 cell isolated from leukemic mice could give rise
to the B220+/MM+ and the B2202/MM+ populations in vitro, fur-
ther indicating the hierarchical organization of the leukemic pop-
ulation (Figure 2D). These B2202/MM+ cells were functionally in-
tact myeloid cells and were able to actively phagocytose yeast
cells (Figure 2D). Furthermore, all the B220+/MM+ and the
B2202/MM+ cells derived from a single B220+/Mac12 cell in vitro
displayed identical genomic DJ rearrangements like the original
progenitor (Figure 2E). In conclusion, these data demonstrated
that the B220+/MM2 cells isolated from leukemic mice are able
to give rise to DJ rearranged myeloid cells and have the highest
proliferative potential at the single-cell level compared to the
MM+ subpopulations.366Next it was determined whether highly purified B220+/MM2
cells generated from a single cell in vitro would be able to cause
acute myeloid leukemia in vivo: all animals (n = 3) succumbed
to acute myeloid leukemia after a short latency time of 35 days
posttransplantation when 13 106 cells per mouse were injected.
Thus, the data demonstrated that single B220+/MM2 cells iso-
lated from a leukemic mouse can initiate the leukemia of the
same phenotype as bone marrow cells freshly transduced with
CALM/AF10 retrovirus. In order to test the hypothesis that the
leukemia-propagating cell resides in the B220+/MM2 compart-
ment, we purified the three distinct populations from leukemic
primary recipients and performed limiting dilution transplanta-
tion assays that allowed us to determine the frequency of the leu-
kemia-propagating cell in the three different subpopulations as
previously described (Kroon et al., 1998). Importantly, the fre-
quency of the leukemia-propagating cell was 1 in 36 cells in
the B220+/MM2 population as opposed to 1 in 437 cells in the
B220+/MM+ and 1 in 19,717 cells in the B2202/MM+ compart-
ment. Thus, the frequency of the leukemia-propagating cell
was over 548-fold higher in the B220+/MM2 population com-
pared to the B2202/MM+ population (Figure 3A; Table S2). Strik-
ingly, in our model removal of the B220+ cells from the leukemic
transplant prevented the development of leukemia in mice, in
contrast to the animals, which were transplanted with leukemic
B220+/MM2 cells and died after a median of 34 days posttrans-
plantation (Figure 3B).
To test the possibility that the leukemic stem cells would also
reside in the cell compartment lacking expression of B220 and
the MMs Gr1 and Mac1 (B2202/Gr12/Mac12), bone marrow
cells of leukemic mice were costained with B220-APC, Gr1-
PE, and Mac1-PE: the proportion of this cell population in the
bone marrow was very small, with a median of 0.03% (range
0.01%–0.05%) in four mice tested. Furthermore, only very few
cells expressed the stem cell-associated markers Sca1 and c-
Kit (Figure S3A). To test this population functionally, we highly
purified this subpopulation from leukemic mice and compared
the clonogenic potential of these cells with the B220+/MM2 sub-
population: while the B2202/Gr12/Mac12 population was not
able to form any colonies in vitro, an equal number of B220+/
MM2 cells generated replatable colonies with a frequency of
85 6 13 blast colonies per 1000 cells (data from three miceCANCER CELL NOVEMBER 2006
A R T I C L EFigure 2. Transformed B220+/MM2 cells are IgH DH-JH positive and can generate IgH DH-JH rearranged myeloid cells at the single-cell level
A: Morphology and genomic DH-JH recombination of the immunoglobulin locus in different populations. Wright-Giemsa-stained cytospins of highly purified
B220+/MM2, B220+/MM+, and B2202/MM+ cells and the genomic DH-JH status in different highly purified subpopulations from a representative leukemic
CALM/AF10 mouse. DH-JH status in B220+/Mac12, B220+/Mac1+, B2202/Mac1+, B220+/Gr12, B220+/Gr1+, and B2202/Gr1+ cells is indicated; the myeloid cell
line 32D was used as a DH-JH naive germline control. GL, germline; MM, myeloid marker. Scale bar, 10 mm.
B: Seeding efficiency of the different populations. Single-cell sorting of the three subpopulations, B220+/Mac12, B220+/Mac1+, and B2202/Mac1+, isolated
from a leukemic bulk cell population was performed in 96-well plates, and single-cell growth was determined after culture for 4–5 weeks in IL3-supplemented
medium. The mean seeding efficiency for each population is indicated (n = 3, plotted as mean values 6 SD).
C:Distribution of gene categories significantly overrepresented in highly purified B220+/Mac12 compared to B2202/Mac1+ cells (Ca) and in B2202/Mac1+ ver-
sus B220+/Mac12 cells (Cb). Analysis was performed by DNA microarray-based expression profiling using a chip with 20,172 PCR-amplified, sequence-verified,
gene-specific DNA fragments (LION Biosciences).
D: Phagocytosis by B2202/Mac1+ cells derived from a single-cell-sorted B220+/Mac12 cell. Single-cell-sorted B220+/Mac12 cells were expanded in vitro, and
the B2202/Mac1+ cells generated from these cells were tested for phagocytosis of the yeast S. cerevisiae. A representative picture of a B2202/Mac1+ phago-
cytosing cell is shown. Scale bar, 5 mm.
E: Clonal DH-JH rearrangements in the three subpopulations. B220+/Mac12, B220+/Mac1+, and B2202/Mac1+ cells generated from a single B220+/Mac12
sorted cell all showed the identical clonal DH-JH3 and DH-JH4 biallellic rearrangements. Genomic DNA from splenic cells from a nontransplanted mouse
and the myeloid cell line 32D were used as positive and negative controls for recombination, respectively. B, B220+/Mac12; B/M, B220+/Mac1+;
M, B2202/Mac1+.transplanted initially with independently transduced bone mar-
row; input number 100–1000 cells/dish in both arms). Impor-
tantly, the B2202/Gr12/Mac12 cells did not show leukemic
engraftment into secondary recipients or induced leukemia,
whereas as few as 25 B220+/MM2 cells caused leukemic en-
graftment of the same phenotype as described before (input
number between 25 and 113 cells for the B2202/Gr12/Mac12
cells [n = 5] and an equal number of cells per mouse for
the B220+/MM2 population [n = 5]) (Table S3). Taken together,
the high frequency of the leukemia-propagating cell in theCANCER CELL NOVEMBER 2006B220+/MM2 population, together with its ability to proliferate
and to give rise to a myeloid DJ rearranged cell population, dem-
onstrated that the leukemia-propagating cell resided in the
B220+/Mac12 cell compartment in this murine model.
More detailed analysis of the cell surface phenotype of
the B220+/MM2 cells characterized them as CD43+/AA4.1+/
CD24low-pos/FLT3med/IL-7Rlow-neg, c-Kitlow-neg, CD192, and
Sca12 (Figures 4A and 4B). The cells did not express CD21,
CD23, sIgM, l5, Bp1, or Igb (Figures S4A and S4B), or CD4 or
NK1.1 (data not shown). Transcriptional profiling by RT-PCR367
A R T I C L Eshowed lineage-promiscuous expression of the lymphoid fac-
tors EBF, VpreB, and Rag2 and the MM MPO (Figure 4C;
Figure S4C). Importantly, there was no transcription of Pax5,
which is compatible with the incomplete rearrangement status
at the IgH locus (data not shown) and the CD19 negativity of
the cells (Figure 4B). In the B220+/Mac1+ and in the B2202/
Mac1+ cells, transcripts for the M-CSF receptor became detect-
able, whereas transcription for EBF was downregulated. There
was no detectable transcription of Gata3, Zfpn1a3 (Aiolos)
(Figure 4C), or mb1 and only low expression of l5 transcripts
(Figure S4C). In addition, we could not detect rearrangements
of the TCRg receptor, specifically Vg 1.1-Jg4, Vg 2/4-Jg1, or
Vg 5/7-Jg1 by PCR (data not shown). The surface marker ex-
pression as well as the transcription factor expression profile
collectively defined the B220+/MM2 population as a lymphoid
progenitor (Figure S5).
In an effort to determine whether an earlier B220-negative cell
could be transformed by the CALM/AF10 fusion gene, we next
analyzed whether transduction of CALM/AF10 into highly
purified B220-negative cells with IgH germline configuration
Figure 3. Frequency of leukemia-propagating cells
A: Determination of the frequency of leukemia-propagating cells. Cohorts
of secondary mice were injected with highly purified B220+/Mac12, B220+/
Mac1+, and B2202/Mac1+ populations from primary leukemic mice in a lim-
iting dilution assay. The frequency of leukemia-propagating cells in each
population is indicated. Details of cell numbers, number of mice per arm,
and the median latency of disease are described in Table S2.
B: Survival of mice transplanted with leukemic BM depleted of B220+ cells
(B2202/Mac1+cells, n = 11; 50 cells [n = 4], 500 cells [n = 4], and 5000 cells
[n = 3] isolated from the primary leukemic population). In comparison the sur-
vival of mice (n = 12) transplanted with B220+/Mac12 cells with the same
range of cell numbers (50 [n = 4], 500 [n = 4]), and 5000 cells [n = 4]) is shown.368resulted in the induction of AML of the same phenotype as de-
scribed for the transduction of unfractionated bone marrow:
two of two animals tested developed acute myeloid leukemia af-
ter transplantation of 1–2 3 105 B220-negative cells proven to
have IgH germline configuration by PCR before injection, indi-
cating that early B220-negative progenitors with IgH germline
configuration can acquire leukemogenic potential after CALM/
AF10 transduction. However, whereas one of the AML cases
showed B220+ cells with IgH DJ rearrangement as described
before, the other case did not display a B220+ subpopulation.
In addition, the leukemic bulk had a germline IgH configuration,
a phenotype not observed in the transplantation assays using
5-FU-mobilized unfractioned bone marrow for viral infection
(Figure S3B and Table 1). In contrast to early B2202 progenitors,
murine cell populations comprising pro-B cells (B220+/CD43+/
CD252; input number 2 3 106 cells per mouse; transduction
efficiency, 10%) and pre-B cells (B220+/CD43+/CD25+ cells;
input number 2 3 105 cells per mouse; transduction efficiency,
2%) did not acquire in vivo repopulating activity with no short-
or long-term engraftment in lethally irradiated mice 4 or 8 weeks
posttransplantation, respectively (data not shown).
To examine whether our findings in the murine CALM/AF10
leukemia model parallel characteristics of human CALM/AF10-
positive AML, patient samples were analyzed for IGDH-JH rear-
rangement status and the presence of a CD45RA (the human
homolog to B220) population. In addition, we further character-
ized the CD45RA+ population by performing CFU-blast colony
assays in vitro and FISH analysis for the presence of the
CALM/AF10 fusion gene. Table S4 summarizes the characteris-
tics of patients diagnosed with AML or in one case with acute
undifferentiated leukemia (AUL); two of the nine patients were
children, six of nine patients had additional genetic alterations
to the CALM/AF10 t(10;11) translocation. Treatment consisted
mainly of chemotherapy with high-dose Ara-C and anthracy-
clines, and outcome was dismal in all the patients with longer
follow-up. Multiplex PCR and clonality analysis by GeneScan-
ning techniques showed that seven out of nine AML samples
demonstrated clonal IG DH-JH rearrangements (Table 2 and
Figure 5A). We could also detect immature TCRd (Dd2,Vd2)
and TCRb (TCRb DJ) as well as TCRg (Vg10) rearrangements
in six out of six patients tested (Table 2).
In all three patients tested, a substantial proportion of
CD45RA+ cells could be detected, ranging from 50.6% to
99.8% of bone marrow cells. In two of the three patients, the
CD45RA-positive population coexpressed CD34. In all the pa-
tients tested, the CD34+/CD45RA+ cells harbored the CALM/
AF10 fusion gene as detected by FISH analysis (Figure 5Bb)
(Table 3). Furthermore, CD34+/CD45RA+/CD10+ cells, corre-
sponding to the stage of early human lymphoid progenitors
(Haddad et al., 2004), were also positive for the fusion gene
(data not shown). The involvement of the CD45RA population
in the malignant transformation process was further supported
by the observation that the CD45RA population generated my-
eloid CFU-blasts (Table 3) in vitro, which showed the identical
IG DH-JH rearrangement status at a single-colony level as de-
tected in the myeloid bulk population (Figure 5C). To test
whether early CD34+/CD45RA2 cells could be positive for the
CALM/AF10 fusion gene, we highly purified CD34+/CD45RA2/
lineage marker (lin)-negative (lin: CD382/CD192/CD102) cells
of one patient with C/A-positive AML. Notably, the fusion gene
could be detected in the majority of cells (92%) in this primitiveCANCER CELL NOVEMBER 2006
A R T I C L EFigure 4. Leukemic B220+/Mac12 cells express lymphoid markers
A: Expression of B cell-associated markers on leukemic B220+/Mac12 cells: flow cytometric analysis after staining with various markers as indicated.
B: Expression of early and late markers on leukemic B220+/Mac12 cells propagated in vitro for Sca1 (Bb) and c-Kit (Bc) or CD19 (Be); Ba and Bd are controls
as indicated.
C: RT-PCR analysis of lineage associated genes. B220+/MM2, B220+/MM+, and B2202/MM+ cells clonally generated from a single B220+/Mac12 cell were an-
alyzed for the expression of genes associated with different hematopoietic lineages as indicated. B220+ sorted cells from the spleen, Mac1+ sorted cells from
the bone marrow, and unsorted BM cells (all populations isolated from a nontransplanted control mouse) were used as controls for lymphoid and myeloid
transcripts, respectively. MPO, myeloperoxidase; EBF, early B cell factor; HPRT, hypoxanthine phosphoribosyl transferase; B220+/MM2, B220+/Mac12 cells;
B220+/MM+, B220+/Mac1+ cells; and B2202/MM+, B2202/Mac1+ cells.cell compartment (Figure 5Ba, patient number 9), indicating the
involvement of early CD45RA-negative cells in the transforma-
tion process in this patient. In summary, these findings indicate
that patients with CALM/AF10-positive AML are characterized
by IG DH-JH rearrangements of their leukemic blasts and
a CD45RA-positive population, which is positive for the leuke-
mia-specific fusion gene and is able to generate myeloid blast
colonies with the clonal IG DH-JH rearrangement ex vivo,
reminiscent of several characteristics of murine CALM/AF10-
induced AML in transplanted mice.
Discussion
Leukemias are considered to originate from a rare subset of
transformed cells, which are able to initiate and maintain theCANCER CELL NOVEMBER 2006disease. In particular, studies in patients with acute myeloid leu-
kemia have shown that the transformation process involves
early hematopoietic progenitor cells characterized by expres-
sion of CD34 and lack of CD38 and the different lineage markers
(Blair et al., 1998; Dick, 2005). The concept that hematopoietic
stem cells (HSCs) are a key target of leukemic transformation
was further supported by murine models, which demonstrated
that HSCs could acquire leukemic stem cell properties by forced
expression of appropriate oncogenes, recurrently found in pa-
tients with AML (Huntly and Gilliland, 2005; Reya et al., 2001).
Furthermore, inactivation of certain transcription factors such
as JunB caused leukemia only when the targeted deletion
took place in the HSC compartment and not in the more dif-
ferentiated cell pool (Passegue´ et al., 2004). However, more
recent data have provided in vivo evidence that also more369
A R T I C L ETable 2. IgH DJ and TCR rearrangements in CALM/AF10 AML patients
Patient
no. Type
IgH DJ rearrangements TCR rearrangements
IgH DJ IgH DJ sequences TCRg TCRd TCRb DJ
1 AML M0 monoclonal
DH3
D39/ATTTTGACTGGTTATTATAAC*GT*CTGGTACTT
CGATCTCTGGGGCCT/JH2
monoclonal Vg10 Dd2 biallelic polyclonal
2 AML M2 monoclonal
biallelic
DH2 DH6
D2-15/TGGTAGCTGCTACTC*TT*TACGGTATGGAC
GTCTGGGGCCA/JH6B D6-13/GGGTATAGCAG
C*GGCTACAAGGGT*ACTACTGGGGCCA/JH4B
monoclonal Vg10 Vd2 monoclonal D1
3 AML M1 polyclonal
DH1–7
— polyclonal Dd2/Dd3 biallelic polyclonal
4 AUL monoclonal
DH1
DH1-26/TATAGTGGGAGCTACT*GTG*CTACTGG
GGCCA/JH4B
monoclonal Vg1-8
and Vg10-11
Dd2 monoclonal TCRb
DJ and TCRb JA
5 AML M1 monoclonal
DH7
ND polyclonal Dd2 biallelic polyclonal
6 AML M1 monoclonal
DH7
ND monoclonal Vg10-11 Dd2 biallelic monoclonal
TCRb DJ
7 AML M1 monoclonal
DH6
DH6-6/TATAGCAGCTCGT*TGT*ACTACTTTGACT
ACTGGGGCCA/JH4B
ND ND ND
8 AML monoclonal
DH7
DH7-27/TAACCACTGGGGAC*CTCCCGGG*
CTTTGACTACGGGGCCA/JH4B
ND ND ND
9 AML M5a polyclonal
DH1-7
— ND ND ND
ND, not determined.differentiated cells can acquire properties of leukemic stem
cells: in a murine bone marrow transplantation model, retrovir-
ally driven expression of the MLL-GAS7 fusion gene induced370acute leukemias with myeloid, lymphoid, or mixed phenotype.
Immunophenotyping, transcriptional profiling, and the ability of
the LSC to induce three distinct leukemia subtypes indicatedFigure 5. CALM/AF10-positive human AML samples show IgH DH-JH rearrangements and express CD45RA(B220)
A: GeneScanning analysis of IgH DH-JH rearrangements in nine cases of human CALM/AF10-positive AML using bone marrow of the leukemic patients with
>80% myeloid blasts and polyclonal nonleukemic control cells. GeneScanning demonstrated a clonal IgH DH-JH rearrangement in seven out of nine cases.
Unspecific background peaks resulting from annealing to nonrearranged alleles in the reactions are indicated with an asterisk.
B: Detection of the CALM/AF10 rearrangement in flow-sorted patient cells. Ba:A representative CD34+/CD45RA2/lin2 cell with the CALM/AF10 fusion, showing
a normal AF10 (red) and a normal CALM (green) locus as well as two red/green signals, indicating the two reciprocal fusion genes (arrowheads) (92% of the cells
were positive for the fusion gene; one representative CALM/AF10-negative cell of the same compartment is shown in Bc) (patient number 9). Bb: A represen-
tative CD34+/CD45RA+ cell carrying the CALM/AF10 fusions, showing the same signal pattern as inBa (fusion signals are indicated by arrowheads) (patient num-
ber 7). Bc: A CD34+/CD45RA2/lin2 cell without CALM/AF10 fusion showing two normal AF10 (red) and two normal CALM (green) signals (patient number 9).
C: Myeloid blast colony formation in methylcellulose of CD45RA+ cells of a representative human AML patient (patient 7, magnification 1003). Lower panel
shows the clonal IgH DJ rearrangement peak from a singly isolated myeloid blast colony analyzed by GeneScan. The rearrangement was identical to the re-
arrangements detected in the leukemic bulk of the patient (Figure 5A).CANCER CELL NOVEMBER 2006
A R T I C L ETable 3. Proportion of CD45RA-positive cells and CFU-blast frequency of C/A-positive AML patients
Patient no.
CD34+/
CD45RA+
Overall
CD45RA+
CD34+/
CD45RA2/lin2b
Positivity for CALM/AF10c
CFU-blast
frequencya
IgH DJ of CFU-blast
coloniesCD34+/CD45RA+ CD34+/CD45RA2/lin2
3 94.52% 98.59% 0.13% + ND 92 6 14 NA
7 96.21% 99.8% 0.01% + ND 12 6 3 monoclonal DH6
9 1.68% 50.6% 33.07% ND + ND ND
ND, not determined; NA, not applicable.
aPer 106 CD45RA+ bone marrow cells isolated from C/A AML patients (0.2–2 3 105 cells plated per dish).
bLineage markers comprised CD38, CD19, and CD10.
cAs determined by CALM- and AF10-specific FISH probes.that the fusion gene targeted a multipotential progenitor in this
murine model (So et al., 2003). In addition, retroviral expression
of the MLL-ENL or MOZ-TIF2 fusion gene in murine myeloid
committed progenitor cells clearly demonstrated that commit-
ted progenitor cells can function as leukemic stem cells in these
models and that transformation of HSC is not mandatory for the
development and maintenance of acute leukemia (Cozzio et al.,
2003; Huntly et al., 2004). The murine data presented here now
provide evidence that a progenitor cell with lymphoid character-
istics can propagate acute myeloid leukemia. Detailed charac-
terization of the leukemic stem cell showed that the cells ex-
pressed B220, CD43, AA4.1, and CD24 but lacked expression
of MMs as well as Sca1. Importantly, transcriptional profiling
demonstrated a lineage-promiscuous expression of lymphoid
factors such as EBF, VpreB, and Rag2 (Busslinger et al., 2000)
with progressive downregulation following differentiation into
the B220+/Mac12 and the B2202/Mac1+ cells together with
the MM MPO. Of note, we did not detect transcription of
Pax5, which is compatible with our finding that the B220+ cells
had an incomplete rearrangement status at the IG DH-JH locus
and did not express CD19. Even though this progenitor showed
characteristics of the early B lineage, the classification of this
CALM/AF10 leukemia-propagating cell according to the differ-
ent B cell classification systems remains difficult because of
its leukemogenic characteristics and the potential impact of
the fusion gene on its cell surface phenotype and transcriptional
network. The phenotype we observed differed from the B220+/
CD19+ cell stage, which is associated with Pax5 positivity and
the entire commitment to the B cell lineage (Hardy, 2003), but
also from the profile of the earliest lymphoid progenitor, the
common lymphoid progenitor (CLP), which lacks expression
of B220 (Kondo et al., 1997).
In our model, a single transformed Pax5-negative progenitor
with lymphoid characteristics was able to generate myeloid
cells with IgH immunoglobulin rearrangements. Interestingly,
Pax52/2 B cell progenitors show lineage-promiscuous tran-
scription of B-lymphoid and myeloid genes, display a remarkable
multilineage potential in vitro, and are able to be directed into the
myeloid lineage (Heavey et al., 2003; Schaniel et al., 2002). In ad-
dition, the latent myeloid differentiation capacity of the CLP,
which does not express Pax5 yet, has become obvious due to
the observation that it can be redirected to the myeloid lineage
by retrovirally induced IL-2Rb chain or GM-CSF receptor
expression (Kondo et al., 2000). Thus, one intriguing possibility
is that CALM/AF10 instructed myeloid development of an early
Pax5-negative lymphoid progenitor in our model. This com-
mitment into the myeloid pathway was irreversible in the C/A
model, as highly purified B220+/Mac12 cells were not able toCANCER CELL NOVEMBER 2006differentiate along the B lineage pathway in vitro on stromal
OP9 feeders in lymphoid growth medium (data not shown).
The scenario that expression of C/A directs the lineage
choice of Pax5-negative lymphoid progenitors is only one po-
tential explanation for the myeloid phenotype of the leukemia.
We cannot exclude that the fusion gene instructed myeloid lin-
eage decision at the later stage of Pax5-positive cells, as it was
recently shown that the myeloid transcription factors C/EBPa
and C/EBPb could convert Pax5-positive B cells into macro-
phages by downregulation of Pax5 expression and upregula-
tion of myeloid genes (Xie et al., 2004). However, we could
not observe any significant downregulation of Pax-5 expression
following CALM/AF10 expression for 48 hr in the in vitro culti-
vated murine pro-B cell line Ba/F3 or primary murine fetal
pre-B cell lines by real-time quantitative PCR and did not ob-
serve repopulating ability of murine pro-B or pre-B cells in le-
thally irradiated mice after transduction with CALM/AF10
(data not shown).
Another important scenario would be that the CALM/AF10 fu-
sion gene targets a rare and early B220-negative progenitor with
IgH germline configuration and activates lymphoid develop-
mental programs in these cells, resulting in a B220+/MM2 IgH
rearranged cell population with high leukemia-propagating po-
tential as described in the murine model. Indeed, highly purified
B220-negative progenitor cells with IgH germline configuration
acquired leukemogenic properties in vivo in two independent
experiments after infection with the CALM/AF10 retrovirus, indi-
cating that an early progenitor cell can be transformed by the fu-
sion gene. Interestingly, one of the mice developed an AML that
lacked a B220+ population and displayed an IgH germline con-
figuration, which was never observed when unfractionated bone
marrow was infected with the CALM/AF10 retrovirus and trans-
planted into recipients. One explanation for this might be that
C/A can target IgH rearranged B220+ lymphoid progenitors, giv-
ing rise to AML with the consistent phenotype of a B220+ trans-
formed progenitor population, as well as early B2202 progeni-
tors with IgH germline configuration, resulting in AML with or
without the B220+ cell population.
Importantly, the experiments performed in this study do not
rule out the other possibility, that the CALM/AF10 fusion gene
had an instructive effect on myeloid progenitors, initiating a lym-
phoid-specific program in these cells. In this scenario a myeloid
cell would acquire lymphoid characteristics as a result of trans-
formation by an appropriate oncogene. Another possibility is
that C/A directly transformed a rare cell subset of B/macro-
phage progenitors, which was identified in fetal liver but also
in adult bone marrow (Lacaud et al., 1998; Montecino-Rodri-
guez et al., 2001). However, this cell was described to be371
A R T I C L ECD19/Pax5 positive and negative for CD45R/B220, a phenotype
different than the phenotype of the LSC described here.
Of note, these different scenarios would result in the develop-
ment of AML with a B220+/MM-negative cell population with
a very high frequency of leukemia repopulating cells, which
would be accessible to an antibody-based B220 depletion. In-
deed antibody-mediated depletion of the B220+/MM2 cells
from leukemic transplants efficiently prevented leukemic devel-
opment in mice, underlining the key role of this population for
disease propagation. One implication of our findings is that in
a subset of AML the leukemia-propagating cell might show a dis-
tinct cell surface and transcriptional phenotype, setting it apart
from the leukemic myeloid bulk population, but also from the
normal stem cell pool. In particular, the expression of lymphoid
antigens would allow to discriminate this cell from the normal he-
matopoietic stem cells, which would facilitate the development
of treatment strategies using the lymphoid surface antigens to
target the leukemia-propagating cell but to spare the normal
stem cell (Passegue´ et al., 2003). As illustrated in the murine
CALM/AF10 leukemia model, such a strategy would have thera-
peutic potential. Depletion of the B220+ transformed progenitor
cells would fail to eradicate the malignant clone, if a rare leuke-
mic B220-negative progenitor cell population existed, which
gives rise to the B220+/MM2 population described. But even in
this scenario, diminishing the B220-positive leukemia-propagat-
ing cells would promise clinical benefit, as mice transplanted
with B220-depleted bone marrow failed to develop leukemia
up to an observation time of 100 days, compared to rapid devel-
opment of AML in mice transplanted with B220+ transformed
progenitors.
Recently, substantial progress has been made to characterize
very early stages in human B cell development (Haddad et al.,
2004; Hou et al., 2005; LeBien, 2000; Ryan et al., 1997). These
reports have shown that similar to the murine system these early
human progenitors express the B220 human homolog CD45RA,
as well as CD34 and CD10, but lack CD19 and Pax5 expression.
In an effort to determine potential similarities between the mu-
rine CALM/AF10 AML and human disease, we analyzed nine pa-
tients with CALM/AF10-positive AML. Interestingly, the cases
tested showed a CD45RA population with coexpression of
CD34 in two of three patients. Furthermore, in seven out of
nine patients tested, clonal IgH immunoglobulin rearrangements
could be detected in the myeloid bulk. The leukemic nature of
the CD45RA population in these cases was indicated by the
presence of the fusion gene, its clonal IgH rearrangement, and
its ability to form CFU-blast colonies ex vivo. Interestingly, in
the CD34+/CD45RA2/lin2 progenitor compartment of one pa-
tient we detected a mosaic of cells carrying the fusion gene or
showing normal signal pattern by FISH, indicating that this cell
compartment might be involved in the malignant transformation
process.
In addition to IgH rearrangements, six of six patients were also
positive for clonal rearrangements of the T cell receptor (TCR).
These observations are in line with reports associating the
CALM/AF10 fusion gene with T-ALL, in particular with T-ALLs
expressing the g/d TCR (Asnafi et al., 2003). In the murine model
the constitutive expression of CALM/AF10 failed to induce T cell
leukemia, and the observed myeloid leukemias did not show the
TCRg rearrangements that were analyzed (Vg 1.1-Jg4, Vg 2/4-
Jg1, or Vg 5/7-Jg1). This could be attributable to various factors
predisposing the murine model to leukemias of the myeloid372lineage, such as the cell population initially used for retroviral in-
fection; the in vitro culture conditions with IL3, IL6, and SCF
stimulation before transplantation; or the level of expression of
the fusion gene in the murine system compared to human dis-
ease. However, real-time PCR quantification of CALM/AF10
transcripts showed low CALM/AF10 expression in both the mu-
rine and human myeloid bulk (data not shown). Insertional muta-
genesis was identified as an important factor in murine leukemo-
genesis (Akagi et al., 2004; Suzuki et al., 2002) and might explain
the predisposition to AML development in the CALM/AF10
model: in an analysis of the proviral integration sites in leukemic
mice, 10 of 18 detected sites were described before as common
integration sites or transposon-tagged cancer genes according
to the Retroviral Tagged Cancer Gene Database (RTCGD; http://
RTCGD.ncifcrf.gov/) (Akagi et al., 2004). However, there were no
recurrent insertion sites or a correlation of the integrations with
the consistent phenotype of the leukemias in this model. As de-
scribed for humanCALM/AF10-positive T-ALLs (Dik et al., 2005;
Soulier et al., 2005), the murine AML cases also displayed aber-
rant expression ofHoxA7 andMeis1 (unpublished data); further-
more, we also observed deregulation of HOX genes in patients
with CALM/AF10-positive AML (unpublished data). This indi-
cates that deregulation of this transcription factor family is a
common characteristic of CALM/AF10 leukemias independent
of the phenotype.
In summary, this murine leukemia model demonstrates that
a progenitor cell with lymphoid characteristics and a phenotype
that differs from that of normal hematopoietic stem cells and the
leukemic myeloid bulk, is able to propagate AML. These data
provide a rationale for the development of therapeutic strategies
targeting the leukemia-propagating stem cell without harming
the normal stem cell pool and raise the hope that such innova-
tive concepts may improve treatment outcome in a subgroup
of patients with AML in the future.
Experimental procedures
Retroviral transduction of primary bone marrow cells
and BM transplantation
Breeding and maintenance of the mice were conducted as described previ-
ously (Rawat et al., 2004). Production of high-titer helper-free retrovirus was
carried out following standard procedures by using the ecotropic packaging
cell line GP+E86 (Schessl et al., 2005). Lethally irradiated (0.80 Gy) mice were
transplanted with either highly purified EGFP+ cells alone (4 3 105 cells per
mouse) (FACSVantage, Becton Dickinson) or with a mixture of transduced
and nontransduced cells (on average 1.763 105 transduced cells with 1.93
105 nontransduced cells per mouse). Lethally irradiated secondary and
tertiary recipients were injected with 1 3 106 BM cells from a primary and
secondary diseased mouse, respectively, with an equal number of nontrans-
duced cells from a syngenic disease-free mouse bone marrow for radiopro-
tection. Both animal and human studies were approved by the Ethics
Committee of Ludwig Maximilians University and abided by the tenets of
the revised World Medical Association Declaration of Helsinki (http://www.
wma.net/e/policy/b3.htm).
In order to determine the frequency of leukemia-propagating cells, B220+/
Mac12, B220+/Mac1+, and B2202/Mac1+ cells were isolated and highly pu-
rified from the BM of a leukemic primary mouse. The sort purity of these cells
was analyzed with the FACSCalibur and determined to be over 98%. In each
cohort 10-fold serial dilutions of these cells were injected intravenously (50
cells to 53 105 cells per mouse cohort) into lethally irradiated secondary re-
cipient mice. Carrier cells (13 106) (nontransduced BM from a syngenic dis-
ease-free mouse) were added to each sample for radioprotection. Diseased
mice were sacrificed and assessed for leukemia development. Mice that did
not develop disease within 20 weeks posttransplantation were sacrificed andCANCER CELL NOVEMBER 2006
A R T I C L Etested for engraftment. The frequency of leukemia-propagating cells was
calculated using Poisson statistics using the L-Calc Limiting dilution analysis
software (Version 1.1 StemSoft Inc., Vancouver, Canada) (Buske et al., 2002).
Patient samples
BM samples from adult patients diagnosed with AML were analyzed. The di-
agnosis of AML was performed according to the French-American-British
criteria and the World Health Organization classification (Bennett et al.,
1985; Harris et al., 1995). Cytomorphology, cytochemistry, cytogenetics,
and molecular genetics were applied in all cases as described below. The
clinical features of patients are provided in Table S4. The study abided by
the rules of the local internal review board and the tenets of the revised
Helsinki protocol (http://www.wma.net/e/policy/b3.htm).
Sorting of cells from human AML patient samples
Frozen mononuclear peripheral blood or bone marrow cells from patients
with AML were rapidly thawed and were washed twice in IMDM with 10%
FBS, resuspended in PBS, and stained with various antibodies. For lineage
depletion experiments, immunostaining was done with FITC-labeled anti-hu-
man CD34 (Beckman Coulter, Marseille, France) and PE-labeled anti-human
CD38, PE-labeled anti-human CD19, PE-labeled anti-human CD10, and PE-
labeled anti-human CD45RA (all from BD Pharmingen, Heidelberg, Ger-
many). Cells were incubated with appropriate antibodies for 20 min on ice
and washed with cold PBS prior to sorting. The trial was approved by the re-
sponsible local ethics committees, and all patients gave written informed
consent according to the Helsinki Declaration.
FISH
Dual Colour Dual Fusion (DCDF) probes were developed with bacterial artifi-
cial chromosome (BAC) clones RP11-418C1 for the 50-AF10 region (Texas
Red; red in Figure 5B), RP11-249M6 for the 30-AF10 region (red), RP11-
12D16 (FITC, green) for the 50-CALM region, and RP11-90K17 (green) for
the 30-CALM region (kindly provided by Dr. Mariano Rocchi, Bari). BAC
DNA preparation, labeling, and FISH were performed as described (Cre-
scenzi et al., 2004). Normal nuclei display a two-red and two-green (2R2G)
hybridization pattern, whereas nuclei carrying the translocation display
a one-red, one-green, twored/green fusion (1R1G2F) pattern. Other hybrid-
ization patterns, e.g., 1R1G1F (found in 0.5%–2% of nuclei) or 1R1G3F
(found in 0.5%–1% of nuclei), were interpreted as technical artifacts.
The cells were directly sorted onto aminoalkylsilane-coated slides (Silane-
Prep Slides, Sigma, Germany) with or without preloading of 15 ml 3% bovine
serum albumin solution in PBS and fixed in 1:3 acetic acid-methanol fixative.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures, five
supplemental figures, and five supplemental tables and can be found with
this article online at http://www.cancercell.org/cgi/content/full/10/5/363/
DC1/.
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